FGFR inhibitors and methods of making and using same
Patent Information
- Application Number
- JP2023529963
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-18
- Filing Date
- 2021-11-18
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2041-11-18
AI Technical Summary
Current FGFR inhibitors, particularly pan-FGFR inhibitors, face challenges with on-target toxicity, such as hyperphosphatemia, and limited efficacy in cancers with FGFR2 gene fusions, amplifications, or mutations, necessitating the development of FGFR2 selective inhibitors with reduced toxicity and improved response rates.
Development of crystalline forms of FGFR inhibitors, including compounds of Formulas I-IV and their solvates, which offer improved water solubility, stability, and ease of formulation, reducing impurities and enhancing therapeutic efficacy.
The crystalline forms of FGFR inhibitors provide enhanced therapeutic efficacy by minimizing toxicity and improving response rates in FGFR2-altered cancers, while maintaining effective FGFR2 inhibition.
Smart Images

Figure 2022109577000001 
Figure 2022109577000002 
Figure 2022109577000003
Abstract
Description
Technical field
[0001] Cross-reference to related applications This application claims the benefit of U.S. Provisional Application No. 63 / 115,319, filed November 18, 2020, which is incorporated herein by reference in its entirety. [Background technology]
[0002] background Fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3 and FGFR4) are receptor tyrosine kinases consisting of an extracellular ligand binding domain and an intracellular tyrosine kinase domain. Binding of FGF ligand leads to receptor dimerization and conformational changes in the intracellular domain, leading to intermolecular phosphorylation of the kinase domain and intracellular tail. Phosphorylated residues serve as docking sites for adapter proteins that drive downstream signaling cascades, resulting in cellular behaviors including proliferation, survival, differentiation, migration, and angiogenesis. Deregulated FGFR signaling may be caused by FGFR gene amplification or fusion, FGFR missense mutations, receptor overexpression due to dysregulation of epigenic and / or transcriptional regulators, or upregulation of FGF ligands in the tumor microenvironment. This can occur through regulation. FGFR is expressed on numerous cell types. Thus, aberrant FGFR signaling is involved in tumorigenesis, tumor progression, and resistance to therapy across numerous tumor types (for a review of FGFR signaling, see N. Turner and R. Grose, Nat. Rev. Cancer 2010, 10:116-129 and references cited therein).
[0003] In multiple FGFR-altered cancers, pan-FGFR1-3 inhibitors produce clinical responses, but on-target toxicity limits the dosing of these inhibitors. One of the most common adverse effects of pan-FGFR inhibition is hyperphosphatemia. Regulation of phosphate reabsorption is mediated by FGFR3 and FGFR1. Therefore, FGFR selective inhibitors that spare FGFR1 are needed (J. Gattineni et al., Am. J. Physiol. Renal Physiol. 2014, 306:F351-F358; X. Han et al., PLoS One 2016, 11:e0147845) Cancers harboring FGFR2 gene fusions, as well as cancers with FGFR2 amplification and / or FGFR2 activating mutations, have been demonstrated to respond to pan-FGFR inhibition, but with low response rates. The efficiency and short duration of response suggest that they were limited by toxicity. Therefore, there is a need for FGFR2 selective inhibitor compounds and methods for treating cancer and other disorders with these compounds. (For a review of pan-FGFR1-3 inhibitors and clinical responses, see I. S. Babina and N.C. Turner, Nat. Rev. Cancer 2017, 17:318-332; M. Katoh, Nat. Rev. Clin. Oncol. 2019, 16: 105-122 and references cited therein). Polymorphism is the ability of a substance to crystallize in more than one crystal lattice arrangement. Crystallization or polymorphism can affect many aspects of the solid state properties of a drug substance. Crystalline forms can differ significantly from amorphous forms, and different crystalline forms of a substance can differ significantly from each other in a number of respects, including solubility, dissolution rate, and / or bioavailability. In general, it is difficult to predict whether a given compound will form various crystalline solid state forms. Predicting the physical properties of these crystalline solid state forms is even more difficult. Additionally, it may be advantageous to have a crystalline form of the therapeutic agent for certain formulations, eg, formulations suitable for subcutaneous use. [Prior art documents] [Non-patent literature]
[0004] [Non-patent document 1] N. Turner and R. Grose, Nat. Rev. Cancer 2010, 10:116-129 [Non-patent document 2] J. Gattineni et al., Am. J. Physiol. Renal Physiol. 2014, 306:F351-F358 [Non-patent document 3] X. Han et al., PLoS One 2016, 11:e0147845 [Non-patent document 4] I. S. Babina and N.C. Turner, Nat. Rev. Cancer 2017, 17:318-332 [Non-patent document 5] M. Katoh, Nat. Rev. Clin. Oncol. 2019, 16:105-122 [Summary of the invention] [Means to solve the problem]
[0005] Summary of the invention The present disclosure is generally directed to compounds of Formulas I-IV and their solvates, as well as their crystalline forms.
[0006] In one embodiment, a compound of formula (I) [ka] or a solvate thereof, where X, m and n are each independently as defined and described in the embodiments herein. In some embodiments, the compound of formula (I) or solvate thereof is in a crystalline form as described herein.
[0007] In another embodiment, a compound of formula (II) [ka] or a solvate thereof, where X, p and q are each independently as defined and described in the embodiments herein. In some embodiments, the compound of formula (II) or solvate thereof is in a crystalline form as described herein.
[0008] In another embodiment, a compound of formula (III) [ka] or a solvate thereof, where X, r and s are each independently as defined and described in the embodiments herein. In some embodiments, the compound of formula (III) or a solvate thereof is in a crystalline form as described herein.
[0009] In another embodiment, a compound of formula (IV) [ka] or a solvate thereof, where X, t, and u are each independently as defined and described in the embodiments herein. In some embodiments, the compound of formula (IV) or a solvate thereof is in a crystalline form as described herein.
[0010] In another aspect, provided herein is a pharmaceutical composition comprising a compound described herein or a solvate or crystalline form thereof and a pharmaceutically acceptable excipient.
[0011] In another aspect, a compound described herein or a solvate thereof for inhibiting FGFR2 activity and treating disorders, diseases and / or conditions described herein, or Methods of using these crystalline forms or pharmaceutical compositions are provided herein. [Brief explanation of the drawing]
[0012] [Figure 1A] FIG. 1A illustrates the X-ray diffraction pattern of Form A of Compound I-1.
[0013] [Figure 1B] FIG. 1B illustrates the characterization of Form A of Compound I-1 by differential scanning calorimetry (DSC).
[0014] [Figure 1C] Figure 1C illustrates the characterization of Form A of compound I-1 by thermogravimetric analysis (TGA).
[0015] [Figure 1D] FIG. 1D illustrates the characterization of Form A of compound I-1 by dynamic water vapor sorption (DVS).
[0016] [Figure 2A] Figure 2A illustrates the X-ray diffraction pattern of Form B of Compound I-1.
[0017] [Figure 2B] Figure 2B illustrates the characterization of Form B of Compound I-1 by differential scanning calorimetry (DSC).
[0018] [Figure 2C] Figure 2C illustrates the characterization of Form B of compound I-1 by thermogravimetric analysis (TGA).
[0019] [Figure 2D] Figure 2D illustrates the characterization of Form B of compound I-1 by dynamic water vapor sorption (DVS).
[0020] [Figure 3A] Figure 3A illustrates the X-ray diffraction pattern of Form C of Compound I-1.
[0021] [Figure 3B] Figure 3B illustrates the characterization of Form C of compound I-1 by differential scanning calorimetry (DSC).
[0022] [Figure 3C] Figure 3C illustrates the characterization of Form C of compound I-1 by thermogravimetric analysis (TGA).
[0023] [Figure 3D] Figure 3D illustrates the characterization of Form C of compound I-1 by dynamic water vapor sorption (DVS).
[0024] [Figure 4A] Figure 4A illustrates the X-ray diffraction pattern of Form D of Compound I-1.
[0025] [Figure 4B] FIG. 4B illustrates the characterization of Form D of Compound I-1 by differential scanning calorimetry (DSC).
[0026] [Figure 4C] Figure 4C illustrates the characterization of Form D of compound I-1 by thermogravimetric analysis (TGA).
[0027] [Figure 4D] FIG. 4D illustrates the characterization of Form D of compound I-1 by dynamic water vapor sorption (DVS).
[0028] [Figure 4E] Figure 4E illustrates the characterization of Form D of compound I-1 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0029] [Figure 5A] Figure 5A illustrates the X-ray diffraction pattern of Form E of Compound I-1.
[0030] [Figure 5B] FIG. 5B illustrates the characterization of Form E of Compound I-1 by differential scanning calorimetry (DSC).
[0031] [Figure 6A] Figure 6A illustrates the X-ray diffraction pattern of Form F of Compound I-1.
[0032] [Figure 6B] Figure 6B illustrates the characterization of Form F of Compound I-1 by differential scanning calorimetry (DSC).
[0033] [Figure 6C] Figure 6C illustrates the characterization of Form F of compound I-1 by thermogravimetric analysis (TGA).
[0034] [Figure 6D] Figure 6D illustrates the characterization of Form F of compound I-1 by dynamic water vapor sorption (DVS).
[0035] [Figure 7A] Figure 7A illustrates the X-ray diffraction pattern of Form G of Compound I-1.
[0036] [Figure 7B] Figure 7B illustrates the characterization of Form G of Compound I-1 by differential scanning calorimetry (DSC).
[0037] [Figure 7C] Figure 7C illustrates the characterization of Form G of compound I-1 by thermogravimetric analysis (TGA).
[0038] [Figure 7D] FIG. 7D illustrates the characterization of Form G of compound I-1 by dynamic water vapor sorption (DVS).
[0039] [Figure 8A] Figure 8A illustrates the X-ray diffraction pattern of Form H of Compound I-1.
[0040] [Figure 8B] Figure 8B illustrates the characterization of Form H of compound I-1 by differential scanning calorimetry (DSC).
[0041] [Figure 8C] Figure 8C illustrates the characterization of Form H of compound I-1 by thermogravimetric analysis (TGA).
[0042] [Figure 8D] FIG. 8D illustrates the characterization of Form H of compound I-1 by dynamic water vapor sorption (DVS).
[0043] [Figure 9A] Figure 9A illustrates the X-ray diffraction pattern of Form I of Compound I-1.
[0044] [Figure 9B] Figure 9B illustrates the characterization of Form I of Compound I-1 by differential scanning calorimetry (DSC).
[0045] [Figure 9C] Figure 9C illustrates the characterization of Form I of compound I-1 by thermogravimetric analysis (TGA).
[0046] [Figure 9D] FIG. 9D illustrates the characterization of Form I of compound I-1 by dynamic water vapor sorption (DVS).
[0047] [Figure 9E] Figure 9E illustrates the characterization of Form I of compound I-1 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0048] [Figure 10A] FIG. 10A illustrates the X-ray diffraction pattern of Form J of Compound I-1.
[0049] [Figure 10B] FIG. 10B illustrates the characterization of Form J of Compound I-1 by differential scanning calorimetry (DSC).
[0050] [Figure 10C] FIG. 10C illustrates the characterization of Form J of compound I-1 by thermogravimetric analysis (TGA).
[0051] [Figure 10D] FIG. 10D illustrates the characterization of Form J of compound I-1 by dynamic water vapor sorption (DVS).
[0052] [Figure 11A] FIG. 11A illustrates the X-ray diffraction pattern of Form K of Compound I-1.
[0053] [Figure 11B] FIG. 11B illustrates the characterization of Form K of compound I-1 by differential scanning calorimetry (DSC).
[0054] [Figure 11C] FIG. 11C illustrates the characterization of Form K of compound I-1 by thermogravimetric analysis (TGA).
[0055] [Figure 11D] FIG. 11D illustrates the characterization of Form K of compound I-1 by dynamic water vapor sorption (DVS).
[0056] [Figure 12] FIG. 12 illustrates the procedure for generating patterns 1-11 corresponding to forms A-K of compound I-1. Pattern 1 corresponds to form A. Pattern 2 corresponds to form B. Pattern 3 corresponds to form C. Pattern 4 corresponds to form D. Pattern 5 corresponds to form E. Pattern 6 corresponds to form F. Pattern 7 corresponds to form G. Pattern 8 corresponds to form H. Pattern 9 corresponds to Form I. Pattern 10 corresponds to form J. Pattern 11 corresponds to form K.
[0057] [Figure 13A] Figure 13A illustrates the X-ray diffraction patterns 1-5 (Forms A-E) of Compound I-2 (free form).
[0058] [Figure 13B] Figure 13B illustrates the X-ray diffraction pattern of Form B of Compound I-2 (free form).
[0059] [Figure 13C] Figure 13C illustrates the characterization of Form B of compound I-2 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0060] [Figure 13D] Figure 13D illustrates the characterization of Form B of Compound I-2 by thermogravimetric analysis (bottom) and differential scanning calorimetry (top).
[0061] [Figure 13E] Figure 13E illustrates the X-ray diffraction pattern of Form B of Compound I-2 before and after static storage at 40C, 75% relative humidity and 25C, 97% relative humidity.
[0062] [Figure 14A] Figure 14A illustrates the X-ray diffraction pattern of Form A of Compound I-3 (HBr salt) before storage and after one week of storage at 40C and 75% relative humidity.
[0063] [Figure 14B] Figure 14B illustrates the characterization of Form A of compound I-3 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0064] [Figure 14C] Figure 14C illustrates the characterization of Form A of compound I-3 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0065] [Figure 15A] Figure 15A illustrates the X-ray diffraction pattern of Form B of Compound I-4 (sulfate salt) before storage and after one week of storage at 40C and 75% relative humidity.
[0066] [Figure 15B] Figure 15B illustrates the characterization of Form B of compound I-4 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0067] [Figure 15C] Figure 15C illustrates the characterization of Form B of compound I-4 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0068] [Figure 16A] Figure 16A illustrates the X-ray diffraction pattern of Form A of Compound I-5 (p-tosylate salt) before storage and after one week of storage at 40C and 75% relative humidity.
[0069] [Figure 16B] Figure 16B illustrates the characterization of Form A of compound I-5 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0070] [Figure 16C] Figure 16C illustrates the characterization of Form A of compound I-5 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0071] [Figure 17A] Figure 17A illustrates the X-ray diffraction pattern of Form A of Compound I-6 (mesylate salt) before storage and after one week of storage at 40C and 75% relative humidity.
[0072] [Figure 17B] Figure 17B illustrates the characterization of Form A of compound I-6 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0073] [Figure 17C] Figure 17C illustrates the characterization of Form A of compound I-6 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0074] [Figure 18A] Figure 18A illustrates the X-ray diffraction pattern of Form A of Compound I-7 (besylate salt) before storage and after one week of storage at 40C and 75% relative humidity.
[0075] [Figure 18B] Figure 18B illustrates the characterization of Form A of compound I-7 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0076] [Figure 18C] Figure 18C illustrates the characterization of Form A of compound I-7 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0077] [Figure 19A] Figure 19A illustrates the X-ray diffraction pattern of Form A of Compound I-8 (maleate salt) before storage and after one week of storage at 40C and 75% relative humidity.
[0078] [Figure 19B] Figure 19B illustrates the characterization of Form A of compound I-8 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0079] [Figure 19C] Figure 19C illustrates the characterization of Form A of compound I-8 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0080] [Figure 20] Figure 20 illustrates the X-ray diffraction pattern of Form A of fumaric acid co-crystal of Compound I-2.
[0081] [Figure 21] Figure 21 illustrates the X-ray diffraction pattern of Form A of malonic acid co-crystal of Compound I-2.
[0082] [Figure 22] Figure 22 illustrates the X-ray diffraction pattern of Form A of benzoic acid co-crystal of Compound I-2.
[0083] [Figure 23] Figure 23 illustrates the X-ray diffraction pattern of Form A of benzamide co-crystal of Compound I-2.
[0084] [Figure 24A] Figure 24A illustrates the X-ray diffraction pattern of Form A of Compound II-1 (free form).
[0085] [Figure 24B] Figure 24B illustrates the characterization of Form A of compound II-1 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0086] [Figure 24C] Figure 24C illustrates the characterization of Form A of Compound II-1 by differential scanning calorimetry (DSC).
[0087] [Figure 24D] Figure 24D illustrates the characterization of Form A of Compound II-1 by thermogravimetric analysis (TGA).
[0088] [Figure 24E] Figure 24E illustrates the XRPD diffractogram of Compound II-1 Form A (bottom) after storage at 40° C. / 75% RH for 7 days (top).
[0089] [Figure 25A] Figure 25A illustrates the X-ray diffraction pattern of Form B of Compound II-1 (free form).
[0090] [Figure 25B] Figure 25B illustrates the characterization of Form B of compound II-1 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0091] [Figure 25C] Figure 25C illustrates the characterization of Form B of Compound II-1 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0092] [Figure 25D] FIG. 25D illustrates the XRPD diffractogram of Form B of compound II-1 (bottom) after storage at 40° C. / 75% RH for 7 days (top).
[0093] [Figure 26A] Figure 26A illustrates the X-ray diffraction pattern of Form A of Compound II-2 (hydrochloride salt).
[0094] [Figure 26B] Figure 26B illustrates the characterization of Form A of compound II-2 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0095] [Figure 26C] Figure 26C illustrates the characterization of Form A of Compound II-2 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0096] [Figure 26D] Figure 26D illustrates the XRPD diffractogram of Compound II-2 Form A (bottom) after storage at 40° C. / 75% RH for 7 days (top).
[0097] [Figure 27A] Figure 27A illustrates the X-ray diffraction pattern of Form A of Compound II-3 (hydrobromide salt).
[0098] [Figure 27B] Figure 27B illustrates the characterization of Form A of compound II-3 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0099] [Figure 27C] Figure 27C illustrates the characterization of Form A of compound II-3 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0100] [Figure 27D] Figure 27D illustrates the XRPD diffractogram of Compound II-3 Form A (bottom) after storage at 40° C. / 75% RH for 7 days (top).
[0101] [Figure 28A] Figure 28A illustrates the X-ray diffraction pattern of Form A of Compound II-4 (tosylate salt).
[0102] [Figure 28B] Figure 28B illustrates the characterization of Form A of compound II-4 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0103] [Figure 28C] Figure 28C illustrates the characterization of Form A of compound II-4 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0104] [Figure 28D] Figure 28D illustrates the XRPD diffractogram of Compound II-4 Form A (bottom) after storage at 40° C. / 75% RH for 7 days (top).
[0105] [Figure 29A] Figure 29A illustrates the X-ray diffraction pattern of Form A of Compound II-5 (mesylate salt).
[0106] [Figure 29B] Figure 29B illustrates the characterization of Form A of compound II-5 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0107] [Figure 29C] Figure 29C illustrates the characterization of Form A of compound II-5 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0108] [Figure 30A] Figure 30A illustrates the X-ray diffraction pattern of Form A of Compound II-6 (besylate salt).
[0109] [Figure 30B] Figure 3OB illustrates the characterization of Form A of compound II-6 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0110] [Figure 30C-1] Figure 30C illustrates the characterization of Form A of compound II-6 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom). [Figure 30C-2] Same as above.
[0111] [Figure 30D] Figure 30D illustrates the XRPD diffractogram of Compound II-6 Form A (bottom) after storage at 40° C. / 75% RH for 7 days (top).
[0112] [Figure 31A] Figure 31A illustrates the X-ray diffraction pattern of Form A of Compound II-7 (fumarate salt).
[0113] [Figure 31B] Figure 31B illustrates the characterization of Form A of compound II-7 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0114] [Figure 31C] Figure 31C illustrates the characterization of Form A of compound II-7 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0115] [Figure 31D] FIG. 31D illustrates the XRPD diffractogram of Form A of compound II-7 (bottom) after storage at 40° C. / 75% RH for 7 days (top).
[0116] [Figure 32A] Figure 32A illustrates the X-ray diffraction pattern of Form A of Compound III-1 (free form).
[0117] [Figure 32B] Figure 32B illustrates the characterization of Form A of compound III-1 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0118] [Figure 32C] Figure 32C illustrates the characterization of Form A of compound III-1 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0119] [Figure 32D] Figure 32D illustrates the XRPD diffractogram of Compound III-1 Form A (top) after storage at 40° C. / 75% RH for 7 days (bottom).
[0120] [Figure 33A] Figure 33A illustrates the X-ray diffraction pattern of Form B of Compound III-1 (free form).
[0121] [Figure 33B] Figure 33B illustrates the characterization of Form B of compound III-1 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0122] [Figure 33C] Figure 33C illustrates the characterization of Form B of compound III-1 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0123] [Figure 33D] Figure 33D illustrates the XRPD diffractogram of Compound III-1 Form B (top) after storage at 40° C. / 75% RH for 7 days (bottom).
[0124] [Figure 34A] Figure 34A illustrates the X-ray diffraction pattern of Form C of Compound III-1 (free form).
[0125] [Figure 34B] Figure 34B illustrates the characterization of Form C of compound III-1 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0126] [Figure 34C] Figure 34C illustrates the characterization of Form C of compound III-1 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0127] [Figure 34D] Figure 34D illustrates the XRPD diffractogram of Form C of compound III-1 (top) after storage at 40° C. / 75% RH for 7 days (bottom).
[0128] [Figure 35A] Figure 35A illustrates the X-ray diffraction pattern of Form A of Compound III-2 (hydrochloride salt).
[0129] [Figure 35B] Figure 35B illustrates the characterization of Form A of compound III-2 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0130] [Figure 35C] Figure 35C illustrates the characterization of Form A of compound III-2 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0131] [Figure 35D] Figure 35D illustrates the XRPD diffractogram of Compound III-2 Form A (top) after storage at 40° C. / 75% RH for 7 days (bottom).
[0132] [Figure 36A]Figure 36A illustrates the X-ray diffraction pattern of Form B of Compound III-2 (hydrochloride salt).
[0133] [Figure 36B] Figure 36B illustrates the characterization of Form B of compound III-2 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0134] [Figure 36C] Figure 36C illustrates the characterization of Form B of compound III-2 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0135] [Figure 36D] Figure 36D illustrates the XRPD diffractogram of Compound III-2 Form B (top) after storage at 40° C. / 75% RH for 7 days (bottom).
[0136] [Figure 37A] Figure 37A illustrates the X-ray diffraction patterns of a mixture of Form C and Form E (top) and Form C (bottom) of Compound III-2 (hydrochloride salt).
[0137] [Figure 37B] Figure 37B illustrates the characterization of a mixture of Form C and Form E of compound III-2 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0138] [Figure 37C] Figure 37C illustrates the characterization of a mixture of Form C and Form E of Compound III-2 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0139] [Figure 37D] Figure 37D illustrates the XRPD diffractogram of a mixture of Form C and Form E of Compound III-2 (top) after storage at 40° C. / 75% RH for 7 days (bottom).
[0140] [Figure 38A] Figure 38A illustrates the X-ray diffraction pattern of Form D of Compound III-2 (hydrochloride salt).
[0141] [Figure 38B] Figure 38B illustrates the characterization of Form D of compound III-2 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0142] [Figure 38C] Figure 38C illustrates the characterization of Form D of compound III-2 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0143] [Figure 38D] Figure 38D illustrates the XRPD diffractogram of Compound III-2 Form D (top) after storage at 40° C. / 75% RH for 7 days (bottom).
[0144] [Figure 39A] Figure 39A illustrates the X-ray diffraction pattern of Form A of Compound III-3 (hydrobromide salt).
[0145] [Figure 39B] Figure 39B illustrates the characterization of Form A of compound III-3 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0146] [Figure 39C] Figure 39C illustrates the characterization of Form A of compound III-3 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0147] [Figure 39D] Figure 39D illustrates the XRPD diffractogram of Compound III-3 Form A (top) after storage at 40° C. / 75% RH for 7 days (bottom).
[0148] [Figure 40A] Figure 40A illustrates the X-ray diffraction pattern of Form A of Compound III-4 (sulfate salt).
[0149] [Figure 40B] Figure 40B illustrates the characterization of Form A of compound III-4 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0150] [Figure 40C] Figure 40C illustrates the characterization of Form A of compound III-4 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0151] [Figure 40D] FIG. 40D illustrates the XRPD diffractogram of Form A of compound III-4 (top) after storage at 40° C. / 75% RH for 7 days (bottom).
[0152] [Figure 41A] Figure 41A illustrates the X-ray diffraction patterns of Form B (bottom) and Form A (top) of Compound III-4 (sulfate salt).
[0153] [Figure 41B] Figure 41B illustrates the characterization of Form A of compound III-4 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0154] [Figure 41C] Figure 41C illustrates the characterization of Form A of compound III-4 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0155] [Figure 41D] FIG. 41D illustrates the XRPD diffractogram of Form A of compound III-4 (top) after storage at 40° C. / 75% RH for 7 days (bottom).
[0156] [Figure 42A] Figure 42A illustrates the X-ray diffraction pattern of Form A of Compound III-5 (mesylate salt).
[0157] [Figure 42B] Figure 42B illustrates the characterization of Form A of compound III-5 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0158] [Figure 42C] Figure 42C illustrates the characterization of Form A of compound III-5 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0159] [Figure 42D] Figure 42D illustrates the XRPD diffractogram of Compound III-5 Form A (top) after storage at 40° C. / 75% RH for 7 days (bottom).
[0160] [Figure 43A] Figure 43A illustrates the X-ray diffraction pattern of Form A of Compound III-6 (tartrate salt).
[0161] [Figure 43B] Figure 43B illustrates the characterization of Form A of compound III-6 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0162] [Figure 43C] Figure 43C illustrates the characterization of Form A of compound III-6 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0163] [Figure 43D] Figure 43D illustrates the XRPD diffractogram of Compound III-6 Form A (top) after storage at 40° C. / 75% RH for 7 days (bottom).
[0164] [Figure 44A] Figure 44A illustrates the X-ray diffraction pattern of Form A of Compound IV-1 (free form).
[0165] [Figure 44B] Figure 44B illustrates the characterization of Form A of compound IV-1 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0166] [Figure 44C] Figure 44C illustrates the characterization of Form A of Compound IV-1 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0167] [Figure 44D] Figure 44D illustrates the XRPD diffractogram of Compound IV-1 Form A (top) after storage at 40° C. / 75% RH for 7 days (bottom).
[0168] [Figure 45A] Figure 45A illustrates the X-ray diffraction pattern of Form A of Compound IV-2 (hydrochloride).
[0169] [Figure 45B] Figure 45B illustrates the characterization of Form A of compound IV-2 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0170] [Figure 45C] Figure 45C illustrates the characterization of Form A of compound IV-2 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0171] [Figure 45D] Figure 45D illustrates the XRPD diffractogram of Compound IV-2 Form A (top) after storage at 40° C. / 75% RH for 7 days (bottom).
[0172] [Figure 46A] Figure 46A illustrates the X-ray diffraction pattern of Form A of Compound IV-3 (tosylate salt).
[0173] [Figure 46B] Figure 46B illustrates the characterization of Form A of compound IV-3 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0174] [Figure 46C] Figure 46C illustrates the characterization of Form A of compound IV-3 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0175] [Figure 46D] Figure 46D illustrates the XRPD diffractogram of Compound IV-3 Form A (top) after storage at 40° C. / 75% RH for 7 days (bottom).
[0176] [Figure 47A] Figure 47A illustrates the X-ray diffraction pattern of Form B of Compound IV-3 (tosylate salt).
[0177] [Figure 47B] Figure 47B illustrates the characterization of Form B of compound IV-3 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0178] [Figure 48A] Figure 48A illustrates the X-ray diffraction pattern of Form A of Compound IV-4 (mesylate salt).
[0179] [Figure 48B] Figure 48B illustrates the characterization of Form A of compound IV-4 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0180] [Figure 48C] Figure 48C illustrates the characterization of Form A of compound IV-4 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0181] [Figure 48D] Figure 48D illustrates the XRPD diffractogram of Compound IV-4 Form A (top) after storage at 40° C. / 75% RH for 7 days (bottom).
[0182] [Figure 49A] Figure 49A illustrates the X-ray diffraction pattern of Form A of Compound IV-5 (besylate salt).
[0183] [Figure 49B] Figure 49B illustrates the characterization of Form A of compound IV-5 by 1H nuclear magnetic resonance (1H NMR) in D6-DMSO at 400MHz.
[0184] [Figure 49C] Figure 49C illustrates the characterization of Form A of compound IV-5 by thermogravimetric analysis (top) and differential scanning calorimetry (bottom).
[0185] [Figure 49D] Figure 49D illustrates the XRPD diffractogram of Compound IV-5 Form A (top) after storage at 40° C. / 75% RH for 7 days (bottom). [Form for carrying out the invention]
[0186] Detailed description of the invention Compound with formula: [ka] are FGFR inhibitors and are found to be useful in treating disorders, diseases and / or conditions, such as the "FGFR2-mediated" disorders, diseases and / or conditions described herein. It was done. It would be desirable to provide solid forms of compounds (eg, free bases or salts or solvates) that offer characteristics such as improved water solubility, stability, and ease of formulation.
[0187] The optimization process allows the compound [ka] As shown in Examples 1 and 2, impurity compound 6: [ka] It has also been found that the liquid chromatography area percentage (LCAP) can be reduced to a liquid chromatography area percentage (LCAP) of less than about 0.15. Therefore, the compounds provided herein [ka] is substantially free of impurities, such as compound 6. Compound of formula (I)
[0188] In some embodiments, a compound of formula (I) [ka] or a solvate thereof, provided herein: m is 1, 2, 3, 4, 5, 6, 7, 8 or 9; n is 0, 0.5, 1, 1.5, 2, 2.5 or 3; X is hydrochloric acid, hydrobromic acid, sulfuric acid, p-toluenesulfonic acid, methanesulfonic acid, benzenesulfonic acid or maleic acid).
[0189] The acid moiety shown as “X” and N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl- It will be recognized by those skilled in the art that 7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide is ionically combined to form a compound of formula (I). It will also be appreciated that when n is 0, X is absent, indicating that the compound of formula (I) is present as a "free base", ie, in "free form".
[0190] It is contemplated that compounds of formula (I) can exist in a variety of physical forms. For example, a compound of formula (I) may be in solution, suspension or in solid form. In certain embodiments, the compound of formula (I) is in solid form. When the compound of formula (I) is in solid form, said compound may be amorphous, crystalline or a mixture thereof. Exemplary solid forms are described in more detail below.
[0191] In some embodiments, compounds of formula (I) may be in hydrate form. In some embodiments, the compound of formula (I) may be in a hemihydrate form.
[0192] In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, m is 7. In some embodiments, m is 8. In some embodiments, m is 9.
[0193] In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 0.5. In some embodiments, n is 1.5. In some embodiments, n is 2.5.
[0194] In some embodiments, X is hydrochloric acid. In some embodiments, X is hydrobromic acid. In some embodiments, X is sulfuric acid. In some embodiments, X is p-toluenesulfonic acid. In some embodiments, X is methanesulfonic acid. In some embodiments, X is benzenesulfonic acid. In some embodiments, X is maleic acid.
[0195] In some embodiments, the invention provides a form of Compound I that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound I, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound I.
[0196] In some embodiments, the compound of formula (I) or a solvate thereof, or a crystalline form thereof, is at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, 98.5, 99, 99.1, 99.2, Present in amounts of 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9% by weight, percentages being relative to the total weight of the composition. In some embodiments, the compound of formula (I) or a solvate thereof, or a crystalline form thereof, contains no more than about 0.40%, no more than about 0.35%, no more than about 0.3% by weight of any single impurity. , no more than about 0.25%, no more than about 0.2%, no more than about 0.15%, no more than about 0.10%, or no more than about 0.05% by weight, percentages being based on the total weight of the composition. In some embodiments, the compound of formula (I) or a solvate thereof, or a crystalline form thereof, contains the impurity compound 6 (the free base and salts of compound 6 or a solvate thereof, or a solid form thereof). 0.40% by weight or less, 0.35% by weight or less, 0.3% by weight or less, 0.25% by weight or less, 0.2% by weight or less, 0.15% by weight or less, 0.10% by weight or less, or 0.05% by weight or less The percentages are based on the total weight of the composition.
[0197] In some embodiments, the compound of formula (I) or a solvate thereof, or a crystalline form thereof, has a total area of at least about 95, 95.5, 96, 96.5, 97, 97.5, Present in amounts of 98.0, 98.5, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 HPLC area %. In some embodiments, the compound of formula (I) or a solvate thereof, or a crystalline form thereof, contains no more than about 0.4, no more than about 0.35 of any single impurity, based on the total area of the HPLC chromatogram. , less than or equal to about 0.3, less than or equal to about 0.25, less than or equal to about 0.2, less than or equal to about 0.15, less than or equal to about 0.10, or less than or equal to about 0.05. In some embodiments, the compound of formula (I) or a solvate thereof, or a crystalline form thereof, has a relative concentration of impurity compound 6 (the free base and salts of compound 6 or their salts) relative to the total area of the HPLC chromatogram. solvates, or solid forms thereof) of less than or equal to about 0.40, less than or equal to about 0.35, less than or equal to about 0.3, less than or equal to about 0.25, less than or equal to about 0.2, less than or equal to about 0.15, less than or equal to about 0.10, or less than or equal to about 0.05 HPLC Area% do not. In some embodiments, the HPLC method is the HPLC method described in Example 1.
[0198] The structures depicted for compounds of formula (I) are also intended to include all tautomeric forms. Additionally, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, replacing hydrogen with deuterium or tritium, or 13 C or 14 Compounds having this structure, excluding the replacement of carbon by a C-rich carbon, are within the scope of this invention.
[0199] In some embodiments, N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[ 2,3-d]pyrimidin-6-yl)phenyl)methacrylamide hydrochloride is provided herein. In some embodiments, N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[ 2,3-d]pyrimidin-6-yl)phenyl)methacrylamide hydrochloride is a monohydrochloride. In some embodiments, N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[ 2,3-d]pyrimidin-6-yl)phenyl)methacrylamide hydrochloride is a dihydrochloride. In some embodiments, N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[ 2,3-d]pyrimidin-6-yl)phenyl)methacrylamide hydrochloride is a trihydrochloride. Compound I-1
[0200] In some embodiments, the compound of formula (I) is compound I-1 [ka] or a solvate thereof.
[0201] In some embodiments, Compound I-1 is an anhydrous solid.
[0202] In some embodiments, Compound I-1 is an amorphous solid. In other embodiments, Compound I-1 is a crystalline solid. In some embodiments, Compound I-1 is a mixture of amorphous and crystalline solid forms.
[0203] In some embodiments, the invention provides a form of Compound I-1 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound I-1, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound I-1.
[0204] In some embodiments, Compound I-1 or a solvate thereof, or a crystalline form thereof, is at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, 98.5, 99, 99.1, 99.2, 99.3, Present in amounts of 99.4, 99.5, 99.6, 99.7, 99.8, 99.9% by weight, percentages being relative to the total weight of the composition. In some embodiments, Compound I-1 or a solvate thereof, or a crystalline form thereof, contains no more than about 0.40 wt.%, no more than about 0.35 wt.%, no more than about 0.3 wt.%, no more than about Contains no more than 0.25%, no more than about 0.2%, no more than about 0.15%, no more than about 0.10%, or no more than about 0.05% by weight, percentages being based on the total weight of the composition. In some embodiments, Compound I-1 or a solvate thereof, or a crystalline form thereof, contains the impurity Compound 6 (including the free base and salts of Compound 6 or solvates thereof, or solid forms thereof). Contains only about 0.40% by weight or less, about 0.35% by weight or less, about 0.3% by weight or less, about 0.25% by weight or less, about 0.2% by weight or less, about 0.15% by weight or less, about 0.10% by weight or less, or about 0.05% by weight or less The percentages are based on the total weight of the composition.
[0205] In some embodiments, Compound I-1 or a solvate thereof, or a crystalline form thereof, has a total area of at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, Present in amounts of 98.5, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 HPLC area %. In some embodiments, Compound I-1 or a solvate thereof, or a crystalline form thereof, reduces any single impurity by about 0.4 or less, about 0.35 or less, or about Contains an HPLC area % of less than or equal to 0.3, less than or equal to about 0.25, less than or equal to about 0.2, less than or equal to about 0.15, less than or equal to about 0.10, or less than or equal to about 0.05. In some embodiments, Compound I-1 or a solvate thereof, or a crystalline form thereof, has a large amount of impurity Compound 6 (the free base and salts of Compound 6 or their solvates) relative to the total area of the HPLC chromatogram. or solid forms thereof) of less than about 0.40, less than about 0.35, less than about 0.3, less than about 0.25, less than about 0.2, less than about 0.15, less than about 0.10, or less than about 0.05. In some embodiments, the HPLC method is the HPLC method described in Example 1.
[0206] The illustrated structure for Compound I-1 is also intended to include all tautomeric forms of Compound I-1. Additionally, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, replacing hydrogen with deuterium or tritium, or 13 C or 14 Compounds having this structure, excluding the replacement of carbon by a C-rich carbon, are within the scope of this invention.
[0207] In certain embodiments, Compound I-1 is a crystalline solid. In other embodiments, Compound I-1 is a crystalline solid that is substantially free of amorphous Compound I-1. As used herein, the term "substantially free of amorphous compound I-1" means that the compound does not contain significant amounts of amorphous compound I-1. In certain embodiments, at least about 95% by weight of crystalline Compound I-1 is present. In yet other embodiments of the invention, at least about 99% by weight of crystalline Compound I-1 is present.
[0208] It has been found that compound I-1 can exist in various solid forms. Exemplary such forms include polymorphs such as those described herein.
[0209] In some embodiments, the solid crystalline form of Compound I-1 is Form A. In some embodiments, Form A of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each about 12.3 2θ, about 24.0 2θ and about 15.6 2θ. In some embodiments, Form A of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each about 12.3 2θ, about 24.0 2θ, about 15.6 2θ, about 12.7 2θ, about 10.4 2θ, about 11.1 2θ and about 15.2 2θ. In some embodiments, Form A of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each about 12.3 2θ, about 24.0 2θ, about 15.6 2θ, about 12.7 2θ, about 10.4 2θ, about 11.1 2θ and about 15.2 2θ. In some embodiments, Form A of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each about 12.3 2θ, about 24.0 2θ, about 15.6 2θ, about 12.7 2θ, about 10.4 2θ, about 11.1 2θ and about 15.2 2θ. In some embodiments, Form A of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each about 12.3 2θ, about 24.0 2θ, about 15.6 2θ, about 12.7 2θ, about 10.4 2θ, about 11.1 2θ and about 15.2 2θ. In some embodiments, Form A of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each about 12.3 2θ, about 24.0 2θ, about 15.6 2θ, about 12.7 2θ, about 10.4 2θ, about 11.1 2θ and about 15.2 2θ. In some embodiments, Form A of Compound I-1 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 1A. In some embodiments, Form A of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 2.1. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 2.1. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 2.1. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 2.1. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 2.1. selected from the group consisting of peaks that are present.
[0210] As used herein, the term "about" in the context of a peak at 2θ degrees refers to a peak at a given 2θ value ±0.2, or a given 2θ value ±0.1, or a given value. It means that you can. For example, a peak at "about 23.8 2θ" means that the peak can be at 23.6 2θ, 23.7 2θ, 23.8 2θ, 23.9 2θ or 24.0 2θ.
[0211] In some embodiments, Form A of Compound I-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 1B. In some embodiments, Form A of Compound I-1 has a thermogravimetric analysis (TGA) pattern that is substantially similar to the thermogravimetric analysis (TGA) pattern illustrated in FIG. 1C. In some embodiments, Form A of Compound I-1 may be characterized by substantial similarity to two or more of these figures at the same time.
[0212] In some embodiments, the solid crystalline form of Compound I-1 is Form B. In some embodiments, Form B of Compound I-I has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 2A. In some embodiments, Form B of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 2.2. selected from the group consisting of peaks that are present. In some embodiments, Form B of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 2.2. selected from the group consisting of peaks that are present. In some embodiments, Form B of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 2.2. selected from the group consisting of peaks that are present. In some embodiments, Form B of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 2.2. selected from the group consisting of peaks that are present. In some embodiments, Form B of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 2.2. selected from the group consisting of peaks that are present.
[0213] In some embodiments, Form B of Compound I-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 2B. In some embodiments, Form B of Compound I-1 has a thermogravimetric analysis (TGA) pattern that is substantially similar to the thermogravimetric analysis (TGA) pattern illustrated in FIG. 2C. In some embodiments, Form B of Compound I-1 may be characterized by substantial similarity to two or more of these figures at the same time.
[0214] In some embodiments, the solid crystalline form of Compound I-1 is Form C. In some embodiments, Form C of Compound I-I has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 3A. In some embodiments, Form C of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 2.3. selected from the group consisting of peaks that are present. In some embodiments, Form C of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 2.3. selected from the group consisting of peaks that are present. In some embodiments, Form C of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 2.3. selected from the group consisting of peaks that are present. In some embodiments, Form C of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 2.3. selected from the group consisting of peaks that are present. In some embodiments, Form C of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 2.3. selected from the group consisting of peaks that are present.
[0215] In some embodiments, Form C of Compound I-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 3B. In some embodiments, Form C of Compound I-1 has a thermogravimetric analysis (TGA) pattern substantially similar to the thermogravimetric analysis (TGA) pattern illustrated in FIG. 3C. In some embodiments, Form C of Compound I-1 may be characterized by substantial similarity to two or more of these figures at the same time.
[0216] In some embodiments, the solid crystalline form of Compound I-1 is Form D. In some embodiments, Form D of Compound I-I has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 4A. In some embodiments, Form D of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 2.4. selected from the group consisting of peaks that are present. In some embodiments, Form D of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 2.4. selected from the group consisting of peaks that are present. In some embodiments, Form D of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 2.4. selected from the group consisting of peaks that are present. In some embodiments, Form D of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 2.4. selected from the group consisting of peaks that are present. In some embodiments, Form D of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 2.4. selected from the group consisting of peaks that are present.
[0217] In some embodiments, Form D of Compound I-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 4B. In some embodiments, Form D of Compound I-1 has a thermogravimetric analysis (TGA) pattern that is substantially similar to the thermogravimetric analysis (TGA) pattern illustrated in FIG. 4C. In some embodiments, Form D of Compound I-1 may be characterized by substantial similarity to two or more of these figures at the same time.
[0218] In some embodiments, the solid crystalline form of Compound I-1 is Form E. In some embodiments, Form E of Compound I-I has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 5A. In some embodiments, Form E of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 2.5. selected from the group consisting of peaks that are present. In some embodiments, Form E of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 2.5. selected from the group consisting of peaks that are present. In some embodiments, Form E of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 2.5. selected from the group consisting of peaks that are present. In some embodiments, Form E of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 2.5. selected from the group consisting of peaks that are present. In some embodiments, Form E of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 2.5. selected from the group consisting of peaks that are present.
[0219] In some embodiments, Form E of Compound I-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 5B. In some embodiments, Form E of Compound I-1 has a thermogravimetric analysis (TGA) pattern that is substantially similar to the thermogravimetric analysis (TGA) pattern illustrated in FIG. 5C. In some embodiments, Form E of Compound I-1 may be characterized by substantial similarity to two or more of these figures at the same time.
[0220] In some embodiments, the solid crystalline form of Compound I-1 is Form F. In some embodiments, Form F of Compound I-I has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 6A. In some embodiments, Form F of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 2.6. selected from the group consisting of peaks that are present. In some embodiments, Form F of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 2.6. selected from the group consisting of peaks that are present. In some embodiments, Form F of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 2.6. selected from the group consisting of peaks that are present. In some embodiments, Form F of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 2.6. selected from the group consisting of peaks that are present. In some embodiments, Form F of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 2.6. selected from the group consisting of peaks that are present.
[0221] In some embodiments, Form F of Compound I-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 6B. In some embodiments, Form F of Compound I-1 has a thermogravimetric analysis (TGA) pattern that is substantially similar to the thermogravimetric analysis (TGA) pattern illustrated in FIG. 6C. In some embodiments, Form F of Compound I-1 may be characterized by substantial similarity to two or more of these figures at the same time.
[0222] In some embodiments, the solid crystalline form of Compound I-1 is Form G. In some embodiments, Form G of Compound I-I has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 7A. In some embodiments, Form G of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 2.7. selected from the group consisting of peaks that are present. In some embodiments, Form G of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 2.7. selected from the group consisting of peaks that are present. In some embodiments, Form G of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 2.7. selected from the group consisting of peaks that are present. In some embodiments, Form G of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 2.7. selected from the group consisting of peaks that are present. In some embodiments, Form G of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 2.7. selected from the group consisting of peaks that are present.
[0223] In some embodiments, Form G of Compound I-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 7B. In some embodiments, Form G of Compound I-1 has a thermogravimetric analysis (TGA) pattern substantially similar to the thermogravimetric analysis (TGA) pattern illustrated in FIG. 7C. In some embodiments, Form G of Compound I-1 may be characterized by substantial similarity to two or more of these figures at the same time.
[0224] In some embodiments, the solid crystalline form of Compound I-1 is Form H. In some embodiments, Form H of Compound I-I has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 8A. In some embodiments, Form H of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 2.8. selected from the group consisting of peaks that are present. In some embodiments, Form H of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 2.8. selected from the group consisting of peaks that are present. In some embodiments, Form H of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 2.8. selected from the group consisting of peaks that are present. In some embodiments, Form H of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 2.8. selected from the group consisting of peaks that are present. In some embodiments, Form H of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 2.8. selected from the group consisting of peaks that are present.
[0225] In some embodiments, Form H of Compound I-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 8B. In some embodiments, Form H of Compound I-1 has a thermogravimetric analysis (TGA) pattern that is substantially similar to the thermogravimetric analysis (TGA) pattern illustrated in FIG. 8C. In some embodiments, Form H of Compound I-1 may be characterized by substantial similarity to two or more of these figures at the same time.
[0226] In some embodiments, the solid crystalline form of Compound I-1 is Form I. In some embodiments, Form I of Compound I-I has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 9A. In some embodiments, Form I of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 2.9. selected from the group consisting of peaks that are present. In some embodiments, Form I of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 2.9. selected from the group consisting of peaks that are present. In some embodiments, Form I of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 2.9. selected from the group consisting of peaks that are present. In some embodiments, Form I of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 2.9. selected from the group consisting of peaks that are present. In some embodiments, Form I of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 2.9. selected from the group consisting of peaks that are present. In some embodiments, Form I of Compound I-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 9B. In some embodiments, Form I of Compound I-1 has a thermogravimetric analysis (TGA) pattern substantially similar to the thermogravimetric analysis (TGA) pattern illustrated in FIG. 9C. In some embodiments, Form I of Compound I-1 may be characterized by substantial similarity in two or more of these figures at the same time.
[0227] In some embodiments, the solid crystalline form of Compound I-1 is Form J. In some embodiments, Form J of Compound I-I has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 10A. In some embodiments, Form J of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 2.10. selected from the group consisting of peaks that are present. In some embodiments, Form J of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 2.10. selected from the group consisting of peaks that are present. In some embodiments, Form J of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 2.10. selected from the group consisting of peaks that are present. In some embodiments, Form J of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 2.10. selected from the group consisting of peaks that are present. In some embodiments, Form J of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 2.10. selected from the group consisting of peaks that are present.
[0228] In some embodiments, Form J of Compound I-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 10B. In some embodiments, Form J of Compound I-1 has a thermogravimetric analysis (TGA) pattern that is substantially similar to the thermogravimetric analysis (TGA) pattern illustrated in FIG. 10C. In some embodiments, Form J of Compound I-1 may be characterized by substantial similarity to two or more of these figures at the same time.
[0229] In some embodiments, the solid crystalline form of Compound I-1 is Form K. In some embodiments, Form K of Compound I-I has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 11A. In some embodiments, Form K of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 2.11. selected from the group consisting of peaks that are present. In some embodiments, Form K of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 2.11. selected from the group consisting of peaks that are present. In some embodiments, Form K of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 2.11. selected from the group consisting of peaks that are present. In some embodiments, Form K of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 2.11. selected from the group consisting of peaks that are present. In some embodiments, Form K of Compound I-1 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 2.11. selected from the group consisting of peaks that are present.
[0230] In some embodiments, Form K of Compound I-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 11B. In some embodiments, Form K of Compound I-1 has a thermogravimetric analysis (TGA) pattern substantially similar to the thermogravimetric analysis (TGA) pattern illustrated in FIG. 11C. In another embodiment, Form K of compound I-1 may be characterized by substantial similarity to two or more of these figures at the same time. Compound I-2
[0231] In another embodiment, the compound of formula (I) is Compound I-2, and Compound I-2 is the free base (or "free form").
[0232] In some embodiments, Compound I-2 is an amorphous solid. In some embodiments, Compound I-2 is a crystalline solid. In some embodiments, Compound I-2 is a mixture of amorphous and crystalline solid forms.
[0233] In some embodiments, the invention provides a form of Compound I-2 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound I-2, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound I-2.
[0234] In some embodiments, Compound I-2 or a solvate thereof, or a crystalline form thereof, is at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, 98.5, 99, 99.1, 99.2, 99.3, Present in amounts of 99.4, 99.5, 99.6, 99.7, 99.8, 99.9% by weight, percentages being relative to the total weight of the composition. In some embodiments, Compound I-2 or a solvate thereof, or a crystalline form thereof, contains no more than about 0.40%, no more than about 0.35%, no more than about 0.3%, no more than about 0.3%, by weight or less of any single impurity. Contains no more than 0.25%, no more than about 0.2%, no more than about 0.15%, no more than about 0.10%, or no more than about 0.05% by weight, percentages being based on the total weight of the composition. In some embodiments, Compound I-2 or a solvate thereof, or a crystalline form thereof, contains the impurity Compound 6 (including the free base and salts of Compound 6 or solvates thereof, or solid forms thereof). Contains only about 0.40% by weight or less, about 0.35% by weight or less, about 0.3% by weight or less, about 0.25% by weight or less, about 0.2% by weight or less, about 0.15% by weight or less, about 0.10% by weight or less, or about 0.05% by weight or less The percentages are based on the total weight of the composition.
[0235] In some embodiments, Compound I-2 or a solvate thereof, or a crystalline form thereof, has a total area of at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, Present in amounts of 98.5, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 HPLC area %. In some embodiments, Compound I-2 or a solvate thereof, or a crystalline form thereof, contains no more than about 0.4, no more than about 0.35, no more than about Contains an HPLC area % of less than or equal to 0.3, less than or equal to about 0.25, less than or equal to about 0.2, less than or equal to about 0.15, less than or equal to about 0.10, or less than or equal to about 0.05. In some embodiments, Compound I-2 or a solvate thereof, or a crystalline form thereof, has a large amount of impurity Compound 6 (the free base and salts of Compound 6 or their solvates) relative to the total area of the HPLC chromatogram. or solid forms thereof) of less than about 0.40, less than about 0.35, less than about 0.3, less than about 0.25, less than about 0.2, less than about 0.15, less than about 0.10, or less than about 0.05. In some embodiments, the HPLC method is the HPLC method described in Example 1.
[0236] The illustrated structure for Compound I-2 is also intended to include all tautomeric forms of Compound I-2. Additionally, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, replacing hydrogen with deuterium or tritium, or 13 C or14 Compounds having this structure, excluding the replacement of carbon by a C-rich carbon, are within the scope of this invention.
[0237] In other embodiments, Compound I-2 is a crystalline solid that is substantially free of amorphous Compound I-2. As used herein, the term "substantially free of amorphous compound I-2" means that the compound does not contain significant amounts of amorphous compound I-2. In certain embodiments, at least about 95% by weight crystalline Compound I-2 is present. In certain embodiments, at least about 99% by weight crystalline Compound I-2 is present.
[0238] It has been found that compound I-2 can exist in various solid forms. Exemplary such forms include polymorphs such as those described herein.
[0239] In certain embodiments, the solid crystalline form of Compound I-2 is Form A. In some embodiments, Form A of Compound I-2 has an X-ray diffraction pattern substantially similar to Pattern 1 illustrated in FIG. 13A.
[0240] In certain embodiments, the solid crystalline form of Compound I-2 is Form B. In some embodiments, Form B of Compound I-2 has an X-ray diffraction pattern substantially similar to Pattern 2 illustrated in FIG. 13A. In certain embodiments, Form B of Compound I-2 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 13B. In certain embodiments, Form B of Compound I-2 has a thermogravimetric analysis (TGA) pattern substantially similar to the thermogravimetric analysis (TGA) pattern illustrated in FIG. 13D. In certain embodiments, Form B of Compound I-2 is subjected to the X It has an X-ray diffraction pattern that is substantially similar to a ray diffraction pattern. In certain embodiments, Form B of Compound I-2 may be characterized by substantial similarity to two or more of these figures at the same time.
[0241] In certain embodiments, the solid crystalline form of Compound I-2 is Form C. In some embodiments, Form C of Compound I-2 has an X-ray diffraction pattern substantially similar to Pattern 3 illustrated in FIG. 13A.
[0242] In certain embodiments, the solid crystalline form of Compound I-2 is Form D. In some embodiments, Form D of Compound I-2 has an X-ray diffraction pattern substantially similar to pattern 4 illustrated in FIG. 13A.
[0243] In certain embodiments, the solid crystalline form of Compound I-2 is Form E. In some embodiments, Form E of Compound I-2 has an X-ray diffraction pattern substantially similar to Pattern 5 illustrated in FIG. 13A. Compound I-3 [ka]
[0244] In another embodiment, the compound of formula (I) is the hydrobromide salt, Compound I-3. In some embodiments, Compound I-3 is a monohydrobromide salt. In some embodiments, Compound I-3 is a dihydrobromide salt. In some embodiments, Compound I-3 is a trihydrobromide salt.
[0245] In some embodiments, Compound I-3 is an amorphous solid. In some embodiments, Compound I-3 is a crystalline solid. In some embodiments, Compound I-3 is a mixture of amorphous and crystalline solid forms.
[0246] In some embodiments, the invention provides a form of Compound I-3 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound I-3, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound I-3.
[0247] In some embodiments, Compound I-3 or a solvate thereof, or a crystalline form thereof, is at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, 98.5, 99, 99.1, 99.2, 99.3, Present in amounts of 99.4, 99.5, 99.6, 99.7, 99.8, 99.9% by weight, percentages being relative to the total weight of the composition. In some embodiments, Compound I-3 or a solvate thereof, or a crystalline form thereof, contains no more than about 0.40 wt.%, no more than about 0.35 wt.%, no more than about 0.3 wt.%, no more than about Contains no more than 0.25%, no more than about 0.2%, no more than about 0.15%, no more than about 0.10%, or no more than about 0.05% by weight, percentages being based on the total weight of the composition. In some embodiments, Compound I-3 or a solvate thereof, or a crystalline form thereof, contains the impurity Compound 6 (including the free base and salts of Compound 6 or solvates thereof, or solid forms thereof). Contains only about 0.40% by weight or less, about 0.35% by weight or less, about 0.3% by weight or less, about 0.25% by weight or less, about 0.2% by weight or less, about 0.15% by weight or less, about 0.10% by weight or less, or about 0.05% by weight or less The percentages are based on the total weight of the composition.
[0248] In some embodiments, Compound I-3 or a solvate thereof, or a crystalline form thereof, has a total area of at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, Present in amounts of 98.5, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 HPLC area %. In some embodiments, Compound I-3 or a solvate thereof, or a crystalline form thereof, contains no more than about 0.4, no more than about 0.35, no more than about 0.4, no more than about 0.35, no more than about Contains an HPLC area % of less than or equal to 0.3, less than or equal to about 0.25, less than or equal to about 0.2, less than or equal to about 0.15, less than or equal to about 0.10, or less than or equal to about 0.05. In some embodiments, Compound I-3 or a solvate thereof, or a crystalline form thereof, has a large amount of impurity Compound 6 (the free base and salts of Compound 6 or their solvates) relative to the total area of the HPLC chromatogram. or solid forms thereof) of less than about 0.40, less than about 0.35, less than about 0.3, less than about 0.25, less than about 0.2, less than about 0.15, less than about 0.10, or less than about 0.05. In some embodiments, the HPLC method is the HPLC method described in Example 1.
[0249] The illustrated structure for Compound I-3 is also intended to include all tautomeric forms of Compound I-3. Additionally, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, replacing hydrogen with deuterium or tritium, or 13 C or 14 Compounds having this structure, excluding the replacement of carbon by a C-rich carbon, are within the scope of this invention.
[0250] In other embodiments, Compound I-3 is a crystalline solid that is substantially free of amorphous Compound I-3. As used herein, the term "substantially free of amorphous compound I-3" means that the compound does not contain significant amounts of amorphous compound I-3. In certain embodiments, at least about 95% by weight of crystalline Compound I-3 is present. In certain embodiments, at least about 99% by weight crystalline Compound I-3 is present.
[0251] In certain embodiments, the solid crystalline form of Compound I-3 has an X-ray diffraction pattern that is substantially similar to any one of the patterns illustrated in FIG. 14A. In certain embodiments, the solid crystalline form of Compound I-3 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 14C. In certain embodiments, the solid crystalline form of Compound I-3 can be characterized by substantial similarity to two or more of these figures at the same time. Compound I-4 [ka]
[0252] In another embodiment, the compound of formula (I) is Compound I-4, which is a sulfate salt (or sulfate ester).
[0253] In some embodiments, Compound I-4 is an amorphous solid. In some embodiments, Compound I-4 is a crystalline solid. In some embodiments, Compound I-4 is a mixture of amorphous and crystalline solid forms.
[0254] In some embodiments, the invention provides a form of Compound I-4 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound I-4, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound I-4.
[0255] In some embodiments, Compound I-4 or a solvate thereof, or a crystalline form thereof, is at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, 98.5, 99, 99.1, 99.2, 99.3, Present in amounts of 99.4, 99.5, 99.6, 99.7, 99.8, 99.9% by weight, percentages being relative to the total weight of the composition. In some embodiments, Compound I-4 or a solvate thereof, or a crystalline form thereof, contains no more than about 0.40%, no more than about 0.35%, no more than about 0.3%, no more than about 0.3%, no more than about 0.3%, by weight or less of any single impurity. Contains no more than 0.25%, no more than about 0.2%, no more than about 0.15%, no more than about 0.10%, or no more than about 0.05% by weight, percentages being based on the total weight of the composition. In some embodiments, Compound I-4 or a solvate thereof, or a crystalline form thereof, contains the impurity Compound 6 (including the free base and salts of Compound 6 or solvates thereof, or solid forms thereof). Contains only about 0.40% by weight or less, about 0.35% by weight or less, about 0.3% by weight or less, about 0.25% by weight or less, about 0.2% by weight or less, about 0.15% by weight or less, about 0.10% by weight or less, or about 0.05% by weight or less The percentages are based on the total weight of the composition.
[0256] In some embodiments, Compound I-4 or a solvate thereof, or a crystalline form thereof, has a total area of at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, Present in amounts of 98.5, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 HPLC area %. In some embodiments, Compound I-4 or a solvate thereof, or a crystalline form thereof, reduces any single impurity by about 0.4 or less, about 0.35 or less, or about Contains an HPLC area % of less than or equal to 0.3, less than or equal to about 0.25, less than or equal to about 0.2, less than or equal to about 0.15, less than or equal to about 0.10, or less than or equal to about 0.05. In some embodiments, Compound I-4 or a solvate thereof, or a crystalline form thereof, has a large amount of impurity Compound 6 (free base and salts of Compound 6 or solvates thereof) relative to the total area of the HPLC chromatogram. or solid forms thereof) of less than about 0.40, less than about 0.35, less than about 0.3, less than about 0.25, less than about 0.2, less than about 0.15, less than about 0.10, or less than about 0.05. In some embodiments, the HPLC method is the HPLC method described in Example 1.
[0257] The illustrated structure for Compound I-4 is also intended to include all tautomeric forms of Compound I-4. Additionally, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, replacing hydrogen with deuterium or tritium, or 13 C or 14 Compounds having this structure, excluding the replacement of carbon by a C-rich carbon, are within the scope of this invention.
[0258] In other embodiments, Compound I-4 is a crystalline solid that is substantially free of amorphous Compound I-4. As used herein, the term "substantially free of amorphous compound I-4" means that the compound does not contain significant amounts of amorphous compound I-4. In certain embodiments, at least about 95% by weight crystalline Compound I-4 is present. In certain embodiments, at least about 99% by weight crystalline Compound I-4 is present.
[0259] In certain embodiments, the solid crystalline form of Compound I-4 has an X-ray diffraction pattern that is substantially similar to any one of the patterns illustrated in FIG. 15A. In certain embodiments, the solid crystalline form of Compound I-4 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 15C. In certain embodiments, the solid crystalline form of Compound I-4 can be characterized by substantial similarity to two of these figures at the same time. Compound I-5 [ka]
[0260] In another embodiment, the compound of formula (I) is p-toluenesulfonate, Compound I-5.
[0261] In some embodiments, Compound I-5 is an amorphous solid. In some embodiments, Compound I-5 is a crystalline solid. In some embodiments, Compound I-5 is a mixture of amorphous and crystalline solid forms.
[0262] In some embodiments, the invention provides a form of Compound I-5 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound I-5, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound I-5.
[0263] In some embodiments, Compound I-5 or a solvate thereof, or a crystalline form thereof, is at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, 98.5, 99, 99.1, 99.2, 99.3, Present in amounts of 99.4, 99.5, 99.6, 99.7, 99.8, 99.9% by weight, percentages being relative to the total weight of the composition. In some embodiments, Compound I-5 or a solvate thereof, or a crystalline form thereof, contains no more than about 0.40 wt.%, no more than about 0.35 wt.%, no more than about 0.3 wt.%, no more than about Contains no more than 0.25%, no more than about 0.2%, no more than about 0.15%, no more than about 0.10%, or no more than about 0.05% by weight, percentages being based on the total weight of the composition. In some embodiments, Compound I-5 or a solvate thereof, or a crystalline form thereof, contains the impurity Compound 6 (including the free base and salts of Compound 6 or solvates thereof, or solid forms thereof). Contains only about 0.40% by weight or less, about 0.35% by weight or less, about 0.3% by weight or less, about 0.25% by weight or less, about 0.2% by weight or less, about 0.15% by weight or less, about 0.10% by weight or less, or about 0.05% by weight or less The percentages are based on the total weight of the composition.
[0264] In some embodiments, Compound I-5 or a solvate thereof, or a crystalline form thereof, has a total area of at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, Present in amounts of 98.5, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 HPLC area %. In some embodiments, Compound I-5 or a solvate thereof, or a crystalline form thereof, contains no more than about 0.4, no more than about 0.35, no more than about Contains an HPLC area % of less than or equal to 0.3, less than or equal to about 0.25, less than or equal to about 0.2, less than or equal to about 0.15, less than or equal to about 0.10, or less than or equal to about 0.05. In some embodiments, Compound I-5 or a solvate thereof, or a crystalline form thereof, has a large amount of impurity Compound 6 (the free base and salts of Compound 6 or their solvates) relative to the total area of the HPLC chromatogram. or solid forms thereof) of less than about 0.40, less than about 0.35, less than about 0.3, less than about 0.25, less than about 0.2, less than about 0.15, less than about 0.10, or less than about 0.05. In some embodiments, the HPLC method is the HPLC method described in Example 1.
[0265] The illustrated structure for Compound I-5 is also intended to include all tautomeric forms of Compound I-5. Additionally, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, replacing hydrogen with deuterium or tritium, or 13 C or 14 Compounds having this structure, excluding the replacement of carbon by a C-rich carbon, are within the scope of this invention.
[0266] In other embodiments, Compound I-5 is a crystalline solid that is substantially free of amorphous Compound I-5. As used herein, the term "substantially free of amorphous compound I-5" means that the compound does not contain significant amounts of amorphous compound I-5. In certain embodiments, at least about 95% by weight crystalline Compound I-5 is present. In certain embodiments, at least about 99% by weight crystalline Compound I-5 is present.
[0267] In certain embodiments, the solid crystalline form of Compound I-5 has an X-ray diffraction pattern substantially similar to any one of the patterns illustrated in FIG. 16A. In certain embodiments, the solid crystalline form of Compound I-5 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 16C. In certain embodiments, the solid crystalline form of Compound I-5 can be characterized by substantial similarity to two or more of these figures at the same time. Compound I-6 [ka]
[0268] In another embodiment, the compound of formula (I) is compound I-6, which is a methanesulfonate salt.
[0269] In some embodiments, Compound I-6 is an amorphous solid. In some embodiments, Compound I-6 is a crystalline solid. In some embodiments, Compound I-6 is a mixture of amorphous and crystalline solid forms.
[0270] In some embodiments, the invention provides a form of Compound I-6 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound I-6, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound I-6.
[0271] In some embodiments, Compound I-6 or a solvate thereof, or a crystalline form thereof, is at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, 98.5, 99, 99.1, 99.2, 99.3, Present in amounts of 99.4, 99.5, 99.6, 99.7, 99.8, 99.9% by weight, percentages being relative to the total weight of the composition. In some embodiments, Compound I-6 or a solvate thereof, or a crystalline form thereof, contains no more than about 0.40 wt.%, no more than about 0.35 wt.%, no more than about 0.3 wt.%, no more than about Contains no more than 0.25%, no more than about 0.2%, no more than about 0.15%, no more than about 0.10%, or no more than about 0.05% by weight, percentages being based on the total weight of the composition. In some embodiments, Compound I-6 or a solvate thereof, or a crystalline form thereof, contains impurity Compound 6 (including the free base and salts of Compound 6 or solvates thereof, or solid forms thereof). Contains only about 0.40% by weight or less, about 0.35% by weight or less, about 0.3% by weight or less, about 0.25% by weight or less, about 0.2% by weight or less, about 0.15% by weight or less, about 0.10% by weight or less, or about 0.05% by weight or less The percentages are based on the total weight of the composition.
[0272] In some embodiments, Compound I-6 or a solvate thereof, or a crystalline form thereof, has a total area of at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, Present in amounts of 98.5, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 HPLC area %. In some embodiments, Compound I-6 or a solvate thereof, or a crystalline form thereof, reduces any single impurity by about 0.4 or less, about 0.35 or less, or about Contains an HPLC area % of less than or equal to 0.3, less than or equal to about 0.25, less than or equal to about 0.2, less than or equal to about 0.15, less than or equal to about 0.10, or less than or equal to about 0.05. In some embodiments, Compound I-6 or a solvate thereof, or a crystalline form thereof, has a large amount of impurity Compound 6 (the free base and salts of Compound 6 or their solvates) relative to the total area of the HPLC chromatogram. or solid forms thereof) of less than about 0.40, less than about 0.35, less than about 0.3, less than about 0.25, less than about 0.2, less than about 0.15, less than about 0.10, or less than about 0.05. In some embodiments, the HPLC method is the HPLC method described in Example 1.
[0273] The illustrated structure for Compound I-6 is also intended to include all tautomeric forms of Compound I-6. Additionally, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, replacing hydrogen with deuterium or tritium, or 13 C or 14 Compounds having this structure, excluding the replacement of carbon by a C-rich carbon, are within the scope of this invention.
[0274] In other embodiments, Compound I-6 is a crystalline solid that is substantially free of amorphous Compound I-6. As used herein, the term "substantially free of amorphous compound I-6" means that the compound does not contain significant amounts of amorphous compound I-6. In certain embodiments, at least about 95% by weight crystalline Compound I-6 is present. In certain embodiments, at least about 99% by weight crystalline Compound I-6 is present.
[0275] In certain embodiments, the solid crystalline form of Compound I-6 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 17A. In certain embodiments, the solid crystalline form of Compound I-6 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 17C. In certain embodiments, the solid crystalline form of Compound I-6 can be characterized by substantial similarity to two of these figures at the same time. Compound I-7 [ka]
[0276] In another embodiment, the compound of formula (I) is compound I-7, which is a benzenesulfonate salt.
[0277] In some embodiments, Compound I-7 is an amorphous solid. In some embodiments, Compound I-7 is a crystalline solid. In some embodiments, Compound I-7 is a mixture of amorphous and crystalline solid forms.
[0278] In some embodiments, the invention provides a form of Compound I-7 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound I-7, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound I-7.
[0279] In some embodiments, Compound I-7 or a solvate thereof, or a crystalline form thereof, is at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, 98.5, 99, 99.1, 99.2, 99.3, Present in amounts of 99.4, 99.5, 99.6, 99.7, 99.8, 99.9% by weight, percentages being relative to the total weight of the composition. In some embodiments, Compound I-7 or a solvate thereof, or a crystalline form thereof, contains no more than about 0.40 wt.%, no more than about 0.35 wt.%, no more than about 0.3 wt.%, no more than about Contains no more than 0.25%, no more than about 0.2%, no more than about 0.15%, no more than about 0.10%, or no more than about 0.05% by weight, percentages being based on the total weight of the composition. In some embodiments, Compound I-7 or a solvate thereof, or a crystalline form thereof, contains the impurity Compound 6 (including the free base and salts of Compound 6 or solvates thereof, or solid forms thereof). Contains only about 0.40% by weight or less, about 0.35% by weight or less, about 0.3% by weight or less, about 0.25% by weight or less, about 0.2% by weight or less, about 0.15% by weight or less, about 0.10% by weight or less, or about 0.05% by weight or less The percentages are based on the total weight of the composition.
[0280] In some embodiments, Compound I-7 or a solvate thereof, or a crystalline form thereof, has a total area of at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, Present in amounts of 98.5, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 HPLC area %. In some embodiments, Compound I-7 or a solvate thereof, or a crystalline form thereof, reduces any single impurity by about 0.4 or less, about 0.35 or less, or about Contains an HPLC area % of less than or equal to 0.3, less than or equal to about 0.25, less than or equal to about 0.2, less than or equal to about 0.15, less than or equal to about 0.10, or less than or equal to about 0.05. In some embodiments, Compound I-7 or a solvate thereof, or a crystalline form thereof, has a large amount of impurity Compound 6 (the free base and salts of Compound 6 or their solvates) relative to the total area of the HPLC chromatogram. or solid forms thereof) of less than about 0.40, less than about 0.35, less than about 0.3, less than about 0.25, less than about 0.2, less than about 0.15, less than about 0.10, or less than about 0.05. In some embodiments, the HPLC method is the HPLC method described in Example 1.
[0281] The illustrated structure for Compound I-7 is also intended to include all tautomeric forms of Compound I-7. Additionally, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, replacing hydrogen with deuterium or tritium, or 13 C or 14 Compounds having this structure, excluding the replacement of carbon by a C-rich carbon, are within the scope of this invention.
[0282] In other embodiments, Compound I-7 is a crystalline solid that is substantially free of amorphous Compound I-7. As used herein, the term "substantially free of amorphous compound I-7" means that the compound does not contain significant amounts of amorphous compound I-7. In certain embodiments, at least about 95% by weight crystalline Compound I-7 is present. In certain embodiments, at least about 99% by weight crystalline Compound I-7 is present.
[0283] In certain embodiments, the solid crystalline form of Compound I-7 has an X-ray diffraction pattern that is substantially similar to any one of the patterns illustrated in FIG. 18A. In certain embodiments, the solid crystalline form of Compound I-7 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 18C. In certain embodiments, the solid crystalline form of Compound I-7 can be characterized by substantial similarity to two of these figures at the same time. Compound I-8 [ka]
[0284] In another embodiment, the compound of formula (I) is the maleate salt compound I-8.
[0285] In some embodiments, Compound I-8 is an amorphous solid. In some embodiments, Compound I-8 is a crystalline solid. In some embodiments, Compound I-8 is a mixture of amorphous and crystalline solid forms.
[0286] In some embodiments, the invention provides a form of Compound I-8 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound I-8, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound I-8.
[0287] In some embodiments, Compound I-8 or a solvate thereof, or a crystalline form thereof, is at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, 98.5, 99, 99.1, 99.2, 99.3, Present in amounts of 99.4, 99.5, 99.6, 99.7, 99.8, 99.9% by weight, percentages being relative to the total weight of the composition. In some embodiments, Compound I-8 or a solvate thereof, or a crystalline form thereof, contains no more than about 0.40 wt.%, no more than about 0.35 wt.%, no more than about 0.3 wt.%, no more than about Contains no more than 0.25%, no more than about 0.2%, no more than about 0.15%, no more than about 0.10%, or no more than about 0.05% by weight, percentages being based on the total weight of the composition. In some embodiments, Compound I-8 or a solvate thereof, or a crystalline form thereof, contains the impurity Compound 6 (including the free base and salts of Compound 6 or a solvate thereof, or a solid form thereof). Contains only about 0.40% by weight or less, about 0.35% by weight or less, about 0.3% by weight or less, about 0.25% by weight or less, about 0.2% by weight or less, about 0.15% by weight or less, about 0.10% by weight or less, or about 0.05% by weight or less The percentages are based on the total weight of the composition.
[0288] In some embodiments, Compound I-8 or a solvate thereof, or a crystalline form thereof, has a total area of at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, Present in amounts of 98.5, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 HPLC area %. In some embodiments, Compound I-8 or a solvate thereof, or a crystalline form thereof, reduces any single impurity by about 0.4 or less, about 0.35 or less, or about Contains an HPLC area % of less than or equal to 0.3, less than or equal to about 0.25, less than or equal to about 0.2, less than or equal to about 0.15, less than or equal to about 0.10, or less than or equal to about 0.05. In some embodiments, Compound I-8 or a solvate thereof, or a crystalline form thereof, has a large amount of impurity Compound 6 (the free base and salts of Compound 6 or their solvates) relative to the total area of the HPLC chromatogram. or solid forms thereof) of less than about 0.40, less than about 0.35, less than about 0.3, less than about 0.25, less than about 0.2, less than about 0.15, less than about 0.10, or less than about 0.05. In some embodiments, the HPLC method is the HPLC method described in Example 1.
[0289] The illustrated structure for Compound I-8 is also intended to include all tautomeric forms of Compound I-8. Additionally, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, replacing hydrogen with deuterium or tritium, or 13 C or 14 Compounds having this structure, excluding the replacement of carbon by a C-rich carbon, are within the scope of this invention.
[0290] In other embodiments, Compound I-8 is a crystalline solid that is substantially free of amorphous Compound I-8. As used herein, the term "substantially free of amorphous compound I-8" means that the compound does not contain significant amounts of amorphous compound I-8. In certain embodiments, at least about 95% by weight crystalline Compound I-8 is present. In certain embodiments, at least about 99% by weight crystalline Compound I-8 is present.
[0291] In certain embodiments, the solid crystalline form of Compound I-8 has an X-ray diffraction pattern that is substantially similar to any one of the patterns illustrated in FIG. 19A. In certain embodiments, the solid crystalline form of Compound I-8 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 19C. In certain embodiments, the solid crystalline form of Compound I-8 can be characterized by substantial similarity to two of these figures at the same time. Compound of formula (II)
[0292] In one embodiment, a compound of formula (II) [ka] or a solvate thereof, provided herein: p is 1, 2, 3, 4, 5, 6, 7, 8 or 9; q is 0, 0.5, 1, 1.5, 2, 2.5 or 3; X is hydrochloric acid, hydrobromic acid, p-toluenesulfonic acid, methanesulfonic acid, benzenesulfonic acid or fumaric acid).
[0293] The acid moiety shown as “X” and (R)-N-(4-(4-amino-7-methyl-5-(4-(pyrrolidine-1-carbonyl)cyclohex-1-en-1-yl) )-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-methylphenyl)methacrylamide will be recognized by those skilled in the art to ionicly bond to form a compound of formula (II). Good morning. It will also be appreciated that if q is 0, then X is absent, indicating that the compound of formula (II) is present as a "free base", ie, in "free form".
[0294] It is contemplated that compounds of formula (II) can exist in a variety of physical forms. For example, the compound of formula (II) may be in solution, suspension or in solid form. In certain embodiments, the compound of formula (II) is in solid form. When the compound of formula (II) is in solid form, said compound may be amorphous, crystalline or a mixture thereof. Exemplary solid forms are described in more detail below.
[0295] In some embodiments, the compound of formula (II) may be in a hydrate form. In some embodiments, the compound of formula (II) may be in a hemihydrate form.
[0296] In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4. In some embodiments, p is 5. In some embodiments, p is 6. In some embodiments, p is 7. In some embodiments, p is 8. In some embodiments, p is 9.
[0297] In some embodiments, q is 0. In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 3. In some embodiments, q is 0.5. In some embodiments, q is 1.5. In some embodiments, q is 2.5.
[0298] In some embodiments, X is hydrochloric acid. In some embodiments, X is hydrobromic acid. In some embodiments, X is p-toluenesulfonic acid. In some embodiments, X is methanesulfonic acid. In some embodiments, X is benzenesulfonic acid. In some embodiments, X is fumaric acid.
[0299] In some embodiments, the invention provides a form of the compound of formula (II) that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of the compound of formula (II), residual solvents, or any other impurities that may result from the preparation and / or isolation of the compound of formula (II).
[0300] In some embodiments, the compound of formula (II) or a solvate thereof, or a crystalline form thereof, is at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, 98.5, 99, 99.1, 99.2, Present in amounts of 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9% by weight, percentages being relative to the total weight of the composition. In some embodiments, the compound of formula (II) or a solvate thereof, or a crystalline form thereof, contains no more than about 0.40%, no more than about 0.35%, no more than about 0.3% by weight of any single impurity. , no more than about 0.25%, no more than about 0.2%, no more than about 0.15%, no more than about 0.10%, or no more than about 0.05% by weight, percentages being based on the total weight of the composition.
[0301] In some embodiments, the compound of formula (II) or a solvate thereof, or a crystalline form thereof, has a total area of at least about 95, 95.5, 96, 96.5, 97, 97.5, Present in amounts of 98.0, 98.5, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 HPLC area %. In some embodiments, the compound of formula (II) or a solvate thereof, or a crystalline form thereof, contains no more than about 0.4, no more than about 0.35 of any single impurity, based on the total area of the HPLC chromatogram. , less than or equal to about 0.3, less than or equal to about 0.25, less than or equal to about 0.2, less than or equal to about 0.15, less than or equal to about 0.10, or less than or equal to about 0.05. In some embodiments, the HPLC method is the HPLC method described in Example 1.
[0302] The structures depicted for compounds of formula (II) are also intended to include all tautomeric forms. Additionally, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, replacing hydrogen with deuterium or tritium, or 13 C or 14 Compounds having this structure, excluding the replacement of carbon by a C-rich carbon, are within the scope of this invention.
[0303] In some embodiments, the compound of formula (II) is Compound II-1, and Compound II-1 is the free base (or "free form"). In some embodiments, Compound II-1 is an amorphous solid. In some embodiments, Compound II-1 is a crystalline solid. In some embodiments, Compound II-1 is a mixture of amorphous and crystalline solid forms.
[0304] In some embodiments, the invention provides a form of Compound II-1 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound II-1, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound II-1. In certain embodiments, at least about 95% by weight Compound II-1 is present. In certain embodiments, at least about 99% by weight Compound II-1 is present.
[0305] In other embodiments, Compound II-1 is a crystalline solid that is substantially free of amorphous Compound II-1. As used herein, the term "substantially free of amorphous compound II-1" means that the compound does not contain significant amounts of amorphous compound II-1. In certain embodiments, at least about 95% by weight of crystalline Compound II-1 is present. In certain embodiments, at least about 99% by weight of crystalline Compound II-1 is present.
[0306] It has been found that compound II-1 can exist in various solid forms. Exemplary such forms include polymorphs such as those described herein.
[0307] In some embodiments, the solid crystalline form of Compound II-1 is Form A. In certain embodiments, Form A of Compound II-1 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 24A. In some embodiments, Form A of Compound II-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 8. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-1 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 8. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-1 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 8. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-1 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 8. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-1 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 8. selected from the group consisting of peaks that are present.
[0308] In certain embodiments, Form A of Compound II-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 24C. In certain embodiments, Form A of Compound II-1 has a thermogravimetric analysis (TGA) pattern substantially similar to the thermogravimetric analysis (TGA) pattern illustrated in FIG. 24D. In certain embodiments, Form A of Compound II-1 can be characterized by substantial similarity to two or more of these figures at the same time.
[0309] In some embodiments, the solid crystalline form of Compound II-1 is Form B. In certain embodiments, Form B of Compound II-1 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 25A. In some embodiments, Form B of Compound II-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 9. selected from the group consisting of peaks that are present. In some embodiments, Form B of Compound II-1 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 9. selected from the group consisting of peaks that are present. In some embodiments, Form B of Compound II-1 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 9. selected from the group consisting of peaks that are present. In some embodiments, Form B of Compound II-1 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 9. selected from the group consisting of peaks that are present. In some embodiments, Form B of Compound II-1 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 9. selected from the group consisting of peaks that are present.
[0310] In certain embodiments, Form B of Compound II-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 25C. In certain embodiments, Form B of Compound II-1 has a thermogravimetric analysis (TGA) pattern that is substantially similar to the thermogravimetric analysis (TGA) pattern illustrated in FIG. 25D. In certain embodiments, Form B of Compound II-1 may be characterized by substantial similarity to two or more of these figures at the same time.
[0311] In another embodiment, the compound of formula (II) is Compound II-2, and Compound II-2 is the hydrochloride salt. In some embodiments, Compound II-2 is the monohydrochloride salt. In some embodiments, Compound II-2 is the dihydrochloride salt. In some embodiments, Compound II-2 is the trihydrochloride salt.
[0312] In some embodiments, Compound II-2 is an amorphous solid. In some embodiments, Compound II-2 is a crystalline solid. In some embodiments, Compound II-2 is a mixture of amorphous and crystalline solid forms.
[0313] In some embodiments, the invention provides a form of Compound II-2 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound II-2, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound II-2. In certain embodiments, at least about 95% by weight Compound II-2 is present. In certain embodiments, at least about 99% by weight Compound II-2 is present.
[0314] In certain embodiments, Compound II-2 is a crystalline solid. In other embodiments, Compound II-2 is a crystalline solid that is substantially free of amorphous Compound II-2. As used herein, the term "substantially free of amorphous compound II-2" means that the compound does not contain significant amounts of amorphous compound II-2. In certain embodiments, at least about 95% by weight of crystalline Compound II-2 is present. In yet other embodiments of the invention, at least about 99% by weight of crystalline Compound II-2 is present.
[0315] In some embodiments, the solid crystalline form of Compound II-2 is Form A. In some embodiments, Form A of Compound II-2 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 26A. In some embodiments, Form A of Compound II-2 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 14. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-2 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 14. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-2 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 14. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-2 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 14. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-2 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 14. selected from the group consisting of peaks that are present.
[0316] In some embodiments, Form A of Compound II-2 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 26C. In some embodiments, Form A of Compound II-2 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 26C. In some embodiments, Form A of Compound II-2 may be characterized by substantial similarity to two or more of these figures at the same time.
[0317] In another embodiment, the compound of formula (II) is Compound II-3, and Compound II-3 is the hydrobromide salt. In some embodiments, Compound II-3 is a monohydrobromide salt. In some embodiments, Compound II-3 is a dihydrobromide salt. In some embodiments, Compound II-3 is a trihydrobromide salt.
[0318] In some embodiments, Compound II-3 is an amorphous solid. In some embodiments, Compound II-3 is a crystalline solid. In some embodiments, Compound II-3 is a mixture of amorphous and crystalline solid forms.
[0319] In some embodiments, the invention provides a form of Compound II-3 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound II-3, residual solvent, or any other impurities that may result from the preparation and / or isolation of Compound II-3. In certain embodiments, at least about 95% by weight Compound II-3 is present. In certain embodiments, at least about 99% by weight Compound II-3 is present.
[0320] In certain embodiments, Compound II-3 is a crystalline solid. In other embodiments, Compound II-3 is a crystalline solid that is substantially free of amorphous Compound II-3. As used herein, the term "substantially free of amorphous compound II-3" means that the compound does not contain significant amounts of amorphous compound II-3. In certain embodiments, at least about 95% by weight of crystalline Compound II-3 is present. In yet other embodiments of the invention, at least about 99% by weight of crystalline Compound II-3 is present.
[0321] In some embodiments, the solid crystalline form of Compound II-3 is Form A. In some embodiments, Form A of Compound II-3 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern of Figure 27A. In some embodiments, Form A of Compound II-3 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 15. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-3 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 15. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-3 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 15. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-3 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 15. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-3 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 15. selected from the group consisting of peaks that are present.
[0322] In some embodiments, Form A of Compound II-3 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 27C. In some embodiments, Form A of Compound II-3 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in Figure 27C. In some embodiments, Form A of Compound II-3 may be characterized by substantial similarity to two or more of these figures at the same time.
[0323] In another embodiment, the compound of formula (II) is Compound II-4, and Compound II-4 is p-toluenesulfonate.
[0324] In some embodiments, Compound II-4 is an amorphous solid. In some embodiments, Compound II-4 is a crystalline solid. In some embodiments, Compound II-4 is a mixture of amorphous and crystalline solid forms.
[0325] In some embodiments, the invention provides a form of Compound II-4 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound II-4, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound II-4. In certain embodiments, at least about 95% by weight Compound II-4 is present. In certain embodiments, at least about 99% by weight Compound II-4 is present.
[0326] In certain embodiments, Compound II-4 is a crystalline solid. In other embodiments, Compound II-4 is a crystalline solid that is substantially free of amorphous Compound II-4. As used herein, the term "substantially free of amorphous compound II-4" means that the compound does not contain significant amounts of amorphous compound II-4. In certain embodiments, at least about 95% by weight of crystalline Compound II-4 is present. In yet other embodiments of the invention, at least about 99% by weight of crystalline Compound II-4 is present.
[0327] In some embodiments, the solid crystalline form of Compound II-4 is Form A. In some embodiments, Form A of Compound II-4 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern of Figure 28A. In some embodiments, Form A of Compound II-4 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 16. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-4 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 16. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-4 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 16. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-4 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 16. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-4 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 16. selected from the group consisting of peaks that are present.
[0328] In some embodiments, Form A of Compound II-4 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 28C. In some embodiments, Form A of Compound II-4 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 28C. In some embodiments, Form A of Compound II-4 may be characterized by substantial similarity to two or more of these figures at the same time.
[0329] In another embodiment, the compound of formula (II) is Compound II-5, and Compound II-5 is a methanesulfonate salt.
[0330] In some embodiments, Compound II-5 is an amorphous solid. In some embodiments, Compound II-5 is a crystalline solid. In some embodiments, Compound II-5 is a mixture of amorphous and crystalline solid forms.
[0331] In some embodiments, the invention provides a form of Compound II-5 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound II-5, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound II-5. In certain embodiments, at least about 95% by weight Compound II-5 is present. In certain embodiments, at least about 99% by weight Compound II-5 is present.
[0332] In certain embodiments, Compound II-5 is a crystalline solid. In other embodiments, Compound II-5 is a crystalline solid that is substantially free of amorphous Compound II-5. As used herein, the term "substantially free of amorphous compound II-5" means that the compound does not contain significant amounts of amorphous compound II-5. In certain embodiments, at least about 95% by weight of crystalline Compound II-5 is present. In yet other embodiments of the invention, at least about 99% by weight of crystalline Compound II-5 is present.
[0333] In some embodiments, the solid crystalline form of Compound II-5 is Form A. In certain embodiments, Form A of Compound II-5 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 29A. In some embodiments, Form A of Compound II-5 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 17. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-5 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 17. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-5 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 17. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-5 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 17. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-5 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 17. selected from the group consisting of peaks that are present.
[0334] In certain embodiments, Form A of Compound II-5 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 29C. In certain embodiments, Form A of Compound II-5 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in Figure 29C. In certain embodiments, Form A of Compound II-5 can be characterized by substantial similarity to two or more of these figures at the same time.
[0335] In another embodiment, the compound of formula (II) is Compound II-6, and Compound II-6 is a benzenesulfonate salt.
[0336] In some embodiments, Compound II-6 is an amorphous solid. In some embodiments, Compound II-6 is a crystalline solid. In some embodiments, Compound II-6 is a mixture of amorphous and crystalline solid forms.
[0337] In some embodiments, the invention provides a form of Compound II-6 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound II-6, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound II-6. In certain embodiments, at least about 95% by weight Compound II-6 is present. In certain embodiments, at least about 99% by weight Compound II-6 is present.
[0338] In certain embodiments, Compound II-6 is a crystalline solid. In other embodiments, Compound II-6 is a crystalline solid that is substantially free of amorphous Compound II-6. As used herein, the term "substantially free of amorphous compound II-6" means that the compound does not contain significant amounts of amorphous compound II-6. In certain embodiments, at least about 95% by weight crystalline Compound II-6 is present. In yet other embodiments of the invention, at least about 99% by weight of crystalline Compound II-6 is present.
[0339] In some embodiments, the solid crystalline form of Compound II-6 is Form A. In certain embodiments, Form A of Compound II-6 has an X-ray diffraction pattern that is substantially similar to any one of the patterns illustrated in FIG. 30A. In some embodiments, Form A of Compound II-6 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 18. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-6 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 18. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-6 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 18. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-6 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 18. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-6 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 18. selected from the group consisting of peaks that are present.
[0340] In certain embodiments, Form A of Compound II-6 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 30C. In certain embodiments, Form A of Compound II-6 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 30C. In certain embodiments, Form A of compound II-6 can be characterized by substantial similarity to two of these figures at the same time.
[0341] In another embodiment, the compound of formula (II) is Compound II-7, and Compound II-7 is a fumarate salt.
[0342] In some embodiments, Compound II-7 is an amorphous solid. In some embodiments, Compound II-7 is a crystalline solid. In some embodiments, Compound II-7 is a mixture of amorphous and crystalline solid forms.
[0343] In some embodiments, the invention provides a form of Compound II-7 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound II-7, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound II-7. In certain embodiments, at least about 95% by weight Compound II-7 is present. In certain embodiments, at least about 99% by weight Compound II-7 is present.
[0344] In certain embodiments, Compound II-7 is a crystalline solid. In other embodiments, Compound II-7 is a crystalline solid that is substantially free of amorphous Compound II-7. As used herein, the term "substantially free of amorphous compound II-7" means that the compound does not contain significant amounts of amorphous compound II-7. In certain embodiments, at least about 95% by weight of crystalline Compound II-7 is present. In yet other embodiments of the invention, at least about 99% by weight of crystalline Compound II-7 is present.
[0345] In some embodiments, the solid crystalline form of Compound II-7 is Form A. In certain embodiments, Form A of Compound II-7 has an X-ray diffraction pattern that is substantially similar to any one of the patterns illustrated in FIG. 31A. In some embodiments, Form A of Compound II-7 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 19. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-7 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 19. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-7 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 19. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-7 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 19. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound II-7 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 19. selected from the group consisting of peaks that are present.
[0346] In certain embodiments, Form A of Compound II-7 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 31C. In certain embodiments, Form A of Compound II-7 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 31C. In certain embodiments, Form A of compound II-7 can be characterized by substantial similarity to two or more of these figures at the same time. Compound of formula (III)
[0347] In one embodiment, a compound of formula (III) [ka] or a solvate thereof, provided herein: r is 1, 2, 3, 4, 5, 6, 7, 8 or 9; s is 0, 0.5, 1, 1.5, 2, 2.5 or 3; X is hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid or tartaric acid).
[0348] The acid moiety shown as "X" and 6-(6-ethynyl-4-methoxypyridin-3-yl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy) It will be recognized by those skilled in the art that phenyl)-4,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine is ionically bonded to form a compound of formula (III). It will also be appreciated that if s is 0, then X is absent, indicating that the compound of formula (III) is present as a "free base", ie, in "free form".
[0349] It is contemplated that compounds of formula (III) can exist in a variety of physical forms. For example, the compound of formula (III) may be in solution, suspension or in solid form. In certain embodiments, the compound of formula (III) is in solid form. When the compound of formula (III) is in solid form, said compound may be amorphous, crystalline or a mixture thereof. Exemplary solid forms are described in more detail below.
[0350] In some embodiments, the compound of formula (III) may be in a hydrate form. In some embodiments, the compound of formula (III) may be in a hemihydrate form.
[0351] In some embodiments, r is 1. In some embodiments, r is 2. In some embodiments, r is 3. In some embodiments, r is 4. In some embodiments, r is 5. In some embodiments, r is 6. In some embodiments, r is 7. In some embodiments, r is 8. In some embodiments, r is 9.
[0352] In some embodiments, s is 0. In some embodiments, s is 1. In some embodiments, s is 2. In some embodiments, s is 3. In some embodiments, s is 0.5. In some embodiments, s is 1.5. In some embodiments, s is 2.5.
[0353] In some embodiments, X is hydrochloric acid. In some embodiments, X is hydrobromic acid. In some embodiments, X is sulfuric acid. In some embodiments, X is methanesulfonic acid. In some embodiments, X is tartaric acid.
[0354] In some embodiments, the invention provides a form of the compound of formula (III) that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of the compound of formula (III), residual solvents, or any other impurities that may result from the preparation and / or isolation of the compound of formula (III).
[0355] In some embodiments, the compound of formula (III) or a solvate thereof, or a crystalline form thereof, is at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, 98.5, 99, 99.1, 99.2, Present in amounts of 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9% by weight, percentages being relative to the total weight of the composition. In some embodiments, the compound of formula (III) or a solvate thereof, or a crystalline form thereof, contains no more than about 0.40%, no more than about 0.35%, no more than about 0.3% by weight of any single impurity. , no more than about 0.25%, no more than about 0.2%, no more than about 0.15%, no more than about 0.10%, or no more than about 0.05% by weight, percentages being based on the total weight of the composition.
[0356] In some embodiments, the compound of formula (III) or a solvate thereof, or a crystalline form thereof, has a total area of at least about 95, 95.5, 96, 96.5, 97, 97.5, Present in amounts of 98.0, 98.5, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 HPLC area %. In some embodiments, the compound of formula (III) or a solvate thereof, or a crystalline form thereof, contains no more than about 0.4, no more than about 0.35 of any single impurity, based on the total area of the HPLC chromatogram. , less than or equal to about 0.3, less than or equal to about 0.25, less than or equal to about 0.2, less than or equal to about 0.15, less than or equal to about 0.10, or less than or equal to about 0.05. In some embodiments, the HPLC method is the HPLC method described in Example 1.
[0357] The structures depicted for compounds of formula (III) are also intended to include all tautomeric forms. Additionally, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, replacing hydrogen with deuterium or tritium, or 13 C or 14 Compounds having this structure, excluding the replacement of carbon by a C-rich carbon, are within the scope of this invention.
[0358] In some embodiments, the compound of formula (III) is Compound III-1, and Compound III-1 is the free base (or "free form"). In some embodiments, Compound III-1 is an amorphous solid. In some embodiments, Compound III-1 is a crystalline solid. In some embodiments, Compound III-1 is a mixture of amorphous and crystalline solid forms.
[0359] In some embodiments, the invention provides a form of Compound III-1 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound III-1, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound III-1. In certain embodiments, at least about 95% by weight Compound III-1 is present. In certain embodiments, at least about 99% by weight Compound III-1 is present.
[0360] In other embodiments, Compound III-1 is a crystalline solid that is substantially free of amorphous Compound III-1. As used herein, the term "substantially free of amorphous compound III-1" means that the compound does not contain significant amounts of amorphous compound III-1. In certain embodiments, at least about 95% by weight crystalline Compound III-1 is present. In certain embodiments, at least about 99% by weight of crystalline Compound III-1 is present.
[0361] It has been found that compound III-1 can exist in various solid forms. Exemplary such forms include polymorphs such as those described herein.
[0362] In some embodiments, the solid crystalline form of Compound III-1 is Form A. In some embodiments, Form A of Compound III-1 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 32A. In some embodiments, Form A of Compound III-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 23. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-1 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 23. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-1 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 23. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-1 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 23. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-1 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 23. selected from the group consisting of peaks that are present.
[0363] In some embodiments, Form A of Compound III-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 32C. In some embodiments, Form A of Compound III-1 has a thermogravimetric analysis pattern substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 32C. In some embodiments, Form A of Compound III-1 may be characterized by substantial similarity to two or more of these figures at the same time.
[0364] In some embodiments, the solid crystalline form of Compound III-1 is Form B. In some embodiments, Form B of Compound III-1 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 33A. In some embodiments, Form B of Compound III-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 33C. In some embodiments, Form A of Compound III-1 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 33C. In some embodiments, Form B of Compound III-1 may be characterized by substantial similarity to two or more of these figures at the same time.
[0365] In some embodiments, the solid crystalline form of Compound III-1 is Form C. In some embodiments, Form C of Compound III-1 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 34A. In some embodiments, Form C of Compound III-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 34C. In some embodiments, Form C of Compound III-1 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 34C. In some embodiments, Form C of Compound III-1 may be characterized by substantial similarity to two or more of these figures at the same time.
[0366] In another embodiment, the compound of formula (III) is Compound III-2, and Compound III-2 is a hydrochloride salt. In some embodiments, Compound III-2 is the monohydrochloride salt. In some embodiments, Compound III-2 is the dihydrochloride salt. In some embodiments, Compound III-2 is the trihydrochloride salt.
[0367] In some embodiments, Compound III-2 is an amorphous solid. In some embodiments, Compound III-2 is a crystalline solid. In some embodiments, Compound III-2 is a mixture of amorphous and crystalline solid forms.
[0368] In some embodiments, the invention provides a form of Compound III-2 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound III-2, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound III-2. In certain embodiments, at least about 95% by weight Compound III-2 is present. In certain embodiments, at least about 99% by weight Compound III-2 is present.
[0369] In other embodiments, Compound III-2 is a crystalline solid that is substantially free of amorphous Compound III-2. As used herein, the term "substantially free of amorphous compound III-2" means that the compound does not contain significant amounts of amorphous compound III-2. In certain embodiments, at least about 95% by weight crystalline Compound III-2 is present. In certain embodiments, at least about 99% by weight crystalline Compound III-2 is present.
[0370] It has been found that compound III-2 can exist in various solid forms. Exemplary such forms include polymorphs such as those described herein.
[0371] In some embodiments, the solid crystalline form of Compound III-2 is Form A. In certain embodiments, Form A of Compound III-2 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 35A. In some embodiments, Form A of Compound III-2 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 31. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-2 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 31. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-2 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 31. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-2 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 31. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-2 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 31. selected from the group consisting of peaks that are present.
[0372] In some embodiments, Form A of Compound III-2 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 35C. In some embodiments, Form A of Compound III-2 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 35C. In some embodiments, Form A of Compound III-2 may be characterized by substantial similarity to two or more of these figures at the same time.
[0373] In some embodiments, the solid crystalline form of Compound III-2 is Form B. In some embodiments, Form B of Compound III-2 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 36A. In some embodiments, Form B of Compound III-2 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 32. selected from the group consisting of peaks that are present. In some embodiments, Form B of Compound III-2 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 32. selected from the group consisting of peaks that are present. In some embodiments, Form B of Compound III-2 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 32. selected from the group consisting of peaks that are present. In some embodiments, Form B of Compound III-2 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 32. selected from the group consisting of peaks that are present. In some embodiments, Form B of Compound III-2 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 32. selected from the group consisting of peaks that are present.
[0374] In some embodiments, Form B of Compound III-2 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 36C. In some embodiments, Form B of Compound III-2 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 36C. In some embodiments, Form B of Compound III-2 may be characterized by substantial similarity to two or more of these figures at the same time.
[0375] In some embodiments, the solid crystalline form of Compound III-2 is Form C. In some embodiments, Form C of Compound III-2 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 37A. In some embodiments, Form C of Compound III-2 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 37C. In some embodiments, Form C of Compound III-2 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 37C. In some embodiments, Form C of compound III-2 can be characterized by substantial similarity to two or more of these figures at the same time.
[0376] In some embodiments, the solid crystalline form of Compound III-2 is Form D. In some embodiments, Form D of Compound III-2 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 38A. In some embodiments, Form D of Compound III-2 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 33. selected from the group consisting of peaks that are present. In some embodiments, Form D of Compound III-2 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 33. selected from the group consisting of peaks that are present. In some embodiments, Form D of Compound III-2 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 33. selected from the group consisting of peaks that are present. In some embodiments, Form D of Compound III-2 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 33. selected from the group consisting of peaks that are present. In some embodiments, Form D of Compound III-2 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 33. selected from the group consisting of peaks that are present.
[0377] In some embodiments, Form D of Compound III-2 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 38C. In some embodiments, Form D of Compound III-2 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in Figure 38C. In some embodiments, Form D of Compound III-2 may be characterized by substantial similarity to two or more of these figures at the same time.
[0378] In another embodiment, the compound of formula (III) is Compound III-3, and Compound III-3 is the hydrobromide salt. In some embodiments, Compound III-3 is a monohydrobromide salt. In some embodiments, Compound III-3 is a dihydrobromide salt. In some embodiments, Compound III-3 is a trihydrobromide salt.
[0379] In some embodiments, Compound III-3 is an amorphous solid. In some embodiments, Compound III-3 is a crystalline solid. In some embodiments, Compound III-3 is a mixture of amorphous and crystalline solid forms.
[0380] In some embodiments, the invention provides a form of Compound III-3 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound III-3, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound III-3. In certain embodiments, at least about 95% by weight Compound III-3 is present. In certain embodiments, at least about 99% by weight Compound III-3 is present.
[0381] In certain embodiments, Compound III-3 is a crystalline solid. In other embodiments, Compound III-3 is a crystalline solid that is substantially free of amorphous Compound III-3. As used herein, the term "substantially free of amorphous compound III-3" means that the compound does not contain significant amounts of amorphous compound III-3. In certain embodiments, at least about 95% by weight of crystalline Compound III-3 is present. In yet other embodiments of the invention, at least about 99% by weight of crystalline Compound III-3 is present.
[0382] In some embodiments, the solid crystalline form of Compound III-3 is Form A. In some embodiments, Form A of Compound III-3 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 39A. In some embodiments, Form A of Compound III-3 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 34. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-3 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 34. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-3 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 34. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-3 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 34. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-3 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 34. selected from the group consisting of peaks that are present.
[0383] In some embodiments, Form A of Compound III-3 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 39C. In some embodiments, Form A of Compound III-3 has a thermogravimetric analysis pattern substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 39C. In some embodiments, Form A of Compound III-3 may be characterized by substantial similarity to two or more of these figures at the same time.
[0384] In another embodiment, the compound of formula (III) is Compound III-4, and Compound III-4 is a sulfate salt (or sulfate ester).
[0385] In some embodiments, Compound III-4 is an amorphous solid. In some embodiments, Compound III-4 is a crystalline solid. In some embodiments, Compound III-4 is a mixture of amorphous and crystalline solid forms.
[0386] In some embodiments, the invention provides a form of Compound III-4 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound III-4, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound III-4. In certain embodiments, at least about 95% by weight Compound III-4 is present. In certain embodiments, at least about 99% by weight Compound III-4 is present.
[0387] In certain embodiments, Compound III-4 is a crystalline solid. In other embodiments, Compound III-4 is a crystalline solid that is substantially free of amorphous Compound III-4. As used herein, the term "substantially free of amorphous compound III-4" means that the compound does not contain significant amounts of amorphous compound III-4. In certain embodiments, at least about 95% by weight of crystalline Compound III-4 is present. In yet other embodiments of the invention, at least about 99% by weight of crystalline Compound III-4 is present.
[0388] It has been found that compound III-4 can exist in various solid forms. Exemplary such forms include polymorphs such as those described herein.
[0389] In some embodiments, the solid crystalline form of Compound III-4 is Form A. In some embodiments, Form A of Compound III-4 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 40A. In some embodiments, Form A of Compound III-4 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 35. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-4 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 35. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-4 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 35. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-4 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 35. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-4 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 35. selected from the group consisting of peaks that are present.
[0390] In some embodiments, Form A of Compound III-4 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 40C. In some embodiments, Form A of Compound III-4 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 40C. In some embodiments, Form A of Compound III-4 may be characterized by substantial similarity to two or more of these figures at the same time.
[0391] In some embodiments, the solid crystalline form of Compound III-4 is Form B. In some embodiments, Form B of Compound III-4 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 41A. In some embodiments, Form B of Compound III-4 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 41C. In some embodiments, Form B of Compound III-4 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 41C. In some embodiments, Form B of Compound III-4 may be characterized by substantial similarity to two or more of these figures at the same time.
[0392] In another embodiment, the compound of formula (III) is Compound III-5, and Compound III-5 is a methanesulfonate salt.
[0393] In some embodiments, Compound III-5 is an amorphous solid. In some embodiments, Compound III-5 is a crystalline solid. In some embodiments, Compound III-5 is a mixture of amorphous and crystalline solid forms.
[0394] In some embodiments, the invention provides a form of Compound III-5 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound III-5, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound III-5. In certain embodiments, at least about 95% by weight Compound III-5 is present. In certain embodiments, at least about 99% by weight Compound III-5 is present.
[0395] In other embodiments, Compound III-5 is a crystalline solid that is substantially free of amorphous Compound III-5. As used herein, the term "substantially free of amorphous compound III-5" means that the compound does not contain significant amounts of amorphous compound III-5. In certain embodiments, at least about 95% by weight of crystalline Compound III-5 is present. In certain embodiments, at least about 99% by weight crystalline Compound III-5 is present.
[0396] In some embodiments, the solid crystalline form of Compound III-5 is Form A. In some embodiments, Form A of Compound III-5 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 42A. In some embodiments, Form A of Compound III-5 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 36. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-5 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 36. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-5 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 36. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-5 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 36. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound III-5 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 36. selected from the group consisting of peaks that are present.
[0397] In some embodiments, Form A of Compound III-5 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 42C. In some embodiments, Form A of Compound III-5 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 42C. In some embodiments, Form A of Compound III-5 may be characterized by substantial similarity to two or more of these figures at the same time.
[0398] In another embodiment, the compound of formula (III) is Compound III-6, and Compound III-6 is a tartaric acid (or tartrate) salt.
[0399] In some embodiments, Compound III-6 is an amorphous solid. In some embodiments, Compound III-6 is a crystalline solid. In some embodiments, Compound III-6 is a mixture of amorphous and crystalline solid forms.
[0400] In some embodiments, the invention provides a form of Compound III-6 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound III-6, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound III-6. In certain embodiments, at least about 95% by weight Compound III-6 is present. In certain embodiments, at least about 99% by weight Compound III-6 is present.
[0401] In other embodiments, Compound III-6 is a crystalline solid that is substantially free of amorphous Compound III-6. As used herein, the term "substantially free of amorphous compound III-6" means that the compound does not contain significant amounts of amorphous compound III-6. In certain embodiments, at least about 95% by weight of crystalline Compound III-6 is present. In certain embodiments, at least about 99% by weight crystalline Compound III-6 is present.
[0402] In some embodiments, the solid crystalline form of Compound III-6 is Form A. In some embodiments, Form A of Compound III-6 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 43A. In some embodiments, Form A of Compound III-6 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 43C. In some embodiments, Form A of Compound III-6 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 43C. In some embodiments, Form A of Compound III-6 may be characterized by substantial similarity to two or more of these figures at the same time. Compound of formula (IV)
[0403] In one embodiment, a compound of formula (IV) [ka] or a solvate thereof, provided herein: t is 1, 2, 3, 4, 5, 6, 7, 8 or 9; u is 0, 0.5, 1, 1.5, 2, 2.5 or 3; X is hydrochloric acid, p-toluenesulfonic acid, methanesulfonic acid or benzenesulfonic acid).
[0404] The acid moiety shown as “X” and 6-(6-ethynyl-2,4-dimethylpyridin-3-yl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl) It will be recognized by those skilled in the art that oxy)phenyl)-4,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine is ionically bonded to form a compound of formula (IV). It will also be appreciated that if u is 0, then X is absent, indicating that the compound of formula (IV) is present as a "free base", ie, in "free form". It will be further appreciated that the compound of formula (IV) can exist as a particular rotamer or as a mixture of rotamers.
[0405] It is contemplated that compounds of formula (IV) can exist in a variety of physical forms. For example, the compound of formula (IV) may be in solution, suspension or in solid form. In certain embodiments, the compound of formula (IV) is in solid form. When the compound of formula (IV) is in solid form, said compound may be amorphous, crystalline or a mixture thereof. Exemplary solid forms are described in more detail below.
[0406] In some embodiments, the compound of formula (IV) may be in a hydrate form. In some embodiments, the compound of formula (IV) may be in a hemihydrate form.
[0407] In some embodiments, t is 1. In some embodiments, t is 2. In some embodiments, t is 3. In some embodiments, t is 4. In some embodiments, t is 5. In some embodiments, t is 6. In some embodiments, t is 7. In some embodiments, t is 8. In some embodiments, t is 9.
[0408] In some embodiments, u is 0. In some embodiments, u is 1. In some embodiments, u is 2. In some embodiments, u is 3. In some embodiments, u is 0.5. In some embodiments, u is 1.5. In some embodiments, u is 2.5.
[0409] In some embodiments, X is hydrochloric acid. In some embodiments, X is p-toluenesulfonic acid. In some embodiments, X is methanesulfonic acid. In some embodiments, X is benzenesulfonic acid.
[0410] In some embodiments, the invention provides a form of the compound of formula (IV) that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of the compound of formula (IV), residual solvents, or any other impurities that may result from the preparation and / or isolation of the compound of formula (IV).
[0411] In some embodiments, the compound of formula (IV) or a solvate thereof, or a crystalline form thereof, is at least about 95, 95.5, 96, 96.5, 97, 97.5, 98.0, 98.5, 99, 99.1, 99.2, Present in amounts of 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9% by weight, percentages being relative to the total weight of the composition. In some embodiments, the compound of formula (IV) or a solvate thereof, or a crystalline form thereof, contains no more than about 0.40%, no more than about 0.35%, no more than about 0.3% by weight of any single impurity. , no more than about 0.25%, no more than about 0.2%, no more than about 0.15%, no more than about 0.10%, or no more than about 0.05% by weight, percentages being based on the total weight of the composition.
[0412] In some embodiments, the compound of formula (IV) or a solvate thereof, or a crystalline form thereof, has a total area of at least about 95, 95.5, 96, 96.5, 97, 97.5, Present in amounts of 98.0, 98.5, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 HPLC area %. In some embodiments, the compound of formula (IV) or a solvate thereof, or a crystalline form thereof, contains no more than about 0.4, no more than about 0.35 of any single impurity, based on the total area of the HPLC chromatogram. , less than or equal to about 0.3, less than or equal to about 0.25, less than or equal to about 0.2, less than or equal to about 0.15, less than or equal to about 0.10, or less than or equal to about 0.05. In some embodiments, the HPLC method is the HPLC method described in Example 1.
[0413] The structures depicted for compounds of formula (IV) are also intended to include all tautomeric forms. Additionally, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, replacing hydrogen with deuterium or tritium, or 13 C or 14 Compounds having this structure, excluding the replacement of carbon by a C-rich carbon, are within the scope of this invention.
[0414] In some embodiments, the compound of formula (IV) is Compound IV-1, and Compound IV-1 is the free base (or "free form"). In some embodiments, Compound IV-1 is an amorphous solid. In some embodiments, Compound IV-1 is a crystalline solid. In some embodiments, Compound IV-1 is a mixture of amorphous and crystalline solid forms.
[0415] In some embodiments, the invention provides a form of Compound IV-1 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound IV-1, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound IV-1. In certain embodiments, at least about 95% by weight Compound IV-1 is present. In certain embodiments, at least about 99% by weight Compound IV-1 is present.
[0416] In other embodiments, Compound IV-1 is a crystalline solid that is substantially free of amorphous Compound IV-1. As used herein, the term "substantially free of amorphous compound IV-1" means that the compound does not contain significant amounts of amorphous compound IV-1. In certain embodiments, at least about 95% by weight of crystalline Compound IV-1 is present. In certain embodiments, at least about 99% by weight of crystalline Compound IV-1 is present.
[0417] In some embodiments, the solid crystalline form of Compound IV-1 is Form A. In some embodiments, Form A of Compound IV-1 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 44A. In some embodiments, Form A of Compound IV-1 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 39. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-1 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 39. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-1 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 39. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-1 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 39. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-1 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 39. selected from the group consisting of peaks that are present.
[0418] In some embodiments, Form A of Compound IV-1 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 44C. In some embodiments, Form A of Compound IV-1 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 44C. In some embodiments, Form A of Compound IV-1 may be characterized by substantial similarity to two or more of these figures at the same time.
[0419] In another embodiment, the compound of formula (IV) is Compound IV-2, and Compound IV-2 is the hydrochloride salt. In some embodiments, Compound IV-2 is the monohydrochloride salt. In some embodiments, Compound IV-2 is the dihydrochloride salt. In some embodiments, Compound IV-2 is the trihydrochloride salt. In some embodiments, Compound IV-2 is an amorphous solid. In some embodiments, Compound IV-2 is a crystalline solid. In some embodiments, Compound IV-2 is a mixture of amorphous and crystalline solid forms.
[0420] In some embodiments, the invention provides a form of Compound IV-2 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound IV-2, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound IV-2. In certain embodiments, at least about 95% by weight Compound IV-2 is present. In certain embodiments, at least about 99% by weight Compound IV-2 is present.
[0421] In other embodiments, Compound IV-2 is a crystalline solid that is substantially free of amorphous Compound IV-2. As used herein, the term "substantially free of amorphous compound IV-2" means that the compound does not contain significant amounts of amorphous compound IV-2. In certain embodiments, at least about 95% by weight crystalline Compound IV-2 is present. In certain embodiments, at least about 99% by weight of crystalline Compound IV-2 is present.
[0422] In some embodiments, the solid crystalline form of Compound IV-2 is Form A. In some embodiments, Form A of Compound IV-2 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 45A. In some embodiments, Form A of Compound IV-2 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 44. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-2 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 44. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-2 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 44. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-2 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 44. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-2 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 44. selected from the group consisting of peaks that are present.
[0423] In some embodiments, Form A of Compound IV-2 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 45C. In some embodiments, Form A of Compound IV-2 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 45C. In some embodiments, Form A of Compound IV-2 may be characterized by substantial similarity to two or more of these figures at the same time.
[0424] In another embodiment, the compound of formula (IV) is Compound IV-3, and Compound IV-3 is p-toluenesulfonate. In some embodiments, Compound IV-3 is an amorphous solid. In some embodiments, Compound IV-3 is a crystalline solid. In some embodiments, Compound IV-3 is a mixture of amorphous and crystalline solid forms.
[0425] In some embodiments, the invention provides a form of Compound IV-3 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound IV-3, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound IV-3. In certain embodiments, at least about 95% by weight Compound IV-3 is present. In certain embodiments, at least about 99% by weight Compound IV-3 is present.
[0426] In other embodiments, Compound IV-3 is a crystalline solid that is substantially free of amorphous Compound IV-3. As used herein, the term "substantially free of amorphous compound IV-3" means that the compound does not contain significant amounts of amorphous compound IV-3. In certain embodiments, at least about 95% by weight crystalline Compound IV-3 is present. In certain embodiments, at least about 99% by weight of crystalline Compound IV-3 is present.
[0427] It has been found that compound IV-3 can exist in various solid forms. Exemplary such forms include polymorphs such as those described herein.
[0428] In some embodiments, the solid crystalline form of Compound IV-3 is Form A. In some embodiments, Form A of Compound IV-3 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 46A. In some embodiments, Form A of Compound IV-3 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 45. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-3 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 45. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-3 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 45. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-3 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 45. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-3 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 45. selected from the group consisting of peaks that are present.
[0429] In some embodiments, Compound IV-3 Form A has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 46C. In some embodiments, Form A of Compound IV-3 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 46C. In some embodiments, Form A of Compound IV-3 may be characterized by substantial similarity to two or more of these figures at the same time.
[0430] In some embodiments, the solid crystalline form of Compound IV-3 is Form B. In some embodiments, Form B of Compound IV-3 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 47A. In some embodiments, Form B of Compound IV-3 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 46. selected from the group consisting of peaks that are present. In some embodiments, Form B of Compound IV-3 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 46. selected from the group consisting of peaks that are present. In some embodiments, Form B of Compound IV-3 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 46. selected from the group consisting of peaks that are present. In some embodiments, Form B of Compound IV-3 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 46. selected from the group consisting of peaks that are present. In some embodiments, Form B of Compound IV-3 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 46. selected from the group consisting of peaks that are present.
[0431] In some embodiments, Form B of Compound IV-3 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 47C. In some embodiments, Form B of Compound IV-3 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 47C. In some embodiments, Form B of Compound IV-3 may be characterized by substantial similarity to two or more of these figures at the same time.
[0432] In another embodiment, the compound of formula (IV) is Compound IV-4, and Compound IV-4 is a methanesulfonate salt. In some embodiments, Compound IV-4 is an amorphous solid. In some embodiments, Compound IV-4 is a crystalline solid. In some embodiments, Compound IV-4 is a mixture of amorphous and crystalline solid forms.
[0433] In some embodiments, the invention provides a form of Compound IV-4 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound IV-4, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound IV-4. In certain embodiments, at least about 95% by weight Compound IV-4 is present. In certain embodiments, at least about 99% by weight Compound IV-4 is present.
[0434] In other embodiments, Compound IV-4 is a crystalline solid that is substantially free of amorphous Compound IV-4. As used herein, the term "substantially free of amorphous compound IV-4" means that the compound does not contain significant amounts of amorphous compound IV-4. In certain embodiments, at least about 95% by weight of crystalline Compound IV-4 is present. In certain embodiments, at least about 99% by weight of crystalline Compound IV-4 is present.
[0435] In some embodiments, the solid crystalline form of Compound IV-4 is Form A. In some embodiments, Form A of Compound IV-4 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 48A. In some embodiments, Form A of Compound IV-4 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 47. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-4 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 47. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-4 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 47. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-4 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 47. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-4 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 47. selected from the group consisting of peaks that are present.
[0436] In some embodiments, Form A of Compound IV-4 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 48C. In some embodiments, Form A of Compound IV-4 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 48C. In some embodiments, Form A of Compound IV-4 may be characterized by substantial similarity to two or more of these figures at the same time.
[0437] In another embodiment, the compound of formula (IV) is Compound IV-5, and Compound IV-5 is a benzenesulfonate salt. In some embodiments, Compound IV-5 is an amorphous solid. In some embodiments, Compound IV-5 is a crystalline solid. In some embodiments, Compound IV-5 is a mixture of amorphous and crystalline solid forms.
[0438] In some embodiments, the invention provides a form of Compound IV-5 that is substantially free of impurities. As used herein, the term "substantially free of impurities" means that the compound does not contain significant amounts of extraneous materials. Such foreign materials may include different forms of Compound IV-5, residual solvents, or any other impurities that may result from the preparation and / or isolation of Compound IV-5. In certain embodiments, at least about 95% by weight Compound IV-5 is present. In certain embodiments, at least about 99% by weight Compound IV-5 is present.
[0439] In other embodiments, Compound IV-5 is a crystalline solid that is substantially free of amorphous Compound IV-5. As used herein, the term "substantially free of amorphous compound IV-5" means that the compound does not contain significant amounts of amorphous compound IV-5. In certain embodiments, at least about 95% by weight of crystalline Compound IV-5 is present. In certain embodiments, at least about 99% by weight crystalline Compound IV-5 is present.
[0440] In some embodiments, the solid crystalline form of Compound IV-5 is Form A. In some embodiments, Form A of Compound IV-5 has an X-ray diffraction pattern substantially similar to the X-ray diffraction pattern illustrated in FIG. 49A. In some embodiments, Form A of Compound IV-5 can be characterized by a powder X-ray diffraction pattern having at least two characteristic peaks at 2θ degrees, each of which is listed in Table 48. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-5 can be characterized by a powder X-ray diffraction pattern having at least three characteristic peaks at 2θ degrees, each of which is listed in Table 48. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-5 can be characterized by a powder X-ray diffraction pattern having at least four characteristic peaks at 2θ degrees, each of which is listed in Table 48. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-5 can be characterized by a powder X-ray diffraction pattern having at least five characteristic peaks at 2θ degrees, each of which is listed in Table 48. selected from the group consisting of peaks that are present. In some embodiments, Form A of Compound IV-5 can be characterized by a powder X-ray diffraction pattern having at least six characteristic peaks at 2θ degrees, each of which is listed in Table 48. selected from the group consisting of peaks that are present.
[0441] In some embodiments, Form A of Compound IV-5 has a differential scanning calorimetry (DSC) pattern that is substantially similar to the differential scanning calorimetry (DSC) pattern illustrated in FIG. 49C. In some embodiments, Form A of Compound IV-5 has a thermogravimetric analysis pattern that is substantially similar to the thermogravimetric analysis pattern illustrated in FIG. 49C. In some embodiments, Form A of Compound IV-5 may be characterized by substantial similarity to two or more of these figures at the same time. Method
[0442] In some embodiments, a compound described herein or a solvate thereof, or a solid form thereof, or a pharmaceutical composition thereof, is used to treat intrahepatic cholangiocarcinoma (ICC) and / or other Provided herein are methods for treating patients with advanced solid tumors. In some embodiments, the patient has an advanced, unresectable solid tumor with FGFR2 alterations. In some embodiments, the patient has measurable or evaluable disease according to RECIST v1.1.
[0443] In some embodiments, Compound I-1 or a solvate thereof, or a solid form thereof, or a pharmaceutical composition thereof, described herein is used to treat intrahepatic cholangiocarcinoma (ICC) and / or Provided herein are methods for treating patients with or other advanced solid tumors. In some embodiments, Compound I-1 or a solvate thereof, or a solid form thereof, or a pharmaceutical composition thereof, described herein is administered orally twice a day. In some embodiments, Compound I-1 described herein or a solvate thereof, or a solid form thereof, or a pharmaceutical composition thereof, is administered orally at 50 mg / dose twice daily. be done.
[0444] In some embodiments, the patient is 18 years old or older. In some embodiments, the patient has a disease that is refractory to standard treatments. In some embodiments, the patient has a disease that does not respond adequately to standard treatments. In some embodiments, the patient has a disease for which there is no standard or curative treatment. In some embodiments, the patient is intolerant of or refuses standard therapy.
[0445] In some embodiments, the patient has an East Coast Cancer Trials Group (ECOG) performance status (PS) of 0 disease and FGFR2 status. In some embodiments, the patient exhibits FGFR2 alterations in the blood and / or tumor by local assessment, defined by one or more of the following: · The FGFR2 fusion involves a genomic translocation predicted to create an oncogenic FGFR2 fusion protein detected by DNA or RNA sequencing, or disrupt FISH. · FGFR2 amplification occurs in tumor tissues at amplified FGFR2 loci with copy number ≥8 [e.g., next generation sequencing (NGS) or per FGFR2 probe; FGFR2 amplification factor ≥4: per fluorescence in situ hybridization (FISH). , reference ratio ≥4]. · FGFR2 mutations are associated with the following primary oncogenic FGFR2 mutations or acquired FGFR2 resistance mutations: H167_N173del, S252X, P253X, Y375X, C382X, M537X, N549X, V564X, E565X, L617X, K641X, K659X and R664X (mesenchymal Numbering based on Form IIIc; X represents any amino acid change).
[0446] In some embodiments, the patient has a histologically or cytologically confirmed diagnosis of unresectable ICC or other progressive unresectable solid tumor. In some embodiments, the patient exhibits FGFR2 genomic alterations (fusions, amplifications or mutations) in the blood and / or tumor tissue by local assessment. In some embodiments, the patient has potential for oncogenic FGFR2 alterations (eg, FGFR2 protein or mRNA overexpression).
[0447] In some embodiments, the patient has a confirmed diagnosis of unresectable ICC with FGFR2 fusion (by blood and / or tumor local assessment) and is treated with a pan-FGFR inhibitor (e.g., pemigatinib, erdafitinib, Previous treatment with infigratinib (TAS-120).
[0448] In some embodiments, the patient has a confirmed diagnosis of unresectable ICC with FGFR2 fusion (by blood and / or tumor local assessment) and is treated with a pan-FGFR inhibitor (e.g., pemigatinib, erdafitinib, No prior treatment with infigratinib, TAS-120).
[0449] In some embodiments, the patient has an advanced, unresectable solid tumor with a FGFR2 fusion other than ICC (by blood and / or tumor local evaluation).
[0450] In some embodiments, the patient has an advanced, unresectable solid tumor with FGFR2 amplification (by blood and / or tumor local evaluation).
[0451] In some embodiments, the patient has an aggressive, unresectable solid tumor with an oncogenic FGFR2 mutation (by blood and / or tumor local evaluation).
[0452] In some embodiments, the patient has a non-proprietary disease whose cancer is a known non-FGFR2 (e.g., EGFR, ALK, ROS, RET, PI3K, HER2, BRAF) that is suitable for approved targeted therapy. Has a primary driver change.
[0453] In some embodiments, the patient does not have a history of or ongoing clinically significant corneal or retinal disorders.
[0454] In some embodiments, the patient does not have any of the following within 14 days prior to the first dose of Compound I-1: a. Platelet count <75×10 9 / L; b. Absolute neutrophil count (ANC)<1×10 9 / L; c. Hemoglobin <8 g / dL (red blood cell transfusions and erythropoietin may be used to reach 8 g / dL, unless administered at least 2 weeks prior to the first dose of Compound I-1). ); d. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 × upper limit of normal (ULN) if liver metastases are present; >5 × ULN if liver metastases are present; e. Total bilirubin >1.5 × ULN, in the presence of Gilbert's disease, >3 × ULN with direct bilirubin >1.5 × ULN; f. Estimated (Cockroft-Gault equation) or measured creatinine clearance <50 mL / min.
[0455] In some embodiments, the patient has no known active human immunodeficiency virus (HIV) or active hepatitis B virus (HBV) and / or hepatitis C virus (HCV).
[0456] In some embodiments, the patient does not have a QTcF>480 msec. In some embodiments, the patient has no history of long QT syndrome or torsade de pointes. In some embodiments, the patient does not have a family history of long QT syndrome.
[0457] In some embodiments, the patient has clinically significant uncontrolled cardiovascular disease, including congestive heart failure grade III or IV, according to New York Heart Association (NYHA) classification; myocardial infarction within the immediately preceding 6 months. or clinically significant uncontrolled arrhythmias (arrythmias), including unstable angina, uncontrolled hypertension (grade 3 or higher), or bradyarrythmias that can cause QT prolongation. ) (e.g., type II second-degree atrioventricular block or third-degree atrioventricular block).
[0458] In some embodiments, the patient does not have central nervous system (CNS) tumor metastases or a primary CNS tumor with progressive neurological symptoms, or the patient receives increased doses of or requiring corticosteroids. In some embodiments, the patient is in need of a corticosteroid to manage a CNS disease and the dose is stable for two weeks before day 1 of cycle 1 (C1D1). In some embodiments, the patient has stable or asymptomatic CNS tumor metastases or a primary CNS.
[0459] In some embodiments, the patient has not received systemic anti-neoplastic therapy or radiation therapy within 14 days or 5 half-lives prior to the first dose of Compound I-1.
[0460] In some embodiments, the patient has not received local liver therapy (eg, TACE or Y90) within 4 weeks prior to C1D1. In some embodiments, the patient has not received a neutrophil growth factor supporting drug within 14 days of the first dose of Compound I-1. In some embodiments, the patient is not in need of treatment involving prohibited drugs or herbal therapies that cannot be interrupted for at least 2 weeks prior to the start of administration of Compound I-1.
[0461] In some embodiments, the patient undergoes a major surgical procedure (such as central venous catheter placement, tumor needle biopsy, etc.) within 14 days of the first dose of Compound I-1, and feeding tube placement is a major surgical procedure. (not considered to be).
[0462] In some embodiments, the patient does not have a history of another primary malignancy diagnosed or requiring treatment within the past year, in which case the primary malignancy is Completely resected basal cell and squamous skin cancer, curatively treated localized prostate cancer, curatively treated localized thyroid cancer, or completely resected in situ at any site. It's not about cancer.
[0463] In some embodiments, the methods provided herein are performed prior to administering a compound (e.g., Compound I-1) or a solvate thereof, or a solid form thereof, or a pharmaceutical composition thereof. or followed by monitoring serum phosphorus and / or calcium levels. In some embodiments, the methods provided herein do not significantly increase serum phosphorus and / or calcium levels. In some embodiments, the methods provided herein provide for the administration of a compound (e.g., Compound I-1) or a solvate thereof, or a solid form thereof, or a pharmaceutical composition thereof, prior to administration. an increase in serum phosphorus and / or calcium levels of no more than about 2%, no more than about 5%, no more than about 10%, no more than about 15%, no more than about 20%, no more than about 25%, or no more than about 30% compared to including.
[0464] In some embodiments, the methods provided herein include limiting the patient's direct exposure to sunlight to avoid potential phototoxicity. In some embodiments, the methods provided herein include applying a sunscreen to the patient. In some embodiments, the methods provided herein include advising the patient to use sunscreen and / or wear sunglasses.
[0465] In some embodiments, methods of inhibiting FGFR2 activity, and thus useful for treating one or more disorders associated with the activity of FGFR2 or variants thereof, are disclosed herein. has been done. Thus, in certain embodiments, the invention provides a method of treating a FGFR2-mediated disorder in a subject, comprising: administering a therapeutically effective amount of a solid form disclosed herein or a pharmaceutically acceptable salt thereof; or administering to a subject a disclosed pharmaceutical composition. In some embodiments, the subject is a human.
[0466] As used herein, the term "FGFR2-mediated" disorder, disease and / or condition refers to any disease or other deleterious condition in which FGFR2 or a variant thereof is known to play a role. means. Accordingly, another embodiment of the invention relates to treating or alleviating the severity of one or more diseases in which FGFR2 or variants thereof are known to play a role. Such FGFR2-mediated disorders include, but are not limited to, proliferative disorders (eg, cancer) and craniosynostosis syndrome.
[0467] In some embodiments, the invention provides a method for treating one or more disorders, wherein the disorder is selected from proliferative disorders and craniosynostosis syndrome; A method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof, or any of the pharmaceutically acceptable compositions described above. provide. In some embodiments, the invention provides a method for treating one or more disorders, wherein the disorder is selected from proliferative disorders and craniosynostosis syndrome; A method is provided comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable composition thereof.
[0468] In some embodiments, the disorder is associated with FGFR2 signaling. FGFR2 and other receptor tyrosine kinases (RTKs) are known to have multiple upstream and downstream signaling pathways (see Turner and Grose, Nat. Rev. Cancer (2010) 10, 116). ), inhibition of FGFR2 can be used to treat disorders associated with aberrant signaling within those pathways. In some embodiments, the disorder is associated with FGF signaling, JAK-STAT signaling, PI3K-Akt signaling, PLC-gamma signaling or MAPK signaling.
[0469] In some embodiments, the method of treatment includes the steps of: i) identifying a subject in need of such treatment; (ii) providing a disclosed compound or a pharmaceutically acceptable salt thereof; and (iii) administering a therapeutically effective amount of the provided compound to treat, inhibit and / or prevent a disease condition or condition in a subject in need of such treatment.
[0470] In some embodiments, the method of treatment includes the steps of: i) identifying a subject in need of such treatment; (ii) administering a composition comprising a disclosed compound or a pharmaceutically acceptable salt thereof; and (iii) administering said composition in a therapeutically effective amount to treat, inhibit and / or prevent a disease condition or condition in a subject in need of such treatment.
[0471] Another aspect of the invention provides a compound as defined herein or a pharmaceutically acceptable salt thereof, or any pharmaceutical composition as described above, for use in the treatment of the disorders described herein. provide something. Another aspect of the invention provides that a compound as defined herein or a pharmaceutically acceptable salt thereof, or any of the pharmaceutical compositions described above, for the treatment of the disorders described herein. Provide use. Similarly, the present invention provides the use of a compound as defined herein or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of the disorders described herein.
[0472] In some embodiments, the disorder is a proliferative disorder. In some embodiments, the proliferative disorder is cancer. In some embodiments, the proliferative disorder is leukemia, breast cancer, lung cancer, colorectal cancer or a combination thereof. In some embodiments, the proliferative disorder is leukemia. In some embodiments, the proliferative disorder is breast cancer. In some embodiments, the proliferative disorder is lung cancer. In some embodiments, the proliferative disorder is colorectal cancer.
[0473] In some embodiments, the proliferative disorder is intrahepatic cholangiocarcinoma, hepatocellular carcinoma, breast cancer, prostate cancer, lung squamous cell carcinoma, thyroid cancer, stomach cancer, ovarian cancer, rectal cancer, endometrial cancer. , non-small cell lung cancer or urothelial cancer. In some embodiments, the proliferative disorder is intrahepatic cholangiocarcinoma, hepatocellular carcinoma, breast cancer, prostate cancer, squamous cell lung cancer, thyroid cancer, gastric cancer, or ovarian cancer. In some embodiments, the proliferative disorder is gastric cancer, breast cancer, triple negative breast cancer or rectal cancer. In some embodiments, the proliferative disorder is endometrial cancer, non-small cell lung cancer, squamous cell lung cancer, gastric cancer, breast cancer, or urothelial cancer.
[0474] In some embodiments, the proliferative disorder is associated with one or more activating mutations in FGFR2. In some embodiments, the activating mutation in FGFR2 is a mutation in one or more of the intracellular kinase domain and the extracellular domain. In some embodiments, the activating mutation in FGFR2 is a mutation to the intracellular kinase domain. In some embodiments, the activating mutation in FGFR2 is a mutation to the extracellular domain. In some embodiments, the activating mutation in FGFR2 is selected from N549K, K659N / M, S252W, P253R and combinations thereof. In some embodiments, the activating mutation in FGFR2 is N549K or K659N / M. In some embodiments, the activating mutation in FGFR2 is N549K. In some embodiments, the activating mutation in FGFR2 is K659N / M. In some embodiments, the activating mutation in FGFR2 is S252W or P253R. In some embodiments, the activating mutation in FGFR2 is S252W. In some embodiments, the activating mutation in FGFR2 is P253R.
[0475] In some embodiments, the proliferative disorder is associated with one or more resistance mutations in FGFR2. In some embodiments, the resistance mutation in FGFR2 is selected from V564F, E565A, N549K / H / T and L617V, and combinations thereof. In some embodiments, the resistance mutation in FGFR2 is V564F. In some embodiments, the resistance mutation in FGFR2 is E565A. In some embodiments, the resistance mutation in FGFR2 is N549K / H / T. In some embodiments, the resistance mutation in FGFR2 is L617V.
[0476] In some embodiments, compounds or compositions of the present disclosure may be useful for inhibiting tumor cell growth. In some embodiments, compounds or compositions of the present disclosure may be useful in ameliorating the pathogenesis of systemic lupus erythematosus. In some embodiments, a compound or composition of the present disclosure may be used to treat Noonan syndrome (NS), Leopard syndrome (Noonan syndrome including lentigo multiplex), diabetes, neuroblastoma, melanoma, juvenile leukemia, juvenile leukemia, Myelomonocytic leukemia (JMML), chronic myelomonocytic leukemia, acute myeloid leukemia, HER2-positive breast cancer, triple-negative breast cancer, ductal carcinoma of the breast, invasive ductal carcinoma of the breast, non-small cell lung cancer (glandular carcinoma of the lung) cancer), colorectal cancer (SW480, SW620, CACO2, HCT116, HT29 colon cancer cell lines), esophageal cancer, gastric cancer, squamous cell carcinoma of the head and neck (SCCHN), and neutropenia (Kostmann syndrome). may be useful in treating a variety of other disorders, including:
[0477] In some embodiments, compounds or compositions of the present disclosure can be used in combination with other treatments and / or cancer treatments. For example, compounds or compositions of the present disclosure can be used in combination with, but are not limited to, antibodies, antibody-drug conjugates, kinase inhibitors, immunomodulators, and histone deacetylase inhibitors. The compounds or compositions of the present disclosure also include WO2018 / 057884, WO2015 / 107495, WO2018 / 172984 and WO2018 / 136265, each of which is incorporated by reference in its entirety; and the references cited therein. Can be used in combination with other treatments and / or cancer treatments as disclosed in . For example, SHP099, RLY1971, RMC-4550, RMC4630, JAB3068, JAB3312 or TNO155.
[0478] In some embodiments, a compound or composition of the present disclosure is a compound of the formula: [ka] or in combination with a pharmaceutically acceptable salt thereof.
[0479] For example, the compounds disclosed herein (or pharmaceutical compositions containing them) may be used alone or in combination with another therapeutic agent to treat one or more of the diseases specified herein. It can be used for the treatment of For example, compounds of formula (I) can be used in combination with the following drugs: BCR-ABL inhibitors: imatinib mesylate; inilotinib hydrochloride; nilotinib; dasatinib; bosutinib; ponatinib; bafetinib; danucertib ;Saracatinib;N-[2-[(1S,4R)-6-[[4-(cyclobutylamino)-5-(tjifluoromethyl)-2-pyrimidinyl]amino]-1,2,3 ,4-tetrahydronaphthalene-1,4-imin-9-yl]-2-oxoethyl]-acetamide. ALK inhibitor: crizotinib; 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl) phenyl)pyrimidine-2,4-diamine, ceritinib, alectinib, brigatinib, entrecinib. BRAF inhibitors: vemurafenib and dabrafenib. FGFR inhibitors: infigratinib, dovitinib, erdafitinib, BLU-554, AZD4547. FLT3 inhibitors: sunitinib malate; midostaurin; tanutinib; sorafenib, lestaurtinib, quizartinib, and crenolanib. KRAS inhibitors: MRTX849, AMG510. MEK inhibitors - trametinib, combimetinib, binimetinib, selumetinib. VEGF receptor inhibitors: bevacizumab, axitinib, aflibercept, (N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide , brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1 ,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate, motesanib(N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)- 2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide, pasireotide, sorafenib. Tyrosine kinase inhibitors: erlotinib hydrochloride, linifanib, sunitinib malate, pazopanib. Epidermal growth factor receptor (EGFR) inhibitors: gefitonib , osimertinib, cetuximab, panitumumab. HER2 receptor inhibitors: trastuzumab, neratinib, lapatinib or lapatinib ditosylate. MET inhibitors: crizotinib, cabozantinib. CD20 antibodies: rituximab, tositumomab, ofatumumab. DNA synthesis inhibitors: capecitabine, gemcitabine Hydrochloride, nelarabine, hydroxycarbamide.Antineoplastic agents: oxaliplatin.HER dimerization inhibitors: pertuzumab.Human granulocyte colony-stimulating factor (G-CSF) modulators: filgrastim.Immune modulators: aftuzumab, lenalidomide, thalidomide CD40 inhibitor: dacetuzumab. Apoptotic receptor agonist (PARA): duranermin. Heat shock protein (HSP) inhibitor: tanespimycin (17-allylamino-17-demethoxygeldanamycin). Hedgehog antagonist: 2 -Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)-benzamide. Proteasome inhibitor: bortezomib. PI3K inhibitor: 4-[2-(1H-indazole-4 -yl)-6-[[4-(methylsulfonyl)piperazin-1-yl]methyl]thieno[3,2-d]pyrimidin-4-yl]mo choline, 2-methyl-2-[4 -[3-Methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propiocyano, buparlisib, taselisib, idelalisib, duvelisib , TGR1202. Phospholipase A2 inhibitor: anagrelide. BCL-2 inhibitor: 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[ [(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide. Mitogen-activated protein kinase kinase (MEK) inhibitor: XL-518. Aromatase inhibitors: exemestane, letrozole, anastrozole, faslodex, tamoxifen. Topoisomerase I inhibitors: irinotecan, topotecan hydrochloride. Topoisomerase II inhibitors: etoposide, teniposide. mTOR inhibitors: temsirolimus, ridaforolimus, everolimus. Osteoclast bone resorption inhibitor: 1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate. CD33 antibody drug conjugate: gemtuzumab ozogamicin. CD22 antibody drug conjugate: inotuzumab ozogamicin. CD20 antibody drug conjugate: ibritumomab tiuxetan. Somatostatin analog: Octreotide. Synthetic interleukin-11 (IL-11): Oprelvequin. Synthetic erythropoietin: darbepoetin alfa. Receptor activator for nuclear factor kappa B (RANK) inhibitor: Denosumab. Thrombopoietin mimetic peptide: romiplostim. Cell growth promoter: Palifermin. Anti-insulin-like growth factor-1 receptor (IGF-1R) antibody: figitumumab. Anti-CSl antibody: Elotuzumab. CD52 antibody: alemtuzumab. CTLA-4 inhibitors: tremelimumab, ipilimumab. PD1 inhibitors: nivolumab; pembrolizumab; immunoadhesins; pidilizumab; and AMP-224. PDL1 inhibitor: MSB0010718C; YW243.55.S70, MPDL3280A; MEDI-4736, MSB-0010718C or MDX-1105. LAG-3 inhibitor: BMS-986016. GITR agonists: GITR fusion proteins and anti-GITR antibodies. Histone deacetylase inhibitor (HDI): Vorinostat. Anti-CTLA4 antibodies: tremelimumab; and ipilimumab. Alkylating agents: Temozolomide, Dactinomycin, Melphalan, Altretamine Carmustine, Bendamustine, Busulfan, Carboplatin, Lomustine, Cisplatin, Chlorambucil, Cyclophosphamide, Dacarbazine, Altretamine, Ifosamide, Procarbazine, Mechlorethamine, Mustine and Mechloroethamine Hydrochloride, Strepto Zosin, Thiotepa. Biological response modifiers: Bacillus Calmette-Guérin, denileukin diftitox. Antitumor antibiotics: doxorubicin, bleomycin, daunorubicin, daunorubicin liposome, mitoxantrone, epirubicin, idarubicin, mitomycin C. Antimicrotubule agent: Estramustine. Cathepsin K inhibitor: odanacatib. Epothilone B analog: Ixabepilone. TpoR agonist: eltrombopag. Antimitotic agent: Docetaxel. Adrenal steroid inhibitors: aminoglutethimide. Anti-androgens: Nilutamide, Androgen receptor inhibitors: Enzalutamide, Abiraterone acetate, Orteronel, Galeterone and Seviteronel, Bicalutamide, Flutamide. Androgen: Fluoxymesterone. CDK inhibitors: albocidib, palbociclib, ribociclib, trilaciclib, abemaciclib. TRK inhibitors: entrectinib, larotrectinib. RET inhibitors: BLU-667, LOXO-292, gonadotropin-releasing hormone (GnRH) receptor agonists: leuprolide or leuprolide acetate. Taxane antineoplastic agent: Cabazitaxel (1-hydroxy,10-dimethoxy-9-oxo-5,20-epoxytax-11-ene-2a,4,13a-triyl-4-acetate-2-benzoate-13-[( 2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate), larotaxel ((2α,5β,7β,10β,13α)-4,10-diacetoxy -1-hydroxy-13-{[(2R,3S)-2-hydroxy-3-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)-3-phenylpropanoyl]oxy}-9 -oxo-5,20-epoxy-7,19-cyclotaxa-11-en-2-ylbenzoate). 5HTla receptor agonist: Xaliproden (also known as SR57746, 1-[2-(2-naphthyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine.
[0480] HPC vaccines: Cervarix® sold by GlaxoSmithKline, Gardasil® sold by Merck;
[0481] Iron chelating agent: deferasirox. Anti-metabolites: Claribine (2-chlorodeoxyadenosine), 5-fluorouracil, 6-thioguanine, pemetrexed, cytarabine, cytarabine liposomes, decitabine, hydroxyurea, fludarabine, floxuridine, cladribine, methotrexate, pentostatin. Bisphosphonate: Pamidronate. Demethylating agents: 5-azacytidine, decitabine.
[0482] Plant alkaloids: paclitaxel protein binding; vinblastine, vincristine, vinorelbine, paclitaxel.
[0483] Retinoids: alitretinoin (sold under the trade name Panretin®), tretinoin (all-trans retinoic acid, also known as ATRA, sold under the trade name Vesanoid®), Isotretinoin (13-cis-retinoic acid, Accutane®, Amnesteem®, Claravis®, Claras®, Decutan®, Isotane®, Izotech® ), Oratane®, Isotret® and Sotret®), bexarotene (sold under the trade name Targretin®). Glucocorticosteroids: Hydrocortisone (also known as cortisone, hydrocortisone sodium succinate, hydrocortisone sodium phosphate, Ala-Cort®, hydrocortisone phosphate, Solu-Cortef®, Hydrocort Acetate®) dexamethasone ((8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2 -hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one ), prednisolone (sold under the trade names Delta-Cortel®, Orapred®, Pediapred® and Prelone®), prednisone (Deltasone®, Liquid Red( methylprednisolone (also known as 6-methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate), sold under the trade names Duralone®, Medralone®, Medrol®, M-Prednisol® and Solu-Medrol®). Cytokines: interleukin-2 (also known as aldesleukin and IL-2, sold under the trademark Proleukin®), interleukin-11 (also known as opleykin, sold under the trade name Proleukin®), interleukin-11 (also known as opleykin, Neumega ( alpha interferon alpha (also known as IFN-alpha and sold under the trade names Intron® A and Roferon-A®) . Estrogen receptor down-modulator: fulvestrant (sold under the trade name Faslodex®). Antiestrogens: Tamoxifen (sold under the trade name Novaldex®). Toremifene (sold under the trade name Fareston®). Selective Estrogen Receptor Modulator (SERM): Raloxifene (sold under the trade name Evista®). Luteinizing hormone-releasing hormone (LHRH) agonists: Goserelin (sold under the trade name Zoladex®);
[0484] Progesterone: Megestrol (also known as megestrol acetate, sold under the trade name Megace®); Various cytotoxic agents: Arsenic trioxide (trade name Trisenox®); Asparaginase (also known as L-asparaginase, L-asparaginase from Erwinia, sold under the trademarks Elspar® and Kidrolase®). Anti-nausea drugs: NK-1 receptor antagonists: casopitant (sold by GlaxoSmithKline under the trade names Rezonic® and Zunrisa®); and
[0485] Cytoprotective agents: amifostine (sold under the trade name Ethyol®), leucovorin (also known as leucovorin calcium, citrovorum factor and folinic acid). Immune checkpoint inhibitors: The term "immune checkpoint" refers to a group of molecules on the cell surface of CD4 and CD8 T cells. Immune checkpoint molecules include, but are not limited to, programmed death 1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), B7H1, B7H4, OX-40, CD137, CD40 and LAG3. is included. Immunotherapeutic agents that can act as immune checkpoint inhibitors useful in the methods of the present disclosure include, but are not limited to, PD-L1, PD-L2, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, Inhibitors of LAIR1, CD160, 2B4 and / or TGFRbeta are included.
[0486] The compounds described herein, in certain embodiments, can function as allosteric inhibitors and block activation of FGFR2 by targeting the autoinhibitory conformation of FGFR2.
[0487] The compounds described herein can be linked to one end of the variable chain, while the other end of the variable chain can be linked to an E3 ligase. Thus, recruitment of FGFR2 to ligase results in destruction of the FGFR2 protein.
[0488] In some embodiments, compounds or compositions of the present disclosure can be used in combination with antibodies. In some embodiments, compounds or compositions of the present disclosure can be used in combination with antibody-drug conjugates. In some embodiments, compounds or compositions of the present disclosure can be used in combination with kinase inhibitors. In some embodiments, compounds or compositions of the present disclosure can be used in combination with immunomodulators. In some embodiments, compounds or compositions of the present disclosure can be used in combination with histone deacetylase inhibitors.
[0489] In some embodiments, the disclosed compounds require treatment at a dosage ranging from about 0.0001 mg to about 100 mg / kg body weight of the subject being treated per day, such as about 1.0 to 10 mg / kg. can be administered to a subject. However, additional variations are within the scope of this disclosure.
[0490] The disclosed compounds can be administered alone or in combination with pharmaceutically acceptable carriers such as diluents, fillers, aqueous solutions and even organic solvents. The compounds and / or compositions of the present disclosure can be administered as tablets, powders, lozenges, syrups, injection solutions, and the like. Additional ingredients such as flavorants, binders, additives, etc. are within the scope of this disclosure.
[0491] In some embodiments, the present disclosure provides a method of treating disease conditions and / or conditions caused by or associated with FGFR2 kinase using a compound disclosed herein or a pharmaceutically acceptable compound thereof. Provided are pharmaceutical compositions and / or uses of medicaments. For example, a subject in need of treatment with an effective amount of a disclosed compound, and optionally an effective amount of an additional compound (e.g., a therapeutic agent) such as those disclosed herein. Provided herein are methods of treating a subject suffering from cancer (eg, leukemia, breast cancer, lung cancer and / or colorectal cancer).
[0492] In some embodiments, the method of treatment includes the steps of: i) identifying a subject in need of such treatment; (ii) administering a compound disclosed herein or a pharmaceutically acceptable salt thereof; and (iii) administering a therapeutically effective amount of said compound to treat, inhibit and / or prevent a disease condition or condition in a subject in need of such treatment.
[0493] In some embodiments, the method of treatment includes the steps of: i) identifying a subject in need of such treatment; (ii) administering a compound disclosed herein or a pharmaceutically acceptable salt thereof; and (iii) administering said composition in a therapeutically effective amount to treat, inhibit and / or prevent a disease condition or condition in a subject in need of such treatment. including.
[0494] In some embodiments, the subject is an animal. Animals include all members of the animal kingdom, including, but not limited to, humans, mice, rats, cats, monkeys, dogs, horses, and pigs. In some embodiments, the subject is a human. In some embodiments, the subject is a mouse, rat, cat, monkey, dog, horse, or pig.
[0495] In some embodiments, methods of treating, preventing and / or inhibiting conditions associated with FGFR2 include the steps of: i) identifying a subject in need of such treatment; (ii) providing a composition comprising a compound or a pharmaceutically acceptable salt thereof, or a compound disclosed herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier; and ( iii) administering said compound or composition in a therapeutically effective amount to treat, prevent and / or suppress a disease condition or condition associated with FGFR2 in a subject in need of such treatment.
[0496] According to the methods of the present disclosure, a compound of the present disclosure is administered to a subject in a therapeutically effective amount, eg, to reduce or ameliorate symptoms associated with FGFR2 kinase activity in the subject. This amount is readily determined by one of skill in the art based on known procedures, including analysis of titration curves established in vivo and the methods and assays disclosed herein.
[0497] In some embodiments, the method comprises administering a therapeutically effective dosage of a compound of the disclosure. In some embodiments, a therapeutically effective dosage is at least about 0.0001 mg / kg body weight, at least about 0.001 mg / kg body weight, at least about 0.01 mg / kg body weight, at least about 0.05 mg / kg body weight, at least about 0.1 mg / kg body weight. kg body weight, at least about 0.25 mg / kg body weight, at least about 0.3 mg / kg body weight, at least about 0.5 mg / kg body weight, at least about 0.75 mg / kg body weight, at least about 1 mg / kg body weight, at least about 2 mg / kg body weight, at least about 3 mg / kg body weight, at least about 4 mg / kg body weight, at least about 5 mg / kg body weight, at least about 6 mg / kg body weight, at least about 7 mg / kg body weight, at least about 8 mg / kg body weight, at least about 9 mg / kg body weight, at least about 10 mg / kg body weight, at least about 15 mg / kg body weight, at least about 20 mg / kg body weight, at least about 25 mg / kg body weight, at least about 30 mg / kg body weight, at least about 40 mg / kg body weight, at least about 50 mg / kg body weight, at least about 75 mg / kg body weight, at least about 100 mg / kg body weight, at least about 200 mg / kg body weight, at least about 250 mg / kg body weight, at least about 300 mg / kg body weight, at least about 350 mg / kg body weight, at least about 400 mg / kg body weight, at least about 450 mg / kg body weight kg body weight, at least about 500 mg / kg body weight, at least about 550 mg / kg body weight, at least about 600 mg / kg body weight, at least about 650 mg / kg body weight, at least about 700 mg / kg body weight, at least about 750 mg / kg body weight, at least about 800 mg / kg body weight body weight, at least about 900 mg / kg body weight, or at least about 1000 mg / kg body weight. Any of the dosages recited herein may constitute an upper or lower dosage range, and may be combined with any other dosage to constitute a dosage range that includes the upper and lower limits. It will be recognized that this may be done.
[0498] In some embodiments, the therapeutically effective dosage is about 0.1 mg to about 10 mg / kg body weight, about 0.1 mg to about 6 mg / kg body weight, about 0.1 mg to about 4 mg / kg body weight, or about 0.1 mg to about 2 mg / kg body weight range.
[0499] In some embodiments, the therapeutically effective dosage is about 1-500 mg, about 2-150 mg, about 2-120 mg, about 2-80 mg, about 2-40 mg, about 5-150 mg, about 5-120 mg, about 5 ~80mg, approximately 10~150mg, approximately 10~120mg, approximately 10~80mg, approximately 10~40mg, approximately 20~150mg, approximately 20~120mg, approximately 20~80mg, approximately 20~40mg, approximately 40~150mg, approximately 40 ~120mg, or in the range of about 40-80mg.
[0500] In some embodiments, the method involves a single dosage or administration (eg, as a single injection or deposit). Alternatively, the method includes once per day to a subject in need thereof for about 2 to about 28 days, or about 7 to about 10 days, or about 7 to about 15 days, or longer. Includes twice-daily, three-times-daily or four-times-daily dosing. In some embodiments, the method includes chronic administration. In yet other embodiments, the methods include administration over weeks, months, years or decades. In yet other embodiments, the method includes administration over several weeks. In yet other embodiments, the method includes administration over several months. In yet other embodiments, the method includes administration over several years. In yet other embodiments, the method includes administration over several decades.
[0501] The dosage administered depends on the pharmacodynamic characteristics of the active ingredient, as well as its mode and route of administration; the time of administration of the active ingredient; the age, sex, health and weight of the recipient; the nature and extent of the symptoms; the type of concurrent treatment, It may vary depending on known factors such as the frequency and desired effect of treatment; and rate of excretion. All of these can be readily determined and used by those skilled in the art to adjust or titrate dosages and / or dosing regimens.
[0502] The precise dose to be employed in the composition will also depend on the route of administration, and should be decided according to the judgment of the practitioner and each subject's circumstances. In specific embodiments of the present disclosure, suitable dosage ranges for oral administration of compounds of the present disclosure are generally from about 1 mg / day to about 1000 mg / day. In some embodiments, the oral dose is about 1 mg / day to about 800 mg / day. In some embodiments, the oral dose is about 1 mg / day to about 500 mg / day. In some embodiments, the oral dose is about 1 mg / day to about 250 mg / day. In some embodiments, the oral dose is about 1 mg / day to about 100 mg / day. In some embodiments, the oral dose is about 5 mg / day to about 50 mg / day. In some embodiments, the oral dose is about 5 mg / day. In some embodiments, the oral dose is about 10 mg / day. In some embodiments, the oral dose is about 20 mg / day. In some embodiments, the oral dose is about 30 mg / day. In some embodiments, the oral dose is about 40 mg / day. In some embodiments, the oral dose is about 50 mg / day. In some embodiments, the oral dose is about 60 mg / day. In some embodiments, the oral dose is about 70 mg / day. In some embodiments, the oral dose is about 100 mg / day. Any of the dosages recited herein may constitute an upper or lower dosage range, and may be combined with any other dosage to constitute a dosage range that includes the upper and lower limits. It will be recognized that this may be done. Composition
[0503] Another aspect of the disclosure provides pharmaceutical compositions comprising a compound disclosed herein formulated with a pharmaceutically acceptable carrier. In particular, the present disclosure provides pharmaceutical compositions comprising the compounds disclosed herein formulated with one or more pharmaceutically acceptable carriers. These formulations include those suitable for oral, topical, buccal, intraocular, parenteral (e.g. subcutaneous, intramuscular, intradermal or intravenous), rectal, vaginal or aerosol administration, but any The most suitable form of administration in a given case will depend on the extent and severity of the condition being treated and the nature of the particular compound used. For example, the disclosed compositions may be formulated as unit doses and / or for oral, subcutaneous or intravenous administration.
[0504] Exemplary pharmaceutical compositions of the present disclosure may be used in the form of pharmaceutical preparations, e.g., in solid, semisolid, or liquid form, which are suitable for external, enteral, or parenteral use. , one or more of the compounds of the disclosure in admixture with organic or inorganic carriers or additives as the active ingredient. The active ingredient can be used in conventional non-toxic pharmaceutically acceptable forms, for example tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions and any other form suitable for use. It may also be compounded with a carrier. The active object compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect on the disease process or condition.
[0505] In some embodiments, pharmaceutically acceptable compositions are disclosed at concentrations ranging from about 0.01 to about 2.0% by weight, such as from 0.01 to about 1% by weight or from about 0.05 to about 0.5% by weight. It may contain a compound and / or a pharmaceutically acceptable salt thereof. The composition may be formulated as a solution, suspension, ointment, capsule, or the like. Pharmaceutical compositions can be prepared as aqueous solutions and can contain additional components, such as preservatives, buffers, tonicity agents, antioxidants, stabilizers, viscosity-adjusting ingredients, etc. .
[0506] For preparing solid compositions such as tablets, the principal active ingredient is combined with a pharmaceutical carrier such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gum, and others. A solid pre-formulated composition containing a homogeneous mixture of a compound of the present disclosure or a non-toxic pharmaceutically acceptable salt thereof mixed with conventional tabletting ingredients such as a pharmaceutical diluent, e.g. water. Can form things. When these preformulated compositions are referred to as homogeneous, the active ingredient is evenly distributed throughout the composition such that the composition is divided into equally effective unit dosage forms such as tablets, pills, and capsules. This means that it can be easily divided into two parts.
[0507] Pharmaceutically acceptable carriers are well known to those skilled in the art and include, for example, adjuvants, diluents, additives, fillers, lubricants, and vehicles. In some embodiments, the carrier is a diluent, adjuvant, additive or vehicle. In some embodiments, the carrier is a diluent, adjuvant or additive. In some embodiments, the carrier is a diluent or adjuvant. In some embodiments, the carrier is an additive. In many cases, pharmaceutically acceptable carriers are chemically inert to the active compound and non-toxic under the conditions of use. Examples of pharmaceutically acceptable carriers can include, for example, water or saline solution, polymers such as polyethylene glycols, carbohydrates and their derivatives, oils, fatty acids or alcohols. Non-limiting examples of oils as pharmaceutical carriers include oils of petroleum, animal, vegetable or synthetic origin, such as, for example, peanut oil, soybean oil, mineral oil, sesame oil. Pharmaceutical carriers can also be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. Additionally, auxiliary agents, stabilizers, thickeners, lubricants and colorants may be used. Other examples of suitable pharmaceutical carriers include, for example, Remington's: The Science and Practice of Pharmacy, 22nd Ed. (Allen, Loyd V., Jr ed., Pharmaceutical Press (2012)); Modern Pharmaceutics, 5 th Ed. (Alexander T. Florence, Juergen Siepmann, CRC Press (2009)); Handbook of Pharmaceutical Excipients, 7 th Ed. (Rowe, Raymond C.; Sheskey, Paul J.; Cook, Walter G.; Fenton, Marian E. eds., Pharmaceutical Press (2012)), each of which is incorporated herein by reference in its entirety. ).
[0508] In some embodiments, the compounds of the present disclosure are formulated into pharmaceutical compositions for administration to a subject in a biologically compatible form suitable for administration in vivo. According to another aspect, the disclosure provides pharmaceutical compositions comprising the disclosed compounds in admixture with pharmaceutically acceptable diluents and / or carriers. A pharmaceutically acceptable carrier is "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to its recipient. Pharmaceutically acceptable carriers as used herein are used as ingredients for pharmaceutical formulations and include analgesics, buffers, binders, disintegrants, diluents, emulsifiers, additives, fillers, glidants. , organic or inorganic materials incorporated as solubilizers, stabilizers, suspending agents, tonicity agents, vehicles and viscosity enhancers. Pharmaceutical excipients such as antioxidants, fragrances, colorants, flavor improvers, preservatives and sweeteners may also be added. Examples of acceptable pharmaceutical carriers include carboxymethylcellulose, crystalline cellulose, glycerin, gum arabic, lactose, magnesium stearate, methylcellulose, powder, saline, sodium alginate, sucrose, starch, talc and water, among others. included. In some embodiments, the term "pharmaceutically acceptable" means approved by a state or national regulatory agency, or approved by the United States Pharmacopoeia or for use in animals, more particularly humans. means listed in another recognized pharmacopoeia.
[0509] Surfactants, such as detergents, are also suitable for use in the formulation. Examples of surfactants include polyvinylpyrrolidone, polyvinyl alcohol, copolymers of vinyl acetate and vinylpyrrolidone, polyethylene glycol, benzyl alcohol, mannitol, glycerol, polyoxyethylated esters of sorbitol or sorbitan; lecithin or sodium carboxymethylcellulose; or acrylic derivatives such as methacrylates; anionic surfactants, such as alkaline stearates, especially sodium stearate, potassium stearate or ammonium stearate; calcium stearate or triethanolamine stearate; alkyl sulfates, especially , sodium lauryl sulfate and sodium cetyl sulfate; sodium dodecylbenzenesulfonate or sodium dioctyl sulfosuccinate; or fatty acids, especially those derived from coconut oil, cationic surfactants, such as formula N + R’R’’R’’’’R’’’’’Y - water-soluble quaternary ammonium salts (R radicals are the same or different optionally hydroxylated hydrocarbon radicals, Y ー are anions of strong acids such as halide anions, sulfate anions and sulfonate anions); cetyltrimethylammonium bromide (one of the cationic surfactants that can be used), the formula N + Amine salt of R'R''R''' (R radical is the same or different, optionally hydroxylated, hydrocarbon radical); octadecylamine hydrochloride (cationic surfactants), nonionic surfactants such as optionally polyoxyethylated esters of sorbitan, in particular polysorbate 80 or polyoxyethylated alkyl ethers; polyethylene glycol stearate. , polyoxyethylated derivatives of castor oil, polyglycerol esters, polyoxyethylated fatty alcohols, polyoxyethylated fatty acids, or copolymers of ethylene oxide and propylene oxide, amphoteric surfactants, such as substituted lauryl compounds of betaine. It will be done.
[0510] The disclosed compounds and pharmaceutically acceptable carriers can be sterile when administered to a subject. Suitable pharmaceutical carriers include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dry skim milk powder, glycerol, propylene, Additives such as glycols, polyethylene glycol 300, water, ethanol, polysorbate 20, etc. may also be included. The composition, if desired, may also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
[0511] Pharmaceutical formulations of the present disclosure are prepared by methods well known in the pharmaceutical art. Optionally, one or more accessory ingredients (eg, buffers, flavoring agents, surfactants, etc.) are also added. The choice of carrier is determined by the solubility and chemical nature of the compound, the chosen route of administration and standard pharmaceutical practice.
[0512] Additionally, the compounds and / or compositions of the present disclosure are administered to human or animal subjects by known procedures, including oral, sublingual or buccal administration. In some embodiments, compounds and / or compositions are administered orally.
[0513] In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, etc.), the subject composition may contain one or more pharmaceutical agents, such as sodium citrate or dicalcium phosphate. Mixed with acceptable carriers and / or any of the following: (1) fillers or extenders such as starch, lactose, sucrose, glucose, mannitol and / or silicic acid, (2) e.g. carboxymethyl cellulose, alginates. (3) water retention agents such as glycerol, (4) agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain silicates and sodium carbonate. disintegrants, (5) dissolution retarders such as paraffins, (6) absorption enhancers such as quaternary ammonium compounds, (7) humectants such as acetyl alcohol and glycerol monostearate, (8) ) absorbents such as kaolin and bentonite clay, (9) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate and mixtures thereof, and (10) colorants. For capsules, tablets and pills, the composition may also include a buffering agent. Solid compositions of a similar type may also be employed as fillers in soft- and hard-filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols.
[0514] For oral administration, formulations of the compounds of the disclosure may be presented in dosage forms such as capsules, tablets, powders, granules, or as suspensions or solutions. Capsule formulations may be gelatin, soft gels or solids. Tablet and capsule formulations may further contain one or more adjuvants, binders, diluents, disintegrants, additives, fillers or lubricants, each of which is known in the art. . Examples of these include carbohydrates such as lactose or sucrose, anhydrous calcium hydrogen phosphate, corn starch, mannitol, xylitol, cellulose or their derivatives, microcrystalline cellulose, gelatin, stearate, silicon dioxide, talc, starch glycol. Contains sodium acid, acacia, flavoring agents, preservatives, buffering agents, disintegrants and colorants. The compositions to be administered orally may contain, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as oils of peppermint, wintergreen or cherry; coloring agents; and It may also contain one or more optional agents, such as preservatives.
[0515] A tablet can be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may contain binders (e.g. gelatin or hydroxypropylmethylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g. sodium starch glycolate or cross-linked sodium carboxymethylcellulose), surfactants or dispersants. It can be prepared using Molded tablets can be made by molding in a suitable machine a mixture of the subject composition moistened with an inert liquid diluent. Tablets and other solid dosage forms such as dragees, capsules, pills and granules may optionally be coated with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulation art. may be scored or prepared using.
[0516] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents, or mixtures thereof, and powders. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the subject composition, the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, etc. Ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene It may also contain fatty acid esters of glycols and sorbitans, cyclodextrins, and mixtures thereof.
[0517] Suspension formulations contain, in addition to the subject composition, suspending agents (such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters), microcrystalline cellulose, aluminum metahydroxide, bentonite, agar and tragacanth, It may also contain mixtures thereof.
[0518] Formulations for rectal or vaginal administration may be presented as suppositories, which contain the subject composition in one or more suitable ingredients, including, for example, cocoa butter, polyethylene glycols, suppository waxes, or salicylates. Can be prepared by mixing with irritating additives or carriers, suppositories are solid at room temperature but liquid at body temperature, thus melting in the body cavity and releasing the active agent.
[0519] Dosage forms for transdermal administration of the subject compositions include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. The active component can be mixed under sterile conditions with a pharmaceutically acceptable carrier and with any preservatives, buffers or propellants that may be required.
[0520] Ointments, pastes, creams and gels contain, in addition to the subject composition, animal and vegetable fats, oils, waxes, paraffin, starches, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acids, It may also contain additives such as talc and zinc oxide, or mixtures thereof.
[0521] Powders and sprays may contain, in addition to the subject composition, additives such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder or mixtures of these substances. The propellant may further contain conventional propellants such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons such as butane and propane.
[0522] Compositions and compounds of the present disclosure may alternatively be administered by aerosol. This is done by preparing aqueous aerosols, liposomal preparations or solid particles containing the compound. Non-aqueous (eg, fluorocarbon propellant) suspensions may be used. Sonic nebulizers may be used to minimize exposure of the drug to shear that can cause degradation of compounds contained in the subject composition. Typically, aqueous aerosols are made by formulating an aqueous solution or suspension of the subject composition with conventional pharmaceutically acceptable carriers and stabilizers. Carriers and stabilizers will vary depending on the requirements of the particular target composition, but typically include nonionic surfactants (Tween®, Pluronic® or polyethylene glycol), serum albumin, sorbitan esters. , amino acids such as oleic acid, lecithin, glycine, buffers, salts, and harmless proteins such as sugars or sugar alcohols. Aerosols are generally prepared from isotonic solutions.
[0523] Pharmaceutical compositions of the present disclosure suitable for parenteral administration can be formulated into one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or immediately prior to use. The subject compositions include a sterile powder that can be reconstituted into a sterile injectable solution or dispersion, which includes antioxidants, buffers, bacteriostatic agents, and the like to mix the formulation with the intended recipient's blood. It may also contain tonicifying solutes, or suspending or thickening agents.
[0524] Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions of the present disclosure include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil. , and injectable organic esters such as ethyl oleate, as well as cyclodextrins. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. For example, the crystalline forms provided herein may be milled to obtain a particular particle size, and in at least some embodiments, such crystalline forms, upon milling, substantially can remain stable.
[0525] For example, provided herein are compositions suitable for subcutaneous administration, including suspensions of the disclosed crystalline forms. Subcutaneous administration may have advantages over intravenous administration, which usually requires a doctor's visit and can be more painful and invasive. A typical dose of a crystalline compound can be about 1 mg to about 8 mg of the compound when administered to a patient. In certain embodiments, pharmaceutically acceptable compositions are formed from the disclosed crystalline forms, e.g., by mixing the crystalline forms with excipients and / or solvents disclosed herein. .
[0526] In certain embodiments, of the subject's body weight, administered daily, once or more times a day, every other day, every 3 or 4 days, every week, every 2 weeks, every 3 weeks, or every 4 weeks. Approximately 0.001mg / kg to approximately 100mg / kg, approximately 0.01mg / kg to approximately 50mg / kg, approximately 0.1mg / kg to approximately 40mg / kg, approximately 0.5mg / kg to approximately 30mg / kg, approximately 0.001mg / kg to The disclosed crystalline forms are suitable for subcutaneous administration at dosage levels sufficient to deliver about 4 mg / kg, about 0.1 mg / kg to about 10 mg / kg, about 1 mg / kg to about 25 mg / kg. Provided herein are compositions comprising: In certain embodiments, the desired dosage is determined using multiple doses (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses). and can be delivered. In certain embodiments, administration may occur once, twice or three times a week.
[0527] Treatment can be continued for longer or shorter periods of time as needed. The compositions may be administered on a regimen of, for example, 1 to 4 times per day, or more times per day. Suitable treatment periods can be, for example, at least about 1 week, at least about 2 weeks, at least about 1 month, at least about 6 months, at least about 1 year, or indefinitely. The treatment period can end when the desired result is achieved, eg, a weight loss goal. The treatment regimen may include a correction phase during which a dose sufficient to effect a reduction in body weight is administered, followed by a maintenance phase during which, e.g. Lower doses sufficient for escalation are administered. Although suitable maintenance doses are likely to be found in the lower portion of the dose ranges provided herein, correction and maintenance doses can be determined without undue experimentation based on the disclosure herein. can be easily established for individual subjects by those skilled in the art. A maintenance dose may be used to maintain a subject's weight that has been previously controlled by other means, including diet and exercise, bariatric procedures such as bypass or banding surgery, or treatment with other pharmacological agents. good.
[0528] Composition In certain embodiments, provided herein is a pharmaceutical composition comprising a crystalline form of Compound I-1 described herein or a solvate thereof. In certain embodiments, the pharmaceutical compositions provided herein include one or more pharmaceutically acceptable excipients described herein. In some embodiments, provided herein are immediate release capsules containing a crystalline form of Compound I-1 (eg, Form A) or a solvate thereof. In some embodiments, the immediate release capsule contains about 10 mg of a crystalline form of Compound I-1 (eg, Form A) or a solvate thereof. In some embodiments, the immediate release capsule contains about 50 mg of a crystalline form of Compound I-1 (eg, Form A) or a solvate thereof. In some embodiments, the immediate release capsule contains about 100 mg of a crystalline form of Compound I-1 (eg, Form A) or a solvate thereof. In some embodiments, the immediate release capsules include a powder blend intermediate that contains a crystalline form of Compound I-1 (e.g., Form A) or a solvate thereof with one or more pharmaceutically active agents. It can be produced by direct blending with acceptable additives. kit
[0529] In one embodiment, a kit is provided for treating or alleviating a contemplated disease or disorder. For example, the disclosed kits include, eg, a crystalline form of a disclosed crystalline compound, eg, a compound of formula (I), disposed in a first container. In some embodiments, the kit may further include a pharmaceutically acceptable excipient, eg, disposed in a second container. Such contemplated kits may include written instructions describing the preparation of a pharmaceutical composition suitable for administration to a patient from the crystalline form. For example, written instructions may include instructions for preparing a pharmaceutically acceptable form for administration to a patient, e.g., by mixing excipients and the crystalline compounds disclosed herein. can be explained. The disclosed kits may further include written instructions describing how to administer the resulting composition to a patient. process
[0530] In some embodiments, a process for preparing a disclosed crystalline form of a compound of formula (I), such as Compound I-1, comprises a) EtOH, ACN, MEK, EtOAc, IPAc, IPA, preparing a solution of compound I-1 in a solvent containing at least one of THF, MtBE, toluene, 1,4 dioxane and water; b) heating the solution to completely dissolve compound I-1; Contemplated herein is a process comprising dissolving, c) adjusting the temperature so that a solid precipitates from solution, and d) isolating a crystalline form of Compound I-1. .
[0531] In some embodiments, the solvent is EtOH. In some embodiments, the solvent includes ACN. In some embodiments, the solvent comprises EtOAc. In some embodiments, the solvent comprises IPAc. In some embodiments, the solvent includes IPA. In some embodiments, the solvent includes THF. In some embodiments, the solvent comprises MtBE. In some embodiments, the solvent includes toluene. In some embodiments, the solvent includes 1,4 dioxane. In some embodiments, the solvent includes EtOH and water (9v / 1v). In some embodiments, heating the solution includes heating the solution to about 50°C. In some embodiments, adjusting the temperature includes cooling the solution to about 5°C.
[0532] A process for preparing a compound of formula I-1, comprising acidifying a compound of formula I-2 with an HCl solution, whereby a compound of formula I-1: [ka] Further disclosed herein is a process comprising forming a.
[0533] In other embodiments, the disclosed process couples methacrylic anhydride with a compound of formula 3, thereby producing a compound of formula I-2: [ka] further comprising the step of forming.
[0534] In other embodiments, the disclosed process couples a compound of formula 1 with a compound of formula 2, thereby producing a compound of formula 3: [ka] further comprising the step of forming. Deuterated analogs
[0535] Deuterated analogs of compounds of formula (I), formula (II), formula (III), or formula (IV) are deuterated analogs of compounds of formula (I), formula (II), formula (III), or formula (IV) that are deuterated using the synthetic processes described herein. It will be recognized by those skilled in the art that the material can be fabricated using the following materials. As used herein, a "deuterated analog" of a formula means a compound having the structure of the formula, except that the structure has at least one replacement of hydrogen by deuterium.
[0536] In one aspect, the synthetic processes and methods detailed herein contemplate the use of deuterated compounds for use in producing deuterated analogs of compounds of formula (I). In some embodiments, this disclosure contemplates deuterated analogs of Formula (I). For example, the following compounds: [ka] Although not limited to, synthesis of deuterated analogs of formula (I) is contemplated.
[0537] In one aspect, the synthetic processes and methods detailed herein contemplate the use of deuterated compounds for use in producing deuterated analogs of compounds of formula (II). In some embodiments, this disclosure contemplates deuterated analogs of formula (II). For example, the following compounds: [ka] [ka] Although not limited to, synthesis of deuterated analogs of formula (II) is contemplated.
[0538] In one aspect, the synthetic processes and methods detailed herein contemplate the use of deuterated compounds for use in producing deuterated analogs of compounds of formula (III). In some embodiments, this disclosure contemplates deuterated analogs of formula (III). For example, the following compounds: [ka] [ka] Although not limited to, the synthesis of deuterated analogs of formula (III) is contemplated.
[0539] In one aspect, the synthetic processes and methods detailed herein contemplate the use of deuterated compounds for use in producing deuterated analogs of compounds of formula (IV). In some embodiments, this disclosure contemplates deuterated analogs of formula (IV). For example, the following compounds: [ka] [ka] Although not limited to, the synthesis of deuterated analogs of formula (IV) is contemplated.
Example
[0540] The compounds described herein can be prepared in a number of ways based on the teachings contained herein and synthetic procedures known in the art. The following non-limiting examples illustrate the disclosure herein.
[0541] X-ray powder diffraction (XRPD): Unless otherwise specified, X-ray powder diffraction patterns are generated using Cu Ka radiation (30 kV, 10 mA), a θ-θ goniometer, a divergent slit (0.2 mm) and a 4.799° aperture. Acquired on a Bruker D2 Phaser Gen 2 using an SSD160 (1D mode) detector with a The software used for data collection was Diffrac.Commander version 6.5.0.1 and data were displayed using Diffra.Eva version 4.2.1.11. XRPD diffractograms were obtained by reflection on a flat silica zero background plate at 15 revolutions per minute under ambient conditions. The data collection range was 3.0-40.0° 2θ with a step width of 0.02025° and a collection time of 0.25 seconds per step.
[0542] Differential Scanning Calorimetry (DSC): DSC data was collected on a TA Instruments Q2000 DSC. A predetermined amount of sample, 2.0-10.0 mg, was placed in an aluminum pan and heated at 10°C / min from 40C to 300C or as per the experimental instructions. A dry nitrogen purge of 100 ml / min was maintained over the sample. Instrument control and data acquisition are obtained using Q Advantage software release version 5.5.23. Data were processed and displayed using TA Universal Analysis 2000 software version 4.5A build 4.5.0.5.
[0543] Thermogravimetric analysis (TGA): TGA data were collected on a TA Instruments Q5000 TGA. A predetermined amount of sample, 2.0-10.0 mg, was placed in an aluminum pan and heated at 10°C / min from 40°C to 300°C or as per the experimental instructions. A purge of dry nitrogen of 25 ml / min was maintained over the sample. Instrument control and data acquisition are obtained using Q Advantage software release version 5.5.23. Data were processed and displayed using TA Universal Analysis 2000 software version 4.5A build 4.5.0.5.
[0544] Dynamic Vapor Sorption (DVS): Dynamic Vapor Sorption (DVS) was performed using a TA Instruments QS000 SA. A predetermined amount of 2.0 to 10.0 mg of the sample was placed in a platinum pan. Samples were equilibrated at 50°C for 60 minutes at 0% relative humidity (RH). The samples were then equilibrated at 25° C. and then the humidity was ramped from 0 to 95% RH in 5% steps every hour. A similar lamp profile was used for the desorption cycle. XRPD analysis was also performed on the post-DVS samples. [Table 1A]
[0545] Ion chromatography (IC): Data were collected on a Metrohm 930 Compact IC Flex equipped with an 858 Professional autosampler and 800 Dosino dosing unit monitor using IC MagicNet software. Accurately weighed samples were prepared as stock solutions in suitable solvents. Quantification was performed by comparison with standard solutions of known concentrations of the ions to be analyzed. Analyzes were performed in duplicate and values represent the average unless otherwise stated. Method of cation chromatography: [Table 1B] Anion chromatography method: [Table 1C] (Example 1) N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine Synthesis of -6-yl)phenyl)methacrylamide hydrochloride (compound I-1) Step 1. Preparation of compound 3 [ka]
[0546] The reaction was started after inert in a glass lined 400L vessel with nitrogen and rinsed with purified water. A 400 L container was charged with purified water (31.4 kg, 2.5 volumes) and anhydrous tribasic potassium phosphate (11.1 kg, 2 equivalents). The mixture was stirred and cooled to 15.4°C. K 3 P.O. 4 The aqueous solution was removed into a clean plastic drum. A 400 L vessel was charged with Compound 1 (12.5 kg, 1 eq.) and Compound 2 (9.6 kg, 1.2 eq.) and then flushed with nitrogen. Dimethylacetamide (DMAc, 94.8 kg, 8 volumes), then K 3 P.O. 4 Aqueous solution was added. K 3 P.O. 4 There was a moderate exotherm upon addition of the aqueous solution. Adjust the addition rate to keep the reaction temperature at 60°C (t max 31.1°C). At this point the reaction mixture was heterogeneous. The contents of the vessel were degassed by nitrogen pressure cycles from 1 barg to 0 barg (3 times). Next, cataCXium A Pd G2 (chloro[(di(1-adamantyl)-N-butylphosphine)-2-(2-aminobiphenyl)]palladium(II), 0.53 kg, 3 mol%) was added to a container, and DMAc (0.93 +0.95 kg). The catalyst formed a thick suspension in DMAc. The contents of the vessel were heated at 80°C for 2 hours. The color of the reaction changed from light brown to dark brown as the reaction progressed. The reaction mixture was cooled to 19.9°C. Purified water (150.2 kg, 12 volumes) was poured into the container over 2 hours while maintaining the contents below 25°C (tr 15.9-20.3°C). The reaction mixture was aged at 15.4°C for 16 hours.
[0547] The mixture was filtered through a large Oyster filter (Φ820mm) and the cake was washed with 1:1 DMAc-water (11.6+12.5kg, 1+1 volume) and then with pure water (50.2kg, 4 volumes) to remove the crude material. A water-moist cake was obtained. The crude filter cake was transferred to a 400L container. The vessel was then charged with MeOH (88.8 kg, 9 volumes) and the contents cooled to below 20°C (tr 16.5°C). Aqueous HCl (4.16 kg, 1.6 eq.) was added using a dosing pump over 12 minutes while maintaining the contents of the vessel below 20° C. (tr 13.9-16.8° C.). V solution = 135L. A large Oyster filter was loaded with Solka-Floc 100NF (6.0 kg, to form a bed approximately 5 cm thick). The contents of the 400L vessel were then filtered through Solka-Floc and the waste cake was washed with MeOH (10.4 kg, 1 volume). Filtration took approximately 1.5 hours. The filtered solution of compound 4·HCl in MeOH was re-injected into the 400L container. A small Oyster filter (Φ416 mm) was charged with Quadrasil MP (7.0 kg, 60% by weight relative to theoretical compound 4) and the contents of the 400 L vessel were recirculated through the scavenger for 4 hours.
[0548] The solution was pumped back into the 400L vessel through the small Oyster filter and the scavenger cake was washed with MeOH (10.2 kg, 1 volume) into the same vessel. I assembled a 110L CUNO unit with a 12'' carbon cartridge (R53SP). The contents of the 400L vessel were recirculated through the carbon cartridge of the CUNO unit for 1 hour. The contents of the CUNO unit were pumped into a 400L container. The unit was then washed with MeOH (10.2 kg, 1 volume). A solution of triethylamine (4.26 kg, 1.6 eq) in MeOH (9.8 kg, 1 volume) was added to a 400 L vessel over 2 hours while maintaining the temperature of the contents below 20 °C (tr 13.0-13.8 °C). and compound 3 was precipitated as the free base. The resulting slurry was aged at 15.2°C for 18 hours. The slurry was filtered through an Oyster filter and the filter cake was rinsed with MeOH (20.2 kg, 2 volumes). The product cake was dried in vacuo at 50° C. for 16 hours. Compound 3 was obtained (11.59 kg, yield: 83.0%). Step 2. Preparation of compound I-1 mixture [ka]
[0549] The glass-lined 400 L reactor was placed under full vacuum for 3 hours before the batch was started to remove traces of residual wash solvent. All processing was performed under nitrogen atmosphere. 2,2,2-trifluoroethanol (TFE) (52.8 kg, 4 volumes) and methacrylic anhydride (7.1 kg, 94% by weight, 43.0 mol, 2.0 equivalents) were charged into the reactor, and the contents were heated at 10°C. It was cooled to A solution of ethylenediamine (0.26 kg, 4.3 mol, 0.2 eq) in TFE (2.8 kg, 0.2 vol) was added keeping the temperature below 30° C. and the contents were aged at 20° C. for 1 hour. A premixed solution of compound 3 (9.5 kg, 21.5 mol, 1.0 eq) in TFE (79.2 kg, 6 volumes) was added and the contents were aged at 20° C. for 16 hours. A clear solution of compound 4 was removed from the reactor into a clean plastic-lined drum.
[0550] All reaction mixtures, solvents and liquid reagents from this point on were passed through a 1.0 micron filter into the vessel to remove cloudiness of the batch. The reaction mixture was re-charged to the 400L vessel and the solution was concentrated under partial vacuum at <45°C to a volume of 19L. The resulting solution was diluted with EtOAc (171 kg, 20 volumes) and the batch was cooled to 20°C. 6N HCl in isopropanol (3.2 kg, 21.5 mol, 1.0 eq) was added over 1 hour while maintaining the contents of the vessel below 25°C. The suspension was then aged at 20°C for 17.5 hours.
[0551] 6N HCl in isopropanol (3.2 kg, 21.5 mol, 1.0 eq) was added over 1 hour while maintaining the contents of the vessel below 25°C. The suspension was then aged at 20°C for 17.5 hours. The mixture was filtered through a large Oyster filter and the cake was washed with EtOAc (17.1 kg (2 volumes) x 2). Filtration was very fast (<10 minutes). A sample was removed from the wet cake and the morphology of the solid was confirmed by XRPD. The polymorph "Form D" was obtained.
[0552] The wet cake was re-charged to the 400L vessel and EtOAc (213.8 kg, 25 volumes) was added. K 2 C.O. 3 A 0.5M solution of (49.7kg, 23.77mol, 1.1eq) was added over 30 minutes. By the end of the addition, the suspension turned into a clear biphasic mixture. The contents were aged for 1 hour. Precipitation of free base is K 2 C.O. 3 Forms within minutes of completion of aqueous addition. A sample was taken from the lower aqueous layer and the pH was checked using pH paper. pH was 9. Filter the mixture through a large Oyster filter and dissolve the cake in EtOAc / H. 2 Washed with O 1:1 (2 volumes). Filtration was fast (<15 minutes). two-phase K 2 C.O. 3 / EtOAc aqueous solution was reintroduced into the 400 L container and the lower aqueous layer was removed. Organic layer with H 2 Washed with O (47.5 kg, 5 volumes) to remove the lower aqueous layer. The wet cake was poured into EtOAc in a 400L vessel. 6N HCl in isopropanol (3.6 kg, 23.7 mol, 1.1 eq) was added over 1 hour while maintaining the contents of the vessel below 25°C. The suspension was then aged at 20°C for 17.5 hours. The mixture was filtered through a large Oyster filter and the cake was washed with EtOAc (17.1 kg (2 volumes) x 2). Filtration was very fast (<10 minutes). A sample was removed from the wet cake and the morphology of the solid was confirmed by XRPD. The polymorph "Form J" was obtained.
[0553] The wet cake was re-charged into the 400L vessel and water (4.8 kg, 0.5 vol) and ethanol (EtOH) (33.8 kg, 4.5 vol) were added. The suspension was warmed from 20 to 50°C over 150 minutes, maintained at 50°C for 180 minutes, and cooled from 50 to 20°C over 150 minutes. The suspension was aged at 20°C for 10 hours. The suspension was rewarmed from 20 to 50°C over 150 minutes, maintained at 50°C for 180 minutes, and cooled from 50 to 20°C over 150 minutes. The suspension was aged at 20°C for 10 hours. A sample was taken and the morphology of the solid was confirmed by XRPD. The polymorph "Form A" was obtained. Filter the mixture through a medium Oyster filter and remove the cake with EtOH / H 2 Washed with O 9:1 (2 volumes). The product was dried in vacuum at 60° C. for 18.5 hours under nitrogen sweep to yield 9.00 kg of compound I-1 (77% yield) and compound 6. Compound I-1: MS[M+1]=510.20. 1 H NMR (400 MHz, DMSO-d6) δ 9.92 (s, 1H), 8.47 (d, J = 5.0 Hz, 1H), 8.21 (s, 1H), 7.78 - 7.66 (m, 2H), 7.33 (m, J = 8.6, 2.3 Hz, 3H), 7.21 - 7.16 (m, 2H), 7.12 (s, 0H), 5.80 (s, 1H), 5.54 (d, J = 1.7 Hz, 1H), 3.59 (s, 3H) ), 2.42 (s, 3H), 1.95 (d, J = 1.2 Hz, 3H).
[0554] HPLC method on column: HALO ES-CN, 4.6×150mm 2.7um; flow rate: 1.0mL / min; column temperature: 40C; mobile phase A: 0.1% TFA in water; mobile phase B: 0.1% TFA in acetonitrile; and the following gradient: [Table 1D] revealed that compound I-1 had a liquid chromatography area percentage (LCAP) of 99.1 and compound 6 (RRT=0.84) had an LCAP of 0.42. (Example 2) Purification of compound I-1 [ka]
[0555] All processing was performed under nitrogen atmosphere. The container was rinsed with methanol (MeOH) (12.6 kg) and discarded to waste. All solvents and liquid reagents from this point on were passed through a 1.0 micron filter into the container to remove cloudiness from the batch. A reactor was charged with the crude mixture containing Compound I-1 (3.8 kg, 7.0 mol, 1.0 equiv.) and impurity Compound 6 from Step 2 of Example 1, and methanol (42.1 kg, 14 vol.) and the contents The material was cooled to 18°C. NaOH(H 2 A solution of 46-51% (1.1 kg, 8.4 mol, 1.2 eq) in MeOH (3.0 kg, 1.0 vol) was added over 5 min. During the addition of NaOH, the solvent was absorbed by the solid to form a gel, which turned into a suspension again after 3-4 minutes.
[0556] The contents were aged for 3 hours at 20°C. A sample was taken and the LCAP of impurity compound 6 in the solid was confirmed by HPLC. The LCAP of compound 6 in solid was 0.02. The suspension was filtered through a small Oyster filter and the cake was washed with MeOH (4 volumes). The wet cake was re-charged to the vessel and ethyl acetate (34.3 kg, 10 volumes) was added. 6N HCl in isopropanol (1.0 kg, 7.0 mol, 1.0 eq) was added over 30 minutes while maintaining the contents of the vessel below 25°C. The suspension was then aged at 20°C for 4 hours. A sample was taken and the LCAP of impurity compound 6 in the solid was confirmed by HPLC. The LCAP of compound 6 in solid was 0.02. The suspension was filtered through a small Oyster filter and the cake was washed with EtOAc (6.9 kg (2 volumes)) and then ethanol (EtOH) (12.0 kg (4 volumes) x 2). A sample was removed from the wet cake and the morphology of the solid was confirmed by XRPD. A mixture of polymorphic forms A and 4 was obtained.
[0557] The wet cake was re-charged to the vessel and water (1.9 kg, 0.5 vol) and ethanol (13.5 kg, 4.5 vol) were added. The suspension was warmed from 20 to 50°C over 150 minutes, maintained at 50°C for 180 minutes, and cooled from 50 to 20°C over 150 minutes. The suspension was aged at 20°C for 10 hours. A sample was taken and the morphology of the solid was confirmed by XRPD. The polymorph "Form A" was obtained. A sample was taken and the LCAP of impurity compound 6 in the solid was confirmed by HPLC (column: HALO ES-CN, 4.6×150mm 2.7um; flow rate: 1.0mL / min; column temperature: 40C; operating time: 25 minutes; Mobile phase A: 0.1% TFA in water; Mobile phase B: 0.1% TFA in acetonitrile; RT1: 7.8 min (compound 6); RT2: 9.1 min (compound I-1)). The LCAP of compound 6 in solid was 0.02. Filter the mixture through a small Oyster filter and dissolve the cake in EtOH / H 2 Washed with O 9:1 (2 volumes). Filtration was very fast (<10 minutes). The product was dried in vacuum at 60° C. for 18.5 hours under a nitrogen sweep to yield 2.8 kg of compound I-1 (74% yield, LCAP=99.9).
[0558] Conclusion: The objective was to develop a process that reduces the level of impurity RRT0.84 from an LCAP of 0.42 to an LCAP of less than 0.15, as shown in Example 1. Using this optimization process, the impurity RRT of 0.84 was reduced to 0.02 LCAP against a target of less than 0.15 LCAP, and the total purity was improved from 99.1 LCAP to 99.9 LCAP. (Example 3) (R)-N-(4-(4-amino-7-methyl-5-(4-(pyrrolidine-1-carbonyl)cyclohex-1-en-1-yl)-7H-pyrrolo[2,3-d ]Synthesis of pyrimidin-6-yl)-3-methylphenyl)methacrylamide (compound II-1) [ka] Step 1. Preparation of N-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methacrylamide [ka]
[0559] In a round bottom flask, 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (10 g, 42.8 mmol), methacryloyl chloride (3.87 g, 42.8 mmol) ), pyridine (10.1 g, 128 mmol), dichloromethane (150 mL), and a stirring bar. The solution was stirred at 0°C for 1 hour. The reaction mixture was quenched with water and extracted with DCM. organic phase with Na 2 S.O. 4 Dried, filtered and evaporated in vacuo. The resulting crude material was purified by silica gel chromatography. Concentration in vacuo gave N-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methacrylamide (12 g, 98%) was obtained as a yellow oil. Step 2: Preparation of N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-methylphenyl)methacrylamide [ka]
[0560] In a round bottom flask, N-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methacrylamide (1 g, 3.48 mmol), 5 -Bromo-6-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1.22g, 3.48mmol), Pd(dppf)Cl 2 (254mg, 348μmol), K 3 P.O. 4 (2.20g, 10.4mmol), DMF / H 2 Charged O(16:1) (15 mL) and a stir bar. The solution was stirred at 50°C for 2 hours. The reaction mixture was quenched with water and extracted with DCM. The organic phase was washed three times with brine and 2 S.O. 4 , filtered and evaporated in vacuo. The resulting crude material was purified by silica gel chromatography. Concentration in vacuo yields N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-methylphenyl)methacrylamide ( 440 mg, 33%) was obtained as a solid. Step 3: (R)-N-(4-(4-amino-7-methyl-5-(4-(pyrrolidine-1-carbonyl)cyclohex-1-en-1-yl)-7H-pyrrolo[2, 3-d]pyrimidin-6-yl)-3-methylphenyl)methacrylamide [ka]
[0561] In a resealable reaction vial, add N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-methylphenyl)methacrylamide. (200mg, 517μmol), 1-[(1R)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-ene-1-carbonyl]pyrrolidine (156mg, 517μmol), Pd(pddf)Cl 2 (37.8mg, 517μmol), Na 2 C.O. 3 (164 mg, 1.55 mmol), DMF (10 mL) and a stir bar, then evacuated and purged with nitrogen three times. The mixture was stirred at 90°C for 2 hours. The reaction mixture was quenched with water and extracted with DCM. The organic phase was washed three times with brine and 2 S.O. 4 , filtered and evaporated in vacuo. The obtained crude material was subjected to preparative HPLC (column: YMC-Actus Triart C18, 30*250, 5um; mobile phase A: water (10MMOL / L NH 4 HCO 3 ), mobile phase B: ACN; flow rate: 50 mL / min; gradient: 40B to 62B in 8 minutes; 220 nm). By lyophilization, (R)-N-(4-(4-amino-7-methyl-5-(4-(pyrrolidine-1-carbonyl)cyclohex-1-en-1-yl)-7H-pyrrolo[2 ,3-d]pyrimidin-6-yl)-3-methylphenyl)methacrylamide (40 mg, 16%) was obtained as a solid. MS[M+1]=499.35.1H NMR (400 MHz, DMSO-d6) δ 9.87 (s, 1H), 8.10 (s, 1H), 7.71 (t, J = 2.7 Hz, 1H), 7.62 (ddd, J = 8.0, 5.6, 2.2 Hz, 1H), 7.18 (dd, J = 8.3, 6.6 Hz, 1H), 6.48 (d, J = 17.0 Hz, 2H), 5.91 - 5.79 (m, 1H), 5.66 (ddt , J = 14.5, 4.1, 2.2 Hz, 1H), 5.54 (t, J = 1.5 Hz, 1H), 3.56 - 3.39 (m, 2H), 3.34 (s, 3H), 3.27 (q, J = 6.9 Hz, 2H), 2.73 (p, J = 6.3 Hz, 1H), 2.21 (q, J = 15.7, 12.1 Hz, 2H), 2.06 (s, 3H), 2.01 - 1.80 (m, 7H), 1.80 - 1.70 (m , 2H), 1.56 (q, J = 7.9, 7.0 Hz, 2H). (Example 4) 6-(6-ethynyl-4-methoxypyridin-3-yl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-4,7-dimethyl-7H- Synthesis of pyrrolo[2,3-d]pyrimidine (compound III-1) [ka] Step 1. Preparation of 5-bromo-2-((tert-butyldimethylsilyl)ethynyl)-4-methoxypyridine [ka]
[0562] In a resealable reaction vial, 5-bromo-2-iodo-4-methoxypyridine (600 mg, 2.00 mmol), CuI (152 mg, 800 μmol), Et 3 N(606mg, 6.00mmol), Pd(PPh 3 ) 2 Cl 2 (280 mg, 400 μmol), DMF (15 mL) and a stir bar, then evacuated and purged with nitrogen three times, tert-butyl(ethynyl)dimethylsilane (280 mg, 2.00 mmol) was added, and the mixture was heated at 50 °C. Stir for 2 hours. The reaction mixture was diluted with water (20 mL) and the aqueous phase was extracted three times with ethyl acetate (20 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting crude material was purified by silica gel chromatography (PE:EA=8:1). Concentration in vacuo gave 5-bromo-2-((tert-butyldimethylsilyl)ethynyl)-4-methoxypyridine (500 mg, 80%) as a solid. Step 2. Preparation of (6-((tert-butyldimethylsilyl)ethynyl)-4-methoxypyridin-3-yl)boronic acid [ka]
[0563] In a resealable reaction vial, 5-bromo-2-((tert-butyldimethylsilyl)ethynyl)-4-methoxypyridine (480 mg, 1.54 mmol), 4,4,5,5-tetramethyl-2-( 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (467 mg, 1.84 mmol), AcOK (452 mg, 4.62 mmol), Pd (dppf) Cl 2 (112 mg, 154 μmol), dioxane (10 mL) and a stir bar, then evacuated and purged with nitrogen three times, and the mixture was stirred at 80° C. for 2 hours. The reaction mixture was diluted with water (15 mL) and the aqueous phase was extracted three times with EA (15 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting crude material was purified by HPLC (acetonitrile / water 0%-60%, 30 minutes). Freeze-drying gave (6-((tert-butyldimethylsilyl)ethynyl)-4-methoxypyridin-3-yl)boronic acid (400 mg, 94%) as a solid. Step 3. 6-(6-((tert-butyldimethylsilyl)ethynyl)-4-methoxypyridin-3-yl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy) ) Phenyl)-4,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine preparation [ka]
[0564] In a resealable reaction vial, add 5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-6-iodo-4,7-dimethyl-7H-pyrrolo[2,3 -d]pyrimidine (520 mg, 1.13 mmol), (6-((tert-butyldimethylsilyl)ethynyl)-4-methoxypyridin-3-yl)boronic acid (380 mg, 1.37 mmol), Na 2 C.O. 3 (358mg, 3.38mmol), Pd(dppf)Cl 2 (82.6 mg, 113 μmol), DMF / H2O=16 / 1 (15 mL) and a stir bar, then evacuated and purged with nitrogen three times, and the mixture was stirred at 90° C. for 1 hour. The reaction mixture was diluted with water (15 mL) and the aqueous phase was extracted three times with DCM (15 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The crude material obtained was purified by HPLC (DCM / MeOH=15 / 1). By lyophilization, 6-(6-((tert-butyldimethylsilyl)ethynyl)-4-methoxypyridin-3-yl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl) Oxy)phenyl)-4,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine (200 mg, 34%) was obtained as a solid. Step 4. 6-(6-ethynyl-4-methoxypyridin-3-yl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-4,7-dimethyl Preparation of -7H-pyrrolo[2,3-d]pyrimidine [ka]
[0565] In a round bottom flask, add 6-(6-((tert-butyldimethylsilyl)ethynyl)-4-methoxypyridin-3-yl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl) )oxy)phenyl)-4,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine (180 mg, 303 μmol), TBAF (638 μg, 638 μmol) and a stir bar were charged. Tetrahydrofuran (5 mL) was added and the solution was stirred at 25° C. for 1 hour. The reaction mixture was diluted with water (10 mL) and the aqueous phase was extracted three times with dichloromethane (10 mL). The combined organic layers were washed 10 times with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The obtained crude material was analyzed by HPLC (column: SunFire Prep C18 OBD column, 19 x 150 mm 5 um 10 nm; mobile phase A: water (0.05% FA), mobile phase B: ACN (0.1% DEA) -- HPLC --; flow rate : 25 mL / min; gradient: 15B to 38B in 8 min; 220 nm). By lyophilization, 6-(6-ethynyl-4-methoxypyridin-3-yl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-4,7- Dimethyl-7H-pyrrolo[2,3-d]pyrimidine (31.1 mg, 21%) was obtained as a brown amorphous solid. MS[M+1]=481.15.1H NMR (400 MHz, DMSO-d6) δ 8.77 (s, 1H), 8.49 (d, J = 5.0 Hz, 1H), 8.29 (s, 1H), 7.42 (s, 1H), 7.36 - 7.27 (m, 2H), 7.19 (d, J = 5.0 Hz, 1H), 7.14 - 7.07 (m, 1H), 4.48 (s, 1H), 3.87 (s, 3H), 3.61 (s , 3H), 2.41 (s, 6H). (Example 5) 6-(6-ethynyl-2,4-dimethylpyridin-3-yl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-4,7-dimethyl- Synthesis of 7H-pyrrolo[2,3-d]pyrimidine (compound IV-1) [ka] Step 1. 6-(6-((tert-butyldimethylsilyl)ethynyl)-2,4-dimethylpyridin-3-yl)-4-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine preparation of [ka]
[0566] In a resealable reaction vial, 4-chloro-6-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidine (1.2 g, 4.1 mmol), N6-((tert-butyldimethylsilyl)ethynyl )-2,4-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.82 g, 4.91 mmol), PAd2nBu Pd-G2 (0.27 g . The mixture was stirred at 70°C for 15 hours. The reaction mixture was concentrated in vacuo. The resulting crude material was purified by silica gel chromatography (eluted with MeOH / DCM=1 / 100-1 / 20). Concentration in vacuo yields 6-(6-((tert-butyldimethylsilyl)ethynyl)-2,4-dimethylpyridin-3-yl)-4-chloro-7-methyl-7H-pyrrolo[2,3 -d]pyrimidine (0.7g, 42%) was obtained as a solid. Step 2. Preparation of 6-(6-((tert-butyldimethylsilyl)ethynyl)-2,4-dimethylpyridin-3-yl)-4,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine [ka]
[0567] In a resealable reaction vial, add 6-(6-((tert-butyldimethylsilyl)ethynyl)-2,4-dimethylpyridin-3-yl)-4-chloro-7-methyl-7H-pyrrolo[2, After charging 3-d]pyrimidine (0.7 g, 1.7 mmol), Pd(PPh3)4 (0.2 g, 0.17 mmol), THF (20 mL) and a stir bar, it was evacuated and purged with nitrogen three times. Zn(CH3)2 (1M, 2.04mL, 2.04mmol). The mixture was stirred at 70°C for 2 hours. The reaction mixture was quenched with water, extracted with DCM, and Na 2 S.O. 4 and concentrated in vacuo. The resulting crude material was purified by silica gel chromatography (eluting with MeOH / DCM=1 / 100-1 / 30). Concentration in vacuo yields 6-(6-((tert-butyldimethylsilyl)ethynyl)-2,4-dimethylpyridin-3-yl)-4,7-dimethyl-7H-pyrrolo[2,3-d ]pyrimidine (0.4 g, 60%) was obtained as a solid. Step 3. 5-Bromo-6-(6-((tert-butyldimethylsilyl)ethynyl)-2,4-dimethylpyridin-3-yl)-4,7-dimethyl-7H-pyrrolo[2,3-d ]Preparation of pyrimidine [ka]
[0568] In a round bottom flask, add 6-(6-((tert-butyldimethylsilyl)ethynyl)-2,4-dimethylpyridin-3-yl)-4,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine. (0.4 g, 1 mmol), DMF (10 mL) and a stirring bar were added. NBS (0.18g, 1mmol) was added. The mixture was stirred for 1 hour. Saturate the reaction with NaHSO 3 Quench with aqueous solution, extract with DCM (50 mL*3), combine the organic phases, wash twice with brine, and 2 S.O. 4 The residue was dissolved in ACN (25 mL), filtered, the filter cake was washed with ACN and dried under reduced pressure to give 5-bromo-6-(6-((tert -butyldimethylsilyl)ethynyl)-2,4-dimethylpyridin-3-yl)-4,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine (440 mg, 94%) was obtained as a solid. Step 4. 6-(6-((tert-butyldimethylsilyl)ethynyl)-2,4-dimethylpyridin-3-yl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl) Preparation of )oxy)phenyl)-4,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine [ka]
[0569] In a round bottom flask, add 5-bromo-6-(6-((tert-butyldimethylsilyl)ethynyl)-2,4-dimethylpyridin-3-yl)-4,7-dimethyl-7H-pyrrolo[2,3 -d]pyrimidine (440 mg, 0.94 mmol), 2-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-4-methyl After charging pyrimidine (371.5 mg, 1.1 mmol), Pd(PPh3)4 (104 mg, 0.09 mmol), K3PO4 (598 mg, 2.82 mmol), DME / H2O (10:1, 10 mL) and a stirring bar, it was evacuated. Purged three times with nitrogen. The mixture was stirred at 90°C for 2 hours. After cooling, the mixture was diluted with water, extracted with DCM and extracted with Na 2 S.O. 4 , evaporated in vacuo and the residue purified by silica gel chromatography (eluted with MeOH / DCM=1 / 100~1 / 10) to give 6-(6-((tert-butyldimethylsilyl)ethynyl) )-2,4-dimethylpyridin-3-yl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-4,7-dimethyl-7H-pyrrolo[2 ,3-d]pyrimidine (300 mg, 54%) was obtained as a solid. Step 5: 6-(6-ethynyl-2,4-dimethylpyridin-3-yl)-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-4,7 -Preparation of dimethyl-7H-pyrrolo[2,3-d]pyrimidine [ka]
[0570] In a round bottom flask, add 6-(6-((tert-butyldimethylsilyl)ethynyl)-2,4-dimethylpyridin-3-yl)-5-(3-fluoro-4-((4-methylpyrimidine-2 -yl)oxy)phenyl)-4,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine (300 mg, 0.51 mmol), THF (10 mL) and a stir bar were charged. TBAF (0.61 mL, 0.61 mmol) was added dropwise. The mixture was stirred at room temperature for 0.5 h. The mixture was diluted with water, extracted with DCM, washed with brine, and washed with Na 2 S.O. 4, evaporated in vacuo and the residue purified by preparative HPLC to give 6-(6-ethynyl-2,4-dimethylpyridin-3-yl)-5-(3-fluoro-4-(( 4-Methylpyrimidin-2-yl)oxy)phenyl)-4,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine (100 mg, 41%) was obtained as a solid. MS[M+1]=479.35. 1 H NMR (400 MHz, DMSO-d6) δ 8.78 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 7.45 (s, 1H), 7.34-7.25 (m, 2H), 7.18 (d, J = 5.0 Hz, 1H), 7.07 (d, J = 8.9 Hz, 1H), 4.39 (s, 1H), 3.51 (s, 3H), 2.44 (s, 3H), 2.40 (s, 3H), 2.19 ( s, 3H), 2.05 (s, 3H).
[0571] Chiral separation of 100mg of target (Column: CHIRALPAK IF, 2*25cm, 5um; Mobile phase A: Hexane (0.5% 2M NH3-MeOH), Mobile phase B: EtOH:DCM=1:1--HPLC; Flow rate: 20mL / min; gradient: 20B to 20B in 15.5 minutes; 220 / 254nm; RT1: 10.826; RT2: 12.649; injection volume: 0.8ml; number of runs: 5). Lyophilization resulted in 6-(6-ethynyl-2,4-dimethylpyridin-3-yl)-5-(3-fluoro-4 Separated rotamers of -((4-methylpyrimidin-2-yl)oxy)phenyl)-4,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine were obtained. (Example 6) N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine -6-yl)phenyl)methacrylamide hydrochloride (compound I-1) polymorphic screening
[0572] Compound I-1(N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2, Polymorphic screening of 3-d]pyrimidin-6-yl)phenyl)methacrylamide hydrochloride) was carried out in 24 different solvents by a temperature cycling method. If no suspended solids were observed when the system was cooled to 25°C, the solution was evaporated. The details of the operating procedure are listed below:
[0573] The conversion of compound I-1 (Form D) was studied under anhydrous and aqueous conditions at 50°C. Table 1 summarizes the results of the Form D conversions investigated in these studies. Compound I-1 (approximately 100 mg, Form D) and the appropriate solvent (10 volumes) were placed in separate 1.5 ml clear glass vials and heated to 50 °C at 0.5 °C / min (over 1 hour). The mixture was stirred at 50°C for 16 hours and cooled at -0.5°C / min (over 1 hour). After this time, the product was isolated by centrifugation at 10,000 RPM for 10 minutes, dried at 40° C. under reduced pressure and analyzed by XRPD, HPLC and 1H NMR. When novel XRPD patterns were identified, dry solids with novel XRPD patterns were also characterized by PLM, DSC and TGA. Further polymorphism screening was performed as shown in the map of identified morphology (Figure 12).
[0574] A summary of the solvents tested can be found in Table 1. [Table 1-1] Form A
[0575] After the polymorphic screening experiment described above, all the solids obtained showed an XRPD pattern containing Form A. Form A was also obtained by heating Form G to 230°C.
[0576] Form A of compound I-1 was then characterized by DSC, TGA and DVS. The DSC scan of Form A in Figure 1B showed a single endothermic peak with an onset of 277.67°C (enthalpy: 140.7 J / g). TGA scan (Figure 1C) showed a weight loss of 0.2503% from 33°C to 80°C and a weight loss of 0.222% from 170°C to 270°C. Dynamic water vapor sorption (DVS) data for Form A of compound I-1 is shown in Figure 1D.
[0577] The XRPD of Form A of Compound I-1 is shown in Figure 1A. Table 2.1 below shows the X-ray diffraction peaks observed for Form A of Compound I-1, where each value is in 2θ degrees: [Table 2.1] Form B
[0578] After the polymorphism screening experiment described above, all the solids obtained showed an XRPD pattern containing form B. Form B was also obtained by addition of aqueous HCl to a solution of the free base in 2-propanol. Additionally, Form B was obtained by heating Form I to about 220°C, Form F to about 220°C, and Form J to about 220°C.
[0579] Form B of compound I-1 was then characterized by DSC, TGA and DVS. DSC scan of Form B in Figure 2B showed an endothermic peak with an onset of about 217°C (enthalpy: 3.86 J / g). TGA scan (Figure 2C) showed a weight loss of 7.15% from about 160 °C to about 250 °C. In summary, Form B is the pure crystalline form of Compound I-1. Dynamic water vapor sorption (DVS) data for Form B of Compound I-1 is shown in Figure 2D.
[0580] The XRPD of Form B of Compound I-1 is shown in Figure 2A. Table 2.2 below shows the X-ray diffraction peaks observed for Form B of Compound I-1, where each value is in 2θ degrees: [Table 2.2-1] [Table 2.2-2] Form C
[0581] After the polymorphic screening experiment described above, all the solids obtained showed an XRPD pattern containing Form C. Form C was also obtained by addition of aqueous HCl to a solution of the free base in ethyl acetate. Additionally, Form C can be obtained from a slurry of Form D in methyl ethyl ketone / water (19 / 1 v / v), methyl acetate / water (19 / 1 v / v) or isopropyl acetate / water (19 / 1 v / v). Obtained.
[0582] Form C of compound I-1 was then characterized by DSC, TGA and DVS. DSC scan of Form C in Figure 3B showed an endothermic peak with an onset of about 190°C (enthalpy: 44.6 J / g). TGA analysis of Form C of compound I-1 is shown in Figure 3B. Dynamic water vapor sorption (DVS) data for Form C of compound I-1 is shown in Figure 3D.
[0583] The XRPD of Form C of compound I-1 is shown in Figure 3A. Table 2.3 below shows the X-ray diffraction peaks observed for Form C of compound I-1, where each value is in 2θ degrees: [Table 2.3-1] [Table 2.3-2] Form D
[0584] After the polymorphism screening experiment described above, all the solids obtained showed an XRPD pattern containing Form D. Form D was also obtained by addition of 6N HCl in 2-propanol to the free base in ethyl acetate (20 volumes).
[0585] Form D of compound I-1 was then subjected to DSC, TGA, DVS and 1 Characterized by H-NMR. DSC scan of Form D in Figure 4B showed an endothermic peak at onset of 156°C (enthalpy: 53.3 J / g). TGA scan (Figure 4C) showed a weight loss of 12.4% from 40 °C to 130 °C. Dynamic water vapor sorption data for Form D of compound I-1 is shown in Figure 4D.
[0586] The XRPD of Form D of Compound I-1 is shown in Figure 4A. Table 2.4 below shows the X-ray diffraction peaks observed for Form D of Compound I-1, where each value is in 2θ degrees: [Table 2.4-1] [Table 2.4-2] Form E
[0587] After the polymorphic screening experiment described above, all solids obtained showed XRPD patterns containing form E. Form E was also obtained by slurrying Form C in ethanol (25 volumes) for 16 hours at 50°C. Additionally, Form E was obtained by heating Form D to 220°C.
[0588] Form E of compound I-1 was then characterized by DSC. A DSC scan of Form E of Compound I-1 is shown in Figure 5B. Dynamic water vapor sorption data for Form E of compound I-1 is shown in Figure 5D.
[0589] XRPD of Form E of Compound I-1 is shown in Figure 5A. Table 2.5 below shows the X-ray diffraction peaks observed for Form E of Compound I-1, where each value is in 2θ degrees: [Table 2.5] Form F
[0590] After the polymorphism screening experiment described above, all the solids obtained showed an XRPD pattern containing form F. Form F was also obtained by addition of HCl to the free base in ethyl acetate, seeded with Form B. Additionally, Form F was obtained by slurrying Form D in ethyl acetate / water (19 / 1 v / v) at 50°C. Form F was also obtained by heating Form I to 120°C.
[0591] Form F of compound I-1 was then characterized by DSC, TGA and DVS. The DSC scan of Form F in Figure 6B showed an endothermic peak with an onset of 162°C (enthalpy: 15.5 J / g). TGA scans (Figure 6B) showed a weight loss of 4.7% from 43°C to 95°C, 1.2°C from 125°C to 160°C, and 4.4% from 220°C to 260°C. Dynamic water vapor sorption data for Form F of compound I-1 is shown in Figure 6D.
[0592] The XRPD of Form F of Compound I-1 is shown in Figure 6A. Table 2.6 below shows the X-ray diffraction peaks observed for Form F of Compound I-1, where each value is in 2θ degrees:
[0593] [Table 2.6] Form G
[0594] After the polymorphism screening experiment described above, all solids obtained showed XRPD patterns containing form G. Form G was also obtained by slurrying Form D in water at 50°C. Additionally, Form G was obtained from a slurry of Form C in 2-propanol at 50°C.
[0595] Form G of compound I-1 was then characterized by DSC, TGA and DVS. DSC scan of Form G in Figure 7B showed an endothermic peak with an onset of about 145°C (enthalpy: 66.9 J / g). TGA scan (Figure 7C) showed a weight loss of 4.2% from 40°C to 140°C. Dynamic water vapor sorption data for Form G of compound I-1 is shown in Figure 7D.
[0596] The XRPD of Form G of compound I-1 is shown in Figure 7A. Table 2.7 below shows the X-ray diffraction peaks observed for Form G of compound I-1, where each value is in 2θ degrees: [Table 2.7] Form H
[0597] After the polymorphic screening experiment described above, all the solids obtained showed an XRPD pattern containing form H. Form H was also obtained from the free base in ethyl acetate (20 volumes) by seeding Form B with HCl.
[0598] Form H of compound I-1 was then characterized by DSC, TGA and DVS. DSC scan of Form H in Figure 8B showed an endothermic peak with an onset of about 186°C (enthalpy: 39.1 J / g). TGA scan (Figure 8B) showed a weight loss of 5.4% from 40°C to 80°C and 3.7% from 190°C to 260°C. Dyna...
Claims
1. A compound in solid form, or a solvate thereof, said compound having the formula I-1: 【Chemistry 49】 or a solvate thereof.
2. The compound of claim 1 , wherein the compound is amorphous or crystalline.
3. 3. The compound of claim 2, wherein the crystalline form is Form A, Form B, Form C, Form D, Form E, Form F, Form G, Form H, Form I, Form J, or Form K.
4. Compounds of formula (I) 【Chemistry 50】 or a solvate thereof, During the ceremony, m is 1, 2, 3, 4, 5, 6, 7, 8 or 9; n is 0, 0.5, 1, 1.5, 2, 2.5 or 3; X is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, p-toluenesulfonic acid, methanesulfonic acid, benzenesulfonic acid or maleic acid; Optionally, said compound is selected from the group consisting of Compound I-2, Compound I-3, Compound I-4, Compound I-5, Compound I-6, Compound I-7, and Compound I-8; Further optionally, the compound or a solvate thereof, wherein said compound is in solid form, amorphous or crystalline.
5. A compound of formula (II) 【Chemistry 17】 or a solvate thereof, During the ceremony, p is 1, 2, 3, 4, 5, 6, 7, 8 or 9; q is 0, 0.5, 1, 1.5, 2, 2.5 or 3; X is hydrochloric acid, hydrobromic acid, p-toluenesulfonic acid, methanesulfonic acid, benzenesulfonic acid or fumaric acid; Optionally, the compound is selected from the group consisting of Compound II-1, Compound II-2, Compound II-3, Compound II-4, Compound II-5, Compound II-6, and Compound II-7; Further optionally, the compound or a solvate thereof, wherein said compound is in solid form, amorphous or crystalline.
6. A compound of formula (III) 【Chemistry 18】 or a solvate thereof, During the ceremony, r is 1, 2, 3, 4, 5, 6, 7, 8 or 9; s is 0, 0.5, 1, 1.5, 2, 2.5 or 3; X is hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid or tartaric acid; Optionally, the compound is selected from the group consisting of Compound III-1, Compound III-2, Compound III-3, Compound III-4, Compound III-5, and Compound III-6; Further optionally, the compound or a solvate thereof, wherein said compound is in solid form, amorphous or crystalline.
7. A compound of formula (IV) 【Chemistry 19】 or a solvate thereof, During the ceremony, t is 1, 2, 3, 4, 5, 6, 7, 8, or 9; u is 0, 0.5, 1, 1.5, 2, 2.5 or 3; X is hydrochloric acid, p-toluenesulfonic acid, methanesulfonic acid or benzenesulfonic acid; Optionally, the compound is selected from the group consisting of Compound IV-1, Compound IV-2, Compound IV-3, Compound IV-4, and Compound IV-5; Further optionally, the compound or a solvate thereof, wherein said compound is in solid form, amorphous or crystalline.
8. 【Chemical 54】 【Chemistry 55】 【Chemistry 56】 or a pharma- ceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier.
10. An immediate release capsule comprising the crystalline solid form of claim 2 or 3, optionally further comprising a pharma- ceutically acceptable carrier or excipient, and optionally, said immediate release capsule comprising a powder blend intermediate; Further optionally, said powder blend intermediate is produced by directly blending said crystalline solid form with one or more pharma- ceutically acceptable carriers or excipients; Further optionally, said immediate release capsule comprises about 10 mg, about 50 mg, or about 100 mg of said crystalline solid form or a solvate thereof.
11. 10. A pharmaceutical composition for use in inhibiting FGFR2 activity in a subject in need thereof, said pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 8, or a pharma- ceutical acceptable salt thereof, and a pharma- ceutical acceptable carrier.
12. A pharmaceutical composition for use in treating a disorder in a subject in need thereof, said pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 8 or a pharma- ceutical acceptable salt thereof and a pharma- ceutical acceptable carrier; Optionally, the pharmaceutical composition for use, wherein the disorder is selected from intrahepatic cholangiocarcinoma, hepatocellular carcinoma, breast cancer, prostate cancer, squamous cell lung carcinoma, thyroid cancer, gastric cancer, ovarian cancer, rectal cancer, endometrial cancer, non-small cell lung cancer and urothelial cancer.
13. The pharmaceutical composition for use according to claim 11 or 12, wherein the pharmaceutical composition is for administration with a therapeutically effective amount of an antibody, antibody-drug conjugate, immunomodulator or histone deacetylase inhibitor.
14. 11. A kit comprising a compound according to any one of claims 1 to 8 or a pharma- ceutically acceptable salt thereof or an immediate release capsule according to claim 10, optionally further comprising written instructions describing the preparation of a pharmaceutical composition suitable for administration to a patient from said compound or a pharma- ceutically acceptable salt thereof or said immediate release capsule and / or written instructions describing how to administer the resulting composition to said patient.
15. 4. A process for preparing the crystalline form of claim 2 or 3, comprising the steps of: a) preparing a solution of compound I-1 in a solvent comprising at least one of EtOH, ACN, MEK, EtOAc, IPAc, IPA, THF, MtBE, toluene, 1,4 dioxane, and water; b) heating the solution to completely dissolve compound I-1; c) adjusting the temperature so that a solid precipitates out of the solution; and d) isolating the crystalline form.
16. The method of claim 1, wherein the solvent comprises EtOH and water (9v / 1v). (ii) the step of heating the solution comprises heating the solution to about 50° C.; and / or 16. The process of claim 15, wherein (iii) the step of adjusting the temperature comprises cooling the solution to about 5°C.
17. A process for preparing a compound of formula I-1, comprising acidifying a compound of formula I-2 with HCl, thereby obtaining the compound of formula I-1: 【Chemistry 51】 and optionally forming Methacrylic anhydride is reacted with the compound of formula 3 to produce the compound of formula I-2: 【Chemistry 52】 and optionally further comprising the step of forming The compound of formula 1 is coupled with a compound of formula 2, thereby producing the compound of formula 3: 【Chemistry 53】 The process further comprising forming
18. 【Chemical 57】 or a salt thereof.
